WO2017200492A1 - Method of treating cancer - Google Patents
Method of treating cancer Download PDFInfo
- Publication number
- WO2017200492A1 WO2017200492A1 PCT/SG2017/050263 SG2017050263W WO2017200492A1 WO 2017200492 A1 WO2017200492 A1 WO 2017200492A1 SG 2017050263 W SG2017050263 W SG 2017050263W WO 2017200492 A1 WO2017200492 A1 WO 2017200492A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cancer
- virus
- cells
- cell
- therapy
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 273
- 201000011510 cancer Diseases 0.000 title claims abstract description 154
- 238000000034 method Methods 0.000 title claims abstract description 60
- 210000002865 immune cell Anatomy 0.000 claims abstract description 35
- 230000001965 increasing effect Effects 0.000 claims abstract description 12
- 210000004881 tumor cell Anatomy 0.000 claims abstract description 11
- 230000003213 activating effect Effects 0.000 claims abstract description 9
- 230000030741 antigen processing and presentation Effects 0.000 claims abstract description 9
- 230000035755 proliferation Effects 0.000 claims abstract description 7
- 230000005867 T cell response Effects 0.000 claims abstract description 6
- 230000002708 enhancing effect Effects 0.000 claims abstract description 6
- 208000007660 Residual Neoplasm Diseases 0.000 claims abstract description 5
- 238000002560 therapeutic procedure Methods 0.000 claims description 53
- 238000011282 treatment Methods 0.000 claims description 49
- 238000002512 chemotherapy Methods 0.000 claims description 40
- AUZONCFQVSMFAP-UHFFFAOYSA-N disulfiram Chemical compound CCN(CC)C(=S)SSC(=S)N(CC)CC AUZONCFQVSMFAP-UHFFFAOYSA-N 0.000 claims description 40
- 239000003112 inhibitor Substances 0.000 claims description 37
- 210000000130 stem cell Anatomy 0.000 claims description 22
- 239000003795 chemical substances by application Substances 0.000 claims description 20
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 claims description 19
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 19
- 229960002563 disulfiram Drugs 0.000 claims description 19
- 239000000427 antigen Substances 0.000 claims description 18
- 238000002648 combination therapy Methods 0.000 claims description 18
- 229910052744 lithium Inorganic materials 0.000 claims description 18
- 108091007433 antigens Proteins 0.000 claims description 17
- 102000036639 antigens Human genes 0.000 claims description 17
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims description 16
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims description 15
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 claims description 15
- 229960002949 fluorouracil Drugs 0.000 claims description 15
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims description 15
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 14
- 244000309459 oncolytic virus Species 0.000 claims description 14
- 206010033128 Ovarian cancer Diseases 0.000 claims description 13
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims description 13
- 229960004316 cisplatin Drugs 0.000 claims description 13
- 239000003814 drug Substances 0.000 claims description 13
- 208000026310 Breast neoplasm Diseases 0.000 claims description 12
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 claims description 12
- 238000001356 surgical procedure Methods 0.000 claims description 12
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 12
- 206010006187 Breast cancer Diseases 0.000 claims description 11
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims description 11
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 claims description 10
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 10
- 229960004117 capecitabine Drugs 0.000 claims description 10
- 229960005277 gemcitabine Drugs 0.000 claims description 10
- 229930012538 Paclitaxel Natural products 0.000 claims description 9
- 229940049595 antibody-drug conjugate Drugs 0.000 claims description 9
- 239000012634 fragment Substances 0.000 claims description 9
- 229960001592 paclitaxel Drugs 0.000 claims description 9
- 230000008685 targeting Effects 0.000 claims description 9
- 206010005003 Bladder cancer Diseases 0.000 claims description 8
- 229960004679 doxorubicin Drugs 0.000 claims description 8
- 201000007270 liver cancer Diseases 0.000 claims description 8
- 229960001756 oxaliplatin Drugs 0.000 claims description 8
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 claims description 8
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 8
- 229940124803 CXCR2 antagonist Drugs 0.000 claims description 7
- 239000000611 antibody drug conjugate Substances 0.000 claims description 7
- 239000002573 chemokine receptor CXCR2 antagonist Substances 0.000 claims description 7
- 239000003534 dna topoisomerase inhibitor Substances 0.000 claims description 7
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 7
- 208000014018 liver neoplasm Diseases 0.000 claims description 7
- 208000020816 lung neoplasm Diseases 0.000 claims description 7
- QZECRCLSIGFCIO-RISCZKNCSA-N n-[2-[(2,3-difluorophenyl)methylsulfanyl]-6-[(2r,3s)-3,4-dihydroxybutan-2-yl]oxypyrimidin-4-yl]azetidine-1-sulfonamide Chemical compound N=1C(SCC=2C(=C(F)C=CC=2)F)=NC(O[C@H](C)[C@@H](O)CO)=CC=1NS(=O)(=O)N1CCC1 QZECRCLSIGFCIO-RISCZKNCSA-N 0.000 claims description 7
- 229940044693 topoisomerase inhibitor Drugs 0.000 claims description 7
- 210000004981 tumor-associated macrophage Anatomy 0.000 claims description 7
- RXIUEIPPLAFSDF-CYBMUJFWSA-N 2-hydroxy-n,n-dimethyl-3-[[2-[[(1r)-1-(5-methylfuran-2-yl)propyl]amino]-3,4-dioxocyclobuten-1-yl]amino]benzamide Chemical compound N([C@H](CC)C=1OC(C)=CC=1)C(C(C1=O)=O)=C1NC1=CC=CC(C(=O)N(C)C)=C1O RXIUEIPPLAFSDF-CYBMUJFWSA-N 0.000 claims description 6
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 6
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims description 6
- 102100040678 Programmed cell death protein 1 Human genes 0.000 claims description 6
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 6
- 229940100198 alkylating agent Drugs 0.000 claims description 6
- 239000002168 alkylating agent Substances 0.000 claims description 6
- 229960004768 irinotecan Drugs 0.000 claims description 6
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 claims description 6
- 210000000822 natural killer cell Anatomy 0.000 claims description 6
- 102100021435 Macrophage-stimulating protein receptor Human genes 0.000 claims description 5
- 206010060862 Prostate cancer Diseases 0.000 claims description 5
- 206010038389 Renal cancer Diseases 0.000 claims description 5
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 5
- 241000700605 Viruses Species 0.000 claims description 5
- 229940045799 anthracyclines and related substance Drugs 0.000 claims description 5
- 230000000340 anti-metabolite Effects 0.000 claims description 5
- 230000000259 anti-tumor effect Effects 0.000 claims description 5
- 229940100197 antimetabolite Drugs 0.000 claims description 5
- 239000002256 antimetabolite Substances 0.000 claims description 5
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 5
- 229940079593 drug Drugs 0.000 claims description 5
- 206010017758 gastric cancer Diseases 0.000 claims description 5
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims description 5
- 201000010982 kidney cancer Diseases 0.000 claims description 5
- 210000000581 natural killer T-cell Anatomy 0.000 claims description 5
- 201000011549 stomach cancer Diseases 0.000 claims description 5
- 241000711404 Avian avulavirus 1 Species 0.000 claims description 4
- 201000009030 Carcinoma Diseases 0.000 claims description 4
- 206010009944 Colon cancer Diseases 0.000 claims description 4
- 241000709687 Coxsackievirus Species 0.000 claims description 4
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims description 4
- 102000004127 Cytokines Human genes 0.000 claims description 4
- 108090000695 Cytokines Proteins 0.000 claims description 4
- 241000709661 Enterovirus Species 0.000 claims description 4
- 241000991587 Enterovirus C Species 0.000 claims description 4
- 101000760175 Homo sapiens Zinc finger protein 35 Proteins 0.000 claims description 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 4
- 241000712079 Measles morbillivirus Species 0.000 claims description 4
- 239000012270 PD-1 inhibitor Substances 0.000 claims description 4
- 239000012668 PD-1-inhibitor Substances 0.000 claims description 4
- 241000702263 Reovirus sp. Species 0.000 claims description 4
- 241000837158 Senecavirus A Species 0.000 claims description 4
- 241000700584 Simplexvirus Species 0.000 claims description 4
- 241000700618 Vaccinia virus Species 0.000 claims description 4
- 241000711975 Vesicular stomatitis virus Species 0.000 claims description 4
- 102100024672 Zinc finger protein 35 Human genes 0.000 claims description 4
- 238000002659 cell therapy Methods 0.000 claims description 4
- 229960004397 cyclophosphamide Drugs 0.000 claims description 4
- 229950002830 enadenotucirev Drugs 0.000 claims description 4
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 4
- 229940091204 imlygic Drugs 0.000 claims description 4
- 210000004698 lymphocyte Anatomy 0.000 claims description 4
- 229940121655 pd-1 inhibitor Drugs 0.000 claims description 4
- 229960005547 pelareorep Drugs 0.000 claims description 4
- 229950008461 talimogene laherparepvec Drugs 0.000 claims description 4
- 241000701161 unidentified adenovirus Species 0.000 claims description 4
- 108010025625 vocimagene amiretrorepvec Proteins 0.000 claims description 4
- NGYNBSHYFOFVLS-LBPRGKRZSA-N 1-[4-chloro-2-hydroxy-3-[(3s)-piperidin-3-yl]sulfonylphenyl]-3-(3-fluoro-2-methylphenyl)urea Chemical compound CC1=C(F)C=CC=C1NC(=O)NC1=CC=C(Cl)C(S(=O)(=O)[C@@H]2CNCCC2)=C1O NGYNBSHYFOFVLS-LBPRGKRZSA-N 0.000 claims description 3
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 3
- 239000012271 PD-L1 inhibitor Substances 0.000 claims description 3
- 239000002671 adjuvant Substances 0.000 claims description 3
- 239000000556 agonist Substances 0.000 claims description 3
- 229930013930 alkaloid Natural products 0.000 claims description 3
- 201000005202 lung cancer Diseases 0.000 claims description 3
- 229940121656 pd-l1 inhibitor Drugs 0.000 claims description 3
- MFZSNESUTRVBQX-XEURHVNRSA-N (2S)-2-amino-6-[4-[[3-[[(2S)-1-[[(1S,2R,3S,5S,6S,16E,18E,20R,21S)-11-chloro-21-hydroxy-12,20-dimethoxy-2,5,9,16-tetramethyl-8,23-dioxo-4,24-dioxa-9,22-diazatetracyclo[19.3.1.110,14.03,5]hexacosa-10,12,14(26),16,18-pentaen-6-yl]oxy]-1-oxopropan-2-yl]-methylamino]-3-oxopropyl]disulfanyl]pentanoylamino]hexanoic acid Chemical compound CO[C@@H]1\C=C\C=C(C)\Cc2cc(OC)c(Cl)c(c2)N(C)C(=O)C[C@H](OC(=O)[C@H](C)N(C)C(=O)CCSSC(C)CCC(=O)NCCCC[C@H](N)C(O)=O)[C@]2(C)O[C@H]2[C@H](C)[C@@H]2C[C@@]1(O)NC(=O)O2 MFZSNESUTRVBQX-XEURHVNRSA-N 0.000 claims description 2
- FQVLRGLGWNWPSS-BXBUPLCLSA-N (4r,7s,10s,13s,16r)-16-acetamido-13-(1h-imidazol-5-ylmethyl)-10-methyl-6,9,12,15-tetraoxo-7-propan-2-yl-1,2-dithia-5,8,11,14-tetrazacycloheptadecane-4-carboxamide Chemical compound N1C(=O)[C@@H](NC(C)=O)CSSC[C@@H](C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@@H]1CC1=CN=CN1 FQVLRGLGWNWPSS-BXBUPLCLSA-N 0.000 claims description 2
- ZOHXWSHGANNQGO-DSIKUUPMSA-N 1-amino-4-[[5-[[(2S)-1-[[(1S,2R,3S,5S,6S,16E,18E,20R,21S)-11-chloro-21-hydroxy-12,20-dimethoxy-2,5,9,16-tetramethyl-8,23-dioxo-4,24-dioxa-9,22-diazatetracyclo[19.3.1.110,14.03,5]hexacosa-10,12,14(26),16,18-pentaen-6-yl]oxy]-1-oxopropan-2-yl]-methylamino]-2-methyl-5-oxopentan-2-yl]disulfanyl]-1-oxobutane-2-sulfonic acid Chemical compound CO[C@@H]([C@@]1(O)C[C@H](OC(=O)N1)[C@@H](C)[C@@H]1O[C@@]1(C)[C@@H](OC(=O)[C@H](C)N(C)C(=O)CCC(C)(C)SSCCC(C(N)=O)S(O)(=O)=O)CC(=O)N1C)\C=C\C=C(C)\CC2=CC(OC)=C(Cl)C1=C2 ZOHXWSHGANNQGO-DSIKUUPMSA-N 0.000 claims description 2
- 229940125668 ADH-1 Drugs 0.000 claims description 2
- 239000012275 CTLA-4 inhibitor Substances 0.000 claims description 2
- 229940045513 CTLA4 antagonist Drugs 0.000 claims description 2
- 101000796901 Gallus gallus Alcohol dehydrogenase 1 Proteins 0.000 claims description 2
- 102000003816 Interleukin-13 Human genes 0.000 claims description 2
- 108090000176 Interleukin-13 Proteins 0.000 claims description 2
- 229940125563 LAG3 inhibitor Drugs 0.000 claims description 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 2
- 108091000080 Phosphotransferase Proteins 0.000 claims description 2
- 101000832889 Scheffersomyces stipitis (strain ATCC 58785 / CBS 6054 / NBRC 10063 / NRRL Y-11545) Alcohol dehydrogenase 2 Proteins 0.000 claims description 2
- 102100037236 Tyrosine-protein kinase receptor UFO Human genes 0.000 claims description 2
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 claims description 2
- 201000009036 biliary tract cancer Diseases 0.000 claims description 2
- 208000020790 biliary tract neoplasm Diseases 0.000 claims description 2
- 229960000455 brentuximab vedotin Drugs 0.000 claims description 2
- 229940126608 cBR96-doxorubicin immunoconjugate Drugs 0.000 claims description 2
- 108700010039 chimeric receptor Proteins 0.000 claims description 2
- 229940029030 dendritic cell vaccine Drugs 0.000 claims description 2
- 238000000502 dialysis Methods 0.000 claims description 2
- 229960003297 gemtuzumab ozogamicin Drugs 0.000 claims description 2
- 229950009672 glembatumumab vedotin Drugs 0.000 claims description 2
- 201000010536 head and neck cancer Diseases 0.000 claims description 2
- 238000000338 in vitro Methods 0.000 claims description 2
- 229950011428 indatuximab ravtansine Drugs 0.000 claims description 2
- 229950004101 inotuzumab ozogamicin Drugs 0.000 claims description 2
- 229940043355 kinase inhibitor Drugs 0.000 claims description 2
- 229950003526 lorvotuzumab mertansine Drugs 0.000 claims description 2
- 229950003734 milatuzumab Drugs 0.000 claims description 2
- 102000020233 phosphotransferase Human genes 0.000 claims description 2
- 239000003757 phosphotransferase inhibitor Substances 0.000 claims description 2
- 229950010074 pinatuzumab vedotin Drugs 0.000 claims description 2
- 229950000143 sacituzumab govitecan Drugs 0.000 claims description 2
- ULRUOUDIQPERIJ-PQURJYPBSA-N sacituzumab govitecan Chemical compound N([C@@H](CCCCN)C(=O)NC1=CC=C(C=C1)COC(=O)O[C@]1(CC)C(=O)OCC2=C1C=C1N(C2=O)CC2=C(C3=CC(O)=CC=C3N=C21)CC)C(=O)COCC(=O)NCCOCCOCCOCCOCCOCCOCCOCCOCCN(N=N1)C=C1CNC(=O)C(CC1)CCC1CN1C(=O)CC(SC[C@H](N)C(O)=O)C1=O ULRUOUDIQPERIJ-PQURJYPBSA-N 0.000 claims description 2
- 208000013077 thyroid gland carcinoma Diseases 0.000 claims description 2
- 229960001612 trastuzumab emtansine Drugs 0.000 claims description 2
- 229960005486 vaccine Drugs 0.000 claims description 2
- BNJNAEJASPUJTO-DUOHOMBCSA-N vadastuximab talirine Chemical compound COc1ccc(cc1)C2=CN3[C@@H](C2)C=Nc4cc(OCCCOc5cc6N=C[C@@H]7CC(=CN7C(=O)c6cc5OC)c8ccc(NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)CCCCCN9C(=O)C[C@@H](SC[C@H](N)C(=O)O)C9=O)C(C)C)cc8)c(OC)cc4C3=O BNJNAEJASPUJTO-DUOHOMBCSA-N 0.000 claims description 2
- 206010014733 Endometrial cancer Diseases 0.000 claims 2
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 2
- 206010005949 Bone cancer Diseases 0.000 claims 1
- 208000018084 Bone neoplasm Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 208000000453 Skin Neoplasms Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 201000007281 estrogen-receptor positive breast cancer Diseases 0.000 claims 1
- 201000000849 skin cancer Diseases 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 76
- 210000001672 ovary Anatomy 0.000 description 23
- 230000000694 effects Effects 0.000 description 22
- 229960001078 lithium Drugs 0.000 description 17
- 210000002540 macrophage Anatomy 0.000 description 15
- 210000004443 dendritic cell Anatomy 0.000 description 13
- 230000005764 inhibitory process Effects 0.000 description 13
- 238000011275 oncology therapy Methods 0.000 description 13
- 239000003642 reactive oxygen metabolite Substances 0.000 description 13
- 206010027476 Metastases Diseases 0.000 description 12
- 210000001165 lymph node Anatomy 0.000 description 12
- 210000000440 neutrophil Anatomy 0.000 description 12
- 206010041823 squamous cell carcinoma Diseases 0.000 description 11
- 210000001519 tissue Anatomy 0.000 description 11
- 239000002246 antineoplastic agent Substances 0.000 description 10
- 229940127089 cytotoxic agent Drugs 0.000 description 10
- 230000009401 metastasis Effects 0.000 description 10
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 description 9
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 description 9
- 101150006084 CHKB gene Proteins 0.000 description 8
- 230000012010 growth Effects 0.000 description 8
- 230000003211 malignant effect Effects 0.000 description 8
- UWXSAYUXVSFDBQ-CYBMUJFWSA-N 4-n-[3-chloro-4-(1,3-thiazol-2-ylmethoxy)phenyl]-6-n-[(4r)-4-methyl-4,5-dihydro-1,3-oxazol-2-yl]quinazoline-4,6-diamine Chemical compound C[C@@H]1COC(NC=2C=C3C(NC=4C=C(Cl)C(OCC=5SC=CN=5)=CC=4)=NC=NC3=CC=2)=N1 UWXSAYUXVSFDBQ-CYBMUJFWSA-N 0.000 description 7
- 239000012661 PARP inhibitor Substances 0.000 description 7
- 229940121906 Poly ADP ribose polymerase inhibitor Drugs 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 238000001959 radiotherapy Methods 0.000 description 7
- 229950006605 varlitinib Drugs 0.000 description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- 101000777277 Homo sapiens Serine/threonine-protein kinase Chk2 Proteins 0.000 description 6
- 102100031075 Serine/threonine-protein kinase Chk2 Human genes 0.000 description 6
- 208000006990 cholangiocarcinoma Diseases 0.000 description 6
- 210000000987 immune system Anatomy 0.000 description 6
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 6
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 6
- 150000003839 salts Chemical class 0.000 description 6
- 208000000587 small cell lung carcinoma Diseases 0.000 description 6
- VVIAGPKUTFNRDU-UHFFFAOYSA-N 6S-folinic acid Natural products C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-UHFFFAOYSA-N 0.000 description 5
- 108020002663 Aldehyde Dehydrogenase Proteins 0.000 description 5
- 102000001267 GSK3 Human genes 0.000 description 5
- 206010025323 Lymphomas Diseases 0.000 description 5
- 102100023712 Poly [ADP-ribose] polymerase 1 Human genes 0.000 description 5
- 229940123237 Taxane Drugs 0.000 description 5
- 230000004913 activation Effects 0.000 description 5
- 208000009956 adenocarcinoma Diseases 0.000 description 5
- 208000002458 carcinoid tumor Diseases 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 230000006378 damage Effects 0.000 description 5
- -1 disodium salt Chemical class 0.000 description 5
- VVIAGPKUTFNRDU-ABLWVSNPSA-N folinic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-ABLWVSNPSA-N 0.000 description 5
- 235000008191 folinic acid Nutrition 0.000 description 5
- 239000011672 folinic acid Substances 0.000 description 5
- 238000009169 immunotherapy Methods 0.000 description 5
- 229960001691 leucovorin Drugs 0.000 description 5
- 150000002642 lithium compounds Chemical class 0.000 description 5
- 230000037361 pathway Effects 0.000 description 5
- 230000003389 potentiating effect Effects 0.000 description 5
- 238000009097 single-agent therapy Methods 0.000 description 5
- 208000017572 squamous cell neoplasm Diseases 0.000 description 5
- 206010044412 transitional cell carcinoma Diseases 0.000 description 5
- 102000005369 Aldehyde Dehydrogenase Human genes 0.000 description 4
- 206010003445 Ascites Diseases 0.000 description 4
- 208000005443 Circulating Neoplastic Cells Diseases 0.000 description 4
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 4
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 4
- 101000868279 Homo sapiens Leukocyte surface antigen CD47 Proteins 0.000 description 4
- 102100032913 Leukocyte surface antigen CD47 Human genes 0.000 description 4
- URCVCIZFVQDVPM-UHFFFAOYSA-N N-[2-(4-hydroxyanilino)-3-pyridinyl]-4-methoxybenzenesulfonamide Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)NC1=CC=CN=C1NC1=CC=C(O)C=C1 URCVCIZFVQDVPM-UHFFFAOYSA-N 0.000 description 4
- 208000007571 Ovarian Epithelial Carcinoma Diseases 0.000 description 4
- 108010064218 Poly (ADP-Ribose) Polymerase-1 Proteins 0.000 description 4
- 210000001015 abdomen Anatomy 0.000 description 4
- 238000009825 accumulation Methods 0.000 description 4
- 230000006907 apoptotic process Effects 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 230000030833 cell death Effects 0.000 description 4
- 231100000196 chemotoxic Toxicity 0.000 description 4
- 230000002604 chemotoxic effect Effects 0.000 description 4
- 210000005266 circulating tumour cell Anatomy 0.000 description 4
- 210000004602 germ cell Anatomy 0.000 description 4
- 239000005556 hormone Substances 0.000 description 4
- 229940088597 hormone Drugs 0.000 description 4
- 230000028993 immune response Effects 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 230000036210 malignancy Effects 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 4
- 235000015097 nutrients Nutrition 0.000 description 4
- 230000002611 ovarian Effects 0.000 description 4
- 238000004393 prognosis Methods 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 208000000649 small cell carcinoma Diseases 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 230000004614 tumor growth Effects 0.000 description 4
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 4
- 108010012934 Albumin-Bound Paclitaxel Proteins 0.000 description 3
- 102100032912 CD44 antigen Human genes 0.000 description 3
- 206010007275 Carcinoid tumour Diseases 0.000 description 3
- PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 3
- 101150084967 EPCAM gene Proteins 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- MPJKWIXIYCLVCU-UHFFFAOYSA-N Folinic acid Natural products NC1=NC2=C(N(C=O)C(CNc3ccc(cc3)C(=O)NC(CCC(=O)O)CC(=O)O)CN2)C(=O)N1 MPJKWIXIYCLVCU-UHFFFAOYSA-N 0.000 description 3
- 108010014905 Glycogen Synthase Kinase 3 Proteins 0.000 description 3
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 description 3
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 3
- 102100023652 Poly [ADP-ribose] polymerase 2 Human genes 0.000 description 3
- 101710144590 Poly [ADP-ribose] polymerase 2 Proteins 0.000 description 3
- 208000026149 Primary peritoneal carcinoma Diseases 0.000 description 3
- 206010039491 Sarcoma Diseases 0.000 description 3
- 201000011683 Small Cell Sarcoma Diseases 0.000 description 3
- 206010041067 Small cell lung cancer Diseases 0.000 description 3
- 206010043276 Teratoma Diseases 0.000 description 3
- 208000024770 Thyroid neoplasm Diseases 0.000 description 3
- 229940122803 Vinca alkaloid Drugs 0.000 description 3
- 229940028652 abraxane Drugs 0.000 description 3
- 230000001028 anti-proliverative effect Effects 0.000 description 3
- 210000000612 antigen-presenting cell Anatomy 0.000 description 3
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 3
- 210000001185 bone marrow Anatomy 0.000 description 3
- 210000000481 breast Anatomy 0.000 description 3
- 230000005907 cancer growth Effects 0.000 description 3
- 229940022399 cancer vaccine Drugs 0.000 description 3
- 238000009566 cancer vaccine Methods 0.000 description 3
- 229960004562 carboplatin Drugs 0.000 description 3
- 229960002436 cladribine Drugs 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 229960003668 docetaxel Drugs 0.000 description 3
- 239000000262 estrogen Substances 0.000 description 3
- 201000010985 invasive ductal carcinoma Diseases 0.000 description 3
- 230000002147 killing effect Effects 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 230000002503 metabolic effect Effects 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 201000002524 peritoneal carcinoma Diseases 0.000 description 3
- 230000005855 radiation Effects 0.000 description 3
- 210000003289 regulatory T cell Anatomy 0.000 description 3
- 230000008093 supporting effect Effects 0.000 description 3
- OMPATGZMNFWVOH-UHFFFAOYSA-N 2-[2,6-difluoro-4-(3-methoxyphenyl)anilino]pyridine-3-carboxylic acid Chemical compound COC1=CC=CC(C=2C=C(F)C(NC=3C(=CC=CN=3)C(O)=O)=C(F)C=2)=C1 OMPATGZMNFWVOH-UHFFFAOYSA-N 0.000 description 2
- XAUDJQYHKZQPEU-KVQBGUIXSA-N 5-aza-2'-deoxycytidine Chemical compound O=C1N=C(N)N=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 XAUDJQYHKZQPEU-KVQBGUIXSA-N 0.000 description 2
- HPLNQCPCUACXLM-PGUFJCEWSA-N ABT-737 Chemical compound C([C@@H](CCN(C)C)NC=1C(=CC(=CC=1)S(=O)(=O)NC(=O)C=1C=CC(=CC=1)N1CCN(CC=2C(=CC=CC=2)C=2C=CC(Cl)=CC=2)CC1)[N+]([O-])=O)SC1=CC=CC=C1 HPLNQCPCUACXLM-PGUFJCEWSA-N 0.000 description 2
- 239000012827 ATM inhibitor Substances 0.000 description 2
- QYZOGCMHVIGURT-UHFFFAOYSA-N AZD-1152 Chemical compound N=1C=NC2=CC(OCCCN(CCO)CC)=CC=C2C=1NC(=NN1)C=C1CC(=O)NC1=CC=CC(F)=C1 QYZOGCMHVIGURT-UHFFFAOYSA-N 0.000 description 2
- YDQWDHRMZQUTBA-UHFFFAOYSA-N Aloe emodin Chemical compound C1=CC=C2C(=O)C3=CC(CO)=CC(O)=C3C(=O)C2=C1O YDQWDHRMZQUTBA-UHFFFAOYSA-N 0.000 description 2
- 206010051810 Angiomyolipoma Diseases 0.000 description 2
- 239000012664 BCL-2-inhibitor Substances 0.000 description 2
- 229940123711 Bcl2 inhibitor Drugs 0.000 description 2
- 206010072813 Breast angiosarcoma Diseases 0.000 description 2
- 208000009458 Carcinoma in Situ Diseases 0.000 description 2
- 201000000274 Carcinosarcoma Diseases 0.000 description 2
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 2
- 206010009253 Clear cell sarcoma of the kidney Diseases 0.000 description 2
- 206010012335 Dependence Diseases 0.000 description 2
- 108010052167 Dihydroorotate Dehydrogenase Proteins 0.000 description 2
- 102100032823 Dihydroorotate dehydrogenase (quinone), mitochondrial Human genes 0.000 description 2
- 229940083266 Dihydroorotate dehydrogenase inhibitor Drugs 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 102100023513 Flotillin-2 Human genes 0.000 description 2
- 101710164820 Flotillin-2 Proteins 0.000 description 2
- 108060006662 GSK3 Proteins 0.000 description 2
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 2
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 2
- 101000884271 Homo sapiens Signal transducer CD24 Proteins 0.000 description 2
- 206010021143 Hypoxia Diseases 0.000 description 2
- 102000004388 Interleukin-4 Human genes 0.000 description 2
- 108090000978 Interleukin-4 Proteins 0.000 description 2
- 208000037396 Intraductal Noninfiltrating Carcinoma Diseases 0.000 description 2
- 206010073094 Intraductal proliferative breast lesion Diseases 0.000 description 2
- 206010073099 Lobular breast carcinoma in situ Diseases 0.000 description 2
- GQYIWUVLTXOXAJ-UHFFFAOYSA-N Lomustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 description 2
- 210000004322 M2 macrophage Anatomy 0.000 description 2
- 206010070665 Mesoblastic nephroma Diseases 0.000 description 2
- 229940122255 Microtubule inhibitor Drugs 0.000 description 2
- 208000019022 Mood disease Diseases 0.000 description 2
- 206010073101 Mucinous breast carcinoma Diseases 0.000 description 2
- ZRKWMRDKSOPRRS-UHFFFAOYSA-N N-Methyl-N-nitrosourea Chemical compound O=NN(C)C(N)=O ZRKWMRDKSOPRRS-UHFFFAOYSA-N 0.000 description 2
- 208000034176 Neoplasms, Germ Cell and Embryonal Diseases 0.000 description 2
- 208000010191 Osteitis Deformans Diseases 0.000 description 2
- 208000027868 Paget disease Diseases 0.000 description 2
- 206010057249 Phagocytosis Diseases 0.000 description 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
- 208000006265 Renal cell carcinoma Diseases 0.000 description 2
- 102100038081 Signal transducer CD24 Human genes 0.000 description 2
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 description 2
- IVTVGDXNLFLDRM-HNNXBMFYSA-N Tomudex Chemical compound C=1C=C2NC(C)=NC(=O)C2=CC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)S1 IVTVGDXNLFLDRM-HNNXBMFYSA-N 0.000 description 2
- 206010073104 Tubular breast carcinoma Diseases 0.000 description 2
- 208000008383 Wilms tumor Diseases 0.000 description 2
- 101100514842 Xenopus laevis mtus1 gene Proteins 0.000 description 2
- 230000003187 abdominal effect Effects 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 208000025084 adenoid cystic breast carcinoma Diseases 0.000 description 2
- 238000009098 adjuvant therapy Methods 0.000 description 2
- 230000002491 angiogenic effect Effects 0.000 description 2
- 238000011319 anticancer therapy Methods 0.000 description 2
- 229940045719 antineoplastic alkylating agent nitrosoureas Drugs 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 239000003719 aurora kinase inhibitor Substances 0.000 description 2
- 230000001363 autoimmune Effects 0.000 description 2
- 230000004900 autophagic degradation Effects 0.000 description 2
- 150000001541 aziridines Chemical class 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 210000001772 blood platelet Anatomy 0.000 description 2
- 201000005389 breast carcinoma in situ Diseases 0.000 description 2
- 201000007476 breast mucinous carcinoma Diseases 0.000 description 2
- 201000000135 breast papillary carcinoma Diseases 0.000 description 2
- 210000000621 bronchi Anatomy 0.000 description 2
- 230000000981 bystander Effects 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 230000022131 cell cycle Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000012829 chemotherapy agent Substances 0.000 description 2
- 208000009060 clear cell adenocarcinoma Diseases 0.000 description 2
- 208000030748 clear cell sarcoma of kidney Diseases 0.000 description 2
- 201000010276 collecting duct carcinoma Diseases 0.000 description 2
- 238000011284 combination treatment Methods 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 229950006418 dactolisib Drugs 0.000 description 2
- JOGKUKXHTYWRGZ-UHFFFAOYSA-N dactolisib Chemical compound O=C1N(C)C2=CN=C3C=CC(C=4C=C5C=CC=CC5=NC=4)=CC3=C2N1C1=CC=C(C(C)(C)C#N)C=C1 JOGKUKXHTYWRGZ-UHFFFAOYSA-N 0.000 description 2
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 2
- 210000004544 dc2 Anatomy 0.000 description 2
- 229960003603 decitabine Drugs 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000007123 defense Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- WVYXNIXAMZOZFK-UHFFFAOYSA-N diaziquone Chemical compound O=C1C(NC(=O)OCC)=C(N2CC2)C(=O)C(NC(=O)OCC)=C1N1CC1 WVYXNIXAMZOZFK-UHFFFAOYSA-N 0.000 description 2
- 208000028715 ductal breast carcinoma in situ Diseases 0.000 description 2
- 201000007273 ductal carcinoma in situ Diseases 0.000 description 2
- 235000013601 eggs Nutrition 0.000 description 2
- 230000002124 endocrine Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 210000000981 epithelium Anatomy 0.000 description 2
- HESCAJZNRMSMJG-KKQRBIROSA-N epothilone A Chemical compound C/C([C@@H]1C[C@@H]2O[C@@H]2CCC[C@@H]([C@@H]([C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1)O)C)=C\C1=CSC(C)=N1 HESCAJZNRMSMJG-KKQRBIROSA-N 0.000 description 2
- HESCAJZNRMSMJG-HGYUPSKWSA-N epothilone A Natural products O=C1[C@H](C)[C@H](O)[C@H](C)CCC[C@H]2O[C@H]2C[C@@H](/C(=C\c2nc(C)sc2)/C)OC(=O)C[C@H](O)C1(C)C HESCAJZNRMSMJG-HGYUPSKWSA-N 0.000 description 2
- 229940011871 estrogen Drugs 0.000 description 2
- 210000001808 exosome Anatomy 0.000 description 2
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 2
- IRSCQMHQWWYFCW-UHFFFAOYSA-N ganciclovir Chemical compound O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 description 2
- 229960002963 ganciclovir Drugs 0.000 description 2
- 201000006585 gastric adenocarcinoma Diseases 0.000 description 2
- 208000016356 hereditary diffuse gastric adenocarcinoma Diseases 0.000 description 2
- 230000007954 hypoxia Effects 0.000 description 2
- 230000007124 immune defense Effects 0.000 description 2
- 230000003308 immunostimulating effect Effects 0.000 description 2
- 201000004933 in situ carcinoma Diseases 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 208000030776 invasive breast carcinoma Diseases 0.000 description 2
- 201000002696 invasive tubular breast carcinoma Diseases 0.000 description 2
- 201000010151 inverted papilloma Diseases 0.000 description 2
- 208000024596 kidney oncocytoma Diseases 0.000 description 2
- 210000000244 kidney pelvis Anatomy 0.000 description 2
- 208000003849 large cell carcinoma Diseases 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 229910003002 lithium salt Inorganic materials 0.000 description 2
- 159000000002 lithium salts Chemical class 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 201000011059 lobular neoplasia Diseases 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- HAVFFEMDLROBGI-UHFFFAOYSA-N m8926c7ilx Chemical compound C1CC(O)CCN1CC1=CC=C(OC=2C3=C(C(NN=C33)=O)C=CC=2)C3=C1 HAVFFEMDLROBGI-UHFFFAOYSA-N 0.000 description 2
- 229940124302 mTOR inhibitor Drugs 0.000 description 2
- 239000003628 mammalian target of rapamycin inhibitor Substances 0.000 description 2
- 208000027202 mammary Paget disease Diseases 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- 208000037819 metastatic cancer Diseases 0.000 description 2
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 2
- 231100000782 microtubule inhibitor Toxicity 0.000 description 2
- 239000002829 mitogen activated protein kinase inhibitor Substances 0.000 description 2
- 208000022951 mixed epithelial stromal tumor Diseases 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- GXPTVXHTZZVLMQ-GCGJSEPQSA-N myrtillin Natural products O[C@H]1O[C@@H](OCC2=C(OC3=CC(=O)C=C(O)C3=C2)c4cc(O)c(O)c(O)c4)[C@H](O)[C@@H](O)[C@@H]1O GXPTVXHTZZVLMQ-GCGJSEPQSA-N 0.000 description 2
- NFVJNJQRWPQVOA-UHFFFAOYSA-N n-[2-chloro-5-(trifluoromethyl)phenyl]-2-[3-(4-ethyl-5-ethylsulfanyl-1,2,4-triazol-3-yl)piperidin-1-yl]acetamide Chemical compound CCN1C(SCC)=NN=C1C1CN(CC(=O)NC=2C(=CC=C(C=2)C(F)(F)F)Cl)CCC1 NFVJNJQRWPQVOA-UHFFFAOYSA-N 0.000 description 2
- 230000017074 necrotic cell death Effects 0.000 description 2
- 230000001338 necrotic effect Effects 0.000 description 2
- 238000006386 neutralization reaction Methods 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000008782 phagocytosis Effects 0.000 description 2
- 230000036470 plasma concentration Effects 0.000 description 2
- 229910052697 platinum Inorganic materials 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 239000002574 poison Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 229940002612 prodrug Drugs 0.000 description 2
- 239000000651 prodrug Substances 0.000 description 2
- 230000009682 proliferation pathway Effects 0.000 description 2
- 210000002307 prostate Anatomy 0.000 description 2
- 239000003197 protein kinase B inhibitor Substances 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 150000003230 pyrimidines Chemical class 0.000 description 2
- 208000005039 renal oncocytoma Diseases 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 230000007480 spreading Effects 0.000 description 2
- 238000003892 spreading Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000003319 supportive effect Effects 0.000 description 2
- ULSUXBXHSYSGDT-UHFFFAOYSA-N tangeretin Chemical compound C1=CC(OC)=CC=C1C1=CC(=O)C2=C(OC)C(OC)=C(OC)C(OC)=C2O1 ULSUXBXHSYSGDT-UHFFFAOYSA-N 0.000 description 2
- 229960004964 temozolomide Drugs 0.000 description 2
- 150000004905 tetrazines Chemical class 0.000 description 2
- 201000002510 thyroid cancer Diseases 0.000 description 2
- 238000011269 treatment regimen Methods 0.000 description 2
- 210000004291 uterus Anatomy 0.000 description 2
- AQTQHPDCURKLKT-JKDPCDLQSA-N vincristine sulfate Chemical compound OS(O)(=O)=O.C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C=O)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 AQTQHPDCURKLKT-JKDPCDLQSA-N 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- DENYZIUJOTUUNY-MRXNPFEDSA-N (2R)-14-fluoro-2-methyl-6,9,10,19-tetrazapentacyclo[14.2.1.02,6.08,18.012,17]nonadeca-1(18),8,12(17),13,15-pentaen-11-one Chemical compound FC=1C=C2C=3C=4C(CN5[C@@](C4NC3C1)(CCC5)C)=NNC2=O DENYZIUJOTUUNY-MRXNPFEDSA-N 0.000 description 1
- HBUBKKRHXORPQB-FJFJXFQQSA-N (2R,3S,4S,5R)-2-(6-amino-2-fluoro-9-purinyl)-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O HBUBKKRHXORPQB-FJFJXFQQSA-N 0.000 description 1
- ZOQQFMKYEOHRMC-KFOCXKDFSA-N (2r,3r,4r,5r,6s)-2-[[(2r,3s,4s,5r,6s)-6-[5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)chromenylium-3-yl]oxy-3,4,5-trihydroxyoxan-2-yl]methoxy]-6-methyloxane-3,4,5-triol;chloride Chemical compound [Cl-].O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OC=2C(=[O+]C3=CC(O)=CC(O)=C3C=2)C=2C=C(O)C(O)=C(O)C=2)O1 ZOQQFMKYEOHRMC-KFOCXKDFSA-N 0.000 description 1
- YXTKHLHCVFUPPT-YYFJYKOTSA-N (2s)-2-[[4-[(2-amino-5-formyl-4-oxo-1,6,7,8-tetrahydropteridin-6-yl)methylamino]benzoyl]amino]pentanedioic acid;(1r,2r)-1,2-dimethanidylcyclohexane;5-fluoro-1h-pyrimidine-2,4-dione;oxalic acid;platinum(2+) Chemical compound [Pt+2].OC(=O)C(O)=O.[CH2-][C@@H]1CCCC[C@H]1[CH2-].FC1=CNC(=O)NC1=O.C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 YXTKHLHCVFUPPT-YYFJYKOTSA-N 0.000 description 1
- ZVAGBRFUYHSUHA-LZOXOEDVSA-N (2z)-2-[(5z)-5-[(3,5-dimethyl-1h-pyrrol-2-yl)methylidene]-4-methoxypyrrol-2-ylidene]indole;methanesulfonic acid Chemical compound CS(O)(=O)=O.COC1=C\C(=C/2N=C3C=CC=CC3=C\2)N\C1=C/C=1NC(C)=CC=1C ZVAGBRFUYHSUHA-LZOXOEDVSA-N 0.000 description 1
- DMASLKHVQRHNES-UPOGUZCLSA-N (3R)-beta,beta-caroten-3-ol Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C DMASLKHVQRHNES-UPOGUZCLSA-N 0.000 description 1
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- JYRJOQGKGMHTOO-SOFGYWHQSA-N (4e)-4-(2-amino-4-oxo-1h-imidazol-5-ylidene)-1,5,6,7-tetrahydropyrrolo[2,3-c]azepin-8-one Chemical compound N1C(N)=NC(=O)\C1=C\1C(C=CN2)=C2C(=O)NCC/1 JYRJOQGKGMHTOO-SOFGYWHQSA-N 0.000 description 1
- JYRJOQGKGMHTOO-VURMDHGXSA-N (4z)-4-(2-amino-4-oxo-1h-imidazol-5-ylidene)-1,5,6,7-tetrahydropyrrolo[2,3-c]azepin-8-one Chemical compound N1C(N)=NC(=O)\C1=C/1C(C=CN2)=C2C(=O)NCC\1 JYRJOQGKGMHTOO-VURMDHGXSA-N 0.000 description 1
- MWWSFMDVAYGXBV-MYPASOLCSA-N (7r,9s)-7-[(2r,4s,5s,6s)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7h-tetracene-5,12-dione;hydrochloride Chemical compound Cl.O([C@@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 MWWSFMDVAYGXBV-MYPASOLCSA-N 0.000 description 1
- FPVKHBSQESCIEP-UHFFFAOYSA-N (8S)-3-(2-deoxy-beta-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol Natural products C1C(O)C(CO)OC1N1C(NC=NCC2O)=C2N=C1 FPVKHBSQESCIEP-UHFFFAOYSA-N 0.000 description 1
- KJPRLNWUNMBNBZ-QPJJXVBHSA-N (E)-cinnamaldehyde Chemical compound O=C\C=C\C1=CC=CC=C1 KJPRLNWUNMBNBZ-QPJJXVBHSA-N 0.000 description 1
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 1
- FYCODPVDEFFWSR-UHFFFAOYSA-N 1-(3-chlorophenyl)-3-[5-[2-(thieno[3,2-d]pyrimidin-4-ylamino)ethyl]-1,3-thiazol-2-yl]urea;methanesulfonic acid Chemical compound CS(O)(=O)=O.N=1C=C(CCN=C2C=3SC=CC=3N=CN2)SC=1NC(O)=NC1=CC=CC(Cl)=C1 FYCODPVDEFFWSR-UHFFFAOYSA-N 0.000 description 1
- CTLOSZHDGZLOQE-UHFFFAOYSA-N 14-methoxy-9-[(4-methylpiperazin-1-yl)methyl]-9,19-diazapentacyclo[10.7.0.02,6.07,11.013,18]nonadeca-1(12),2(6),7(11),13(18),14,16-hexaene-8,10-dione Chemical compound O=C1C2=C3C=4C(OC)=CC=CC=4NC3=C3CCCC3=C2C(=O)N1CN1CCN(C)CC1 CTLOSZHDGZLOQE-UHFFFAOYSA-N 0.000 description 1
- QFWCYNPOPKQOKV-UHFFFAOYSA-N 2-(2-amino-3-methoxyphenyl)chromen-4-one Chemical compound COC1=CC=CC(C=2OC3=CC=CC=C3C(=O)C=2)=C1N QFWCYNPOPKQOKV-UHFFFAOYSA-N 0.000 description 1
- GFMMXOIFOQCCGU-UHFFFAOYSA-N 2-(2-chloro-4-iodoanilino)-N-(cyclopropylmethoxy)-3,4-difluorobenzamide Chemical compound C=1C=C(I)C=C(Cl)C=1NC1=C(F)C(F)=CC=C1C(=O)NOCC1CC1 GFMMXOIFOQCCGU-UHFFFAOYSA-N 0.000 description 1
- RWEVIPRMPFNTLO-UHFFFAOYSA-N 2-(2-fluoro-4-iodoanilino)-N-(2-hydroxyethoxy)-1,5-dimethyl-6-oxo-3-pyridinecarboxamide Chemical compound CN1C(=O)C(C)=CC(C(=O)NOCCO)=C1NC1=CC=C(I)C=C1F RWEVIPRMPFNTLO-UHFFFAOYSA-N 0.000 description 1
- QYKHWEFPFAGNEV-UHFFFAOYSA-N 2-[4-[6-chloro-2-[4-(dimethylamino)phenyl]-1h-imidazo[4,5-b]pyridin-7-yl]piperazin-1-yl]-n-(1,3-thiazol-2-yl)acetamide Chemical compound C1=CC(N(C)C)=CC=C1C(NC1=NC=C2Cl)=NC1=C2N1CCN(CC(=O)NC=2SC=CN=2)CC1 QYKHWEFPFAGNEV-UHFFFAOYSA-N 0.000 description 1
- SXJDCULZDFWMJC-UHFFFAOYSA-N 2-amino-6-bromo-4-(1-cyano-2-ethoxy-2-oxoethyl)-4H-1-benzopyran-3-carboxylic acid ethyl ester Chemical compound C1=C(Br)C=C2C(C(C#N)C(=O)OCC)C(C(=O)OCC)=C(N)OC2=C1 SXJDCULZDFWMJC-UHFFFAOYSA-N 0.000 description 1
- NDMPLJNOPCLANR-UHFFFAOYSA-N 3,4-dihydroxy-15-(4-hydroxy-18-methoxycarbonyl-5,18-seco-ibogamin-18-yl)-16-methoxy-1-methyl-6,7-didehydro-aspidospermidine-3-carboxylic acid methyl ester Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 NDMPLJNOPCLANR-UHFFFAOYSA-N 0.000 description 1
- HDBQZGJWHMCXIL-UHFFFAOYSA-N 3,7-dihydropurine-2-thione Chemical compound SC1=NC=C2NC=NC2=N1 HDBQZGJWHMCXIL-UHFFFAOYSA-N 0.000 description 1
- XEZLBMHDUXSICI-UHFFFAOYSA-N 3-(1-ethylpiperidin-4-yl)oxy-5,8,10-triazatricyclo[7.4.0.02,7]trideca-1(9),2,4,6,10,12-hexaene-4-carbonitrile Chemical compound C1CN(CC)CCC1OC1=C(C#N)N=CC2=C1C1=CC=CN=C1N2 XEZLBMHDUXSICI-UHFFFAOYSA-N 0.000 description 1
- WGPXKFOFEXJMBD-UHFFFAOYSA-N 3-[N-[3-[(dimethylamino)methyl]phenyl]-C-phenylcarbonimidoyl]-2-hydroxy-1H-indole-6-carboxamide Chemical compound CN(C)CC1=CC(=CC=C1)N=C(C2=CC=CC=C2)C3=C(NC4=C3C=CC(=C4)C(=O)N)O WGPXKFOFEXJMBD-UHFFFAOYSA-N 0.000 description 1
- ZGXOBLVQIVXKEB-UHFFFAOYSA-N 3-[N-[3-[(dimethylamino)methyl]phenyl]-C-phenylcarbonimidoyl]-2-hydroxy-N,N-dimethyl-1H-indole-6-carboxamide Chemical compound CN(C)CC1=CC(=CC=C1)N=C(C2=CC=CC=C2)C3=C(NC4=C3C=CC(=C4)C(=O)N(C)C)O ZGXOBLVQIVXKEB-UHFFFAOYSA-N 0.000 description 1
- GSCPDZHWVNUUFI-UHFFFAOYSA-N 3-aminobenzamide Chemical compound NC(=O)C1=CC=CC(N)=C1 GSCPDZHWVNUUFI-UHFFFAOYSA-N 0.000 description 1
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 1
- MOVBBVMDHIRCTG-LJQANCHMSA-N 4-[(3s)-1-azabicyclo[2.2.2]oct-3-ylamino]-3-(1h-benzimidazol-2-yl)-6-chloroquinolin-2(1h)-one Chemical compound C([N@](CC1)C2)C[C@@H]1[C@@H]2NC1=C(C=2NC3=CC=CC=C3N=2)C(=O)NC2=CC=C(Cl)C=C21 MOVBBVMDHIRCTG-LJQANCHMSA-N 0.000 description 1
- IMXHGCRIEAKIBU-UHFFFAOYSA-N 4-[6-[4-(methoxycarbonylamino)phenyl]-4-(4-morpholinyl)-1-pyrazolo[3,4-d]pyrimidinyl]-1-piperidinecarboxylic acid methyl ester Chemical compound C1=CC(NC(=O)OC)=CC=C1C1=NC(N2CCOCC2)=C(C=NN2C3CCN(CC3)C(=O)OC)C2=N1 IMXHGCRIEAKIBU-UHFFFAOYSA-N 0.000 description 1
- XXSSGBYXSKOLAM-UHFFFAOYSA-N 5-bromo-n-(2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodoanilino)benzamide Chemical compound OCC(O)CONC(=O)C1=CC(Br)=C(F)C(F)=C1NC1=CC=C(I)C=C1F XXSSGBYXSKOLAM-UHFFFAOYSA-N 0.000 description 1
- SSPYSWLZOPCOLO-UHFFFAOYSA-N 6-azauracil Chemical compound O=C1C=NNC(=O)N1 SSPYSWLZOPCOLO-UHFFFAOYSA-N 0.000 description 1
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
- 102100026802 72 kDa type IV collagenase Human genes 0.000 description 1
- 101710151806 72 kDa type IV collagenase Proteins 0.000 description 1
- RFWGABANNQMHMZ-UHFFFAOYSA-N 8-acetoxy-7-acetyl-6,7,7a,8-tetrahydro-5H-benzo[g][1,3]dioxolo[4',5':4,5]benzo[1,2,3-de]quinoline Natural products CC=C1C(CC(=O)OCCC=2C=C(O)C(O)=CC=2)C(C(=O)OC)=COC1OC1OC(CO)C(O)C(O)C1O RFWGABANNQMHMZ-UHFFFAOYSA-N 0.000 description 1
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 description 1
- BUROJSBIWGDYCN-GAUTUEMISA-N AP 23573 Chemical compound C1C[C@@H](OP(C)(C)=O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 BUROJSBIWGDYCN-GAUTUEMISA-N 0.000 description 1
- KVLFRAWTRWDEDF-IRXDYDNUSA-N AZD-8055 Chemical compound C1=C(CO)C(OC)=CC=C1C1=CC=C(C(=NC(=N2)N3[C@H](COCC3)C)N3[C@H](COCC3)C)C2=N1 KVLFRAWTRWDEDF-IRXDYDNUSA-N 0.000 description 1
- 208000036764 Adenocarcinoma of the esophagus Diseases 0.000 description 1
- 208000003200 Adenoma Diseases 0.000 description 1
- 102100034540 Adenomatous polyposis coli protein Human genes 0.000 description 1
- 229940126638 Akt inhibitor Drugs 0.000 description 1
- 208000001446 Anaplastic Thyroid Carcinoma Diseases 0.000 description 1
- 206010002240 Anaplastic thyroid cancer Diseases 0.000 description 1
- 201000003076 Angiosarcoma Diseases 0.000 description 1
- 102000002804 Ataxia Telangiectasia Mutated Proteins Human genes 0.000 description 1
- 108010004586 Ataxia Telangiectasia Mutated Proteins Proteins 0.000 description 1
- 229940123877 Aurora kinase inhibitor Drugs 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 102100037086 Bone marrow stromal antigen 2 Human genes 0.000 description 1
- 208000007690 Brenner tumor Diseases 0.000 description 1
- 206010073258 Brenner tumour Diseases 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- 208000003170 Bronchiolo-Alveolar Adenocarcinoma Diseases 0.000 description 1
- 206010058354 Bronchioloalveolar carcinoma Diseases 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- 102100040840 C-type lectin domain family 7 member A Human genes 0.000 description 1
- 102100024217 CAMPATH-1 antigen Human genes 0.000 description 1
- 101150013553 CD40 gene Proteins 0.000 description 1
- 108010065524 CD52 Antigen Proteins 0.000 description 1
- 101150113634 CDKN1A gene Proteins 0.000 description 1
- 229940127562 CSL324 Drugs 0.000 description 1
- FVLVBPDQNARYJU-XAHDHGMMSA-N C[C@H]1CCC(CC1)NC(=O)N(CCCl)N=O Chemical compound C[C@H]1CCC(CC1)NC(=O)N(CCCl)N=O FVLVBPDQNARYJU-XAHDHGMMSA-N 0.000 description 1
- 101100463133 Caenorhabditis elegans pdl-1 gene Proteins 0.000 description 1
- 206010065305 Cancer in remission Diseases 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- VWDXGKUTGQJJHJ-UHFFFAOYSA-N Catenarin Natural products C1=C(O)C=C2C(=O)C3=C(O)C(C)=CC(O)=C3C(=O)C2=C1O VWDXGKUTGQJJHJ-UHFFFAOYSA-N 0.000 description 1
- 229940123587 Cell cycle inhibitor Drugs 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 102100039496 Choline transporter-like protein 4 Human genes 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 206010010144 Completed suicide Diseases 0.000 description 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 description 1
- JYRJOQGKGMHTOO-UHFFFAOYSA-N Debromohymenialdisine hydrochloride Natural products N1C(N)=NC(=O)C1=C1C(C=CN2)=C2C(=O)NCC1 JYRJOQGKGMHTOO-UHFFFAOYSA-N 0.000 description 1
- GCPYCNBGGPHOBD-UHFFFAOYSA-N Delphinidin Natural products OC1=Cc2c(O)cc(O)cc2OC1=C3C=C(O)C(=O)C(=C3)O GCPYCNBGGPHOBD-UHFFFAOYSA-N 0.000 description 1
- OIZFQAFWYYKPMR-PEVLUNPASA-N Delphinidin 3-O-glucoside Natural products O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)C=1[C-](c2cc(O)c(O)c(O)c2)[O+]c2c(c(O)cc(O)c2)C=1 OIZFQAFWYYKPMR-PEVLUNPASA-N 0.000 description 1
- HKVGJQVJNQRJPO-UHFFFAOYSA-N Demethyloleuropein Natural products O1C=C(C(O)=O)C(CC(=O)OCCC=2C=C(O)C(O)=CC=2)C(=CC)C1OC1OC(CO)C(O)C(O)C1O HKVGJQVJNQRJPO-UHFFFAOYSA-N 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 208000007033 Dysgerminoma Diseases 0.000 description 1
- 239000010282 Emodin Substances 0.000 description 1
- RBLJKYCRSCQLRP-UHFFFAOYSA-N Emodin-dianthron Natural products O=C1C2=CC(C)=CC(O)=C2C(=O)C2=C1CC(=O)C=C2O RBLJKYCRSCQLRP-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 description 1
- 206010016935 Follicular thyroid cancer Diseases 0.000 description 1
- 208000022072 Gallbladder Neoplasms Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- 206010018404 Glucagonoma Diseases 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
- YOOXNSPYGCZLAX-UHFFFAOYSA-N Helminthosporin Natural products C1=CC(O)=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O YOOXNSPYGCZLAX-UHFFFAOYSA-N 0.000 description 1
- 208000001258 Hemangiosarcoma Diseases 0.000 description 1
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 description 1
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 description 1
- 101000924577 Homo sapiens Adenomatous polyposis coli protein Proteins 0.000 description 1
- 101000740785 Homo sapiens Bone marrow stromal antigen 2 Proteins 0.000 description 1
- 101000889282 Homo sapiens Choline transporter-like protein 4 Proteins 0.000 description 1
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 description 1
- 101001068133 Homo sapiens Hepatitis A virus cellular receptor 2 Proteins 0.000 description 1
- 101000984199 Homo sapiens Leukocyte immunoglobulin-like receptor subfamily A member 4 Proteins 0.000 description 1
- 101001137987 Homo sapiens Lymphocyte activation gene 3 protein Proteins 0.000 description 1
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 description 1
- 101000979623 Homo sapiens Nucleoside diphosphate kinase B Proteins 0.000 description 1
- 101000610551 Homo sapiens Prominin-1 Proteins 0.000 description 1
- 101000845170 Homo sapiens Thymic stromal lymphopoietin Proteins 0.000 description 1
- 101000801234 Homo sapiens Tumor necrosis factor receptor superfamily member 18 Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- OBYGAPWKTPDTAS-OCAPTIKFSA-N ICRF-193 Chemical compound N1([C@H](C)[C@H](C)N2CC(=O)NC(=O)C2)CC(=O)NC(=O)C1 OBYGAPWKTPDTAS-OCAPTIKFSA-N 0.000 description 1
- XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 description 1
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 description 1
- 102000037982 Immune checkpoint proteins Human genes 0.000 description 1
- 108091008036 Immune checkpoint proteins Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102100023915 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102000003812 Interleukin-15 Human genes 0.000 description 1
- 108090000172 Interleukin-15 Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 102000000588 Interleukin-2 Human genes 0.000 description 1
- 108010038452 Interleukin-3 Receptors Proteins 0.000 description 1
- 102000010790 Interleukin-3 Receptors Human genes 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 102000017578 LAG3 Human genes 0.000 description 1
- 208000018142 Leiomyosarcoma Diseases 0.000 description 1
- 102100025555 Leukocyte immunoglobulin-like receptor subfamily A member 4 Human genes 0.000 description 1
- 206010061523 Lip and/or oral cavity cancer Diseases 0.000 description 1
- 208000007433 Lymphatic Metastasis Diseases 0.000 description 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
- 102000043136 MAP kinase family Human genes 0.000 description 1
- 108091054455 MAP kinase family Proteins 0.000 description 1
- 229940124647 MEK inhibitor Drugs 0.000 description 1
- 102000043129 MHC class I family Human genes 0.000 description 1
- 108091054437 MHC class I family Proteins 0.000 description 1
- 229940124640 MK-2206 Drugs 0.000 description 1
- 101710175243 Major antigen Proteins 0.000 description 1
- 102100030412 Matrix metalloproteinase-9 Human genes 0.000 description 1
- 108010015302 Matrix metalloproteinase-9 Proteins 0.000 description 1
- 208000009018 Medullary thyroid cancer Diseases 0.000 description 1
- 208000003445 Mouth Neoplasms Diseases 0.000 description 1
- 206010073149 Multiple endocrine neoplasia Type 2 Diseases 0.000 description 1
- 206010073148 Multiple endocrine neoplasia type 2A Diseases 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 1
- VIUAUNHCRHHYNE-JTQLQIEISA-N N-[(2S)-2,3-dihydroxypropyl]-3-(2-fluoro-4-iodoanilino)-4-pyridinecarboxamide Chemical compound OC[C@@H](O)CNC(=O)C1=CC=NC=C1NC1=CC=C(I)C=C1F VIUAUNHCRHHYNE-JTQLQIEISA-N 0.000 description 1
- PQAPVTKIEGUPRN-UHFFFAOYSA-N N-[4-(2-tert-butylphenyl)sulfonylphenyl]-2,3,4-trihydroxy-5-[(2-propan-2-ylphenyl)methyl]benzamide Chemical compound CC(C)C1=CC=CC=C1CC1=CC(C(=O)NC=2C=CC(=CC=2)S(=O)(=O)C=2C(=CC=CC=2)C(C)(C)C)=C(O)C(O)=C1O PQAPVTKIEGUPRN-UHFFFAOYSA-N 0.000 description 1
- BLTCBVOJNNKFKC-QUDYQQOWSA-N N-acetylsphingosine Chemical compound CCCCCCCCCCCCC\C=C\[C@@H](O)[C@H](CO)NC(C)=O BLTCBVOJNNKFKC-QUDYQQOWSA-N 0.000 description 1
- 206010028767 Nasal sinus cancer Diseases 0.000 description 1
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 description 1
- 206010061306 Nasopharyngeal cancer Diseases 0.000 description 1
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 description 1
- 206010052399 Neuroendocrine tumour Diseases 0.000 description 1
- 102100023258 Nucleoside diphosphate kinase B Human genes 0.000 description 1
- 206010030137 Oesophageal adenocarcinoma Diseases 0.000 description 1
- 206010061534 Oesophageal squamous cell carcinoma Diseases 0.000 description 1
- RFWGABANNQMHMZ-HYYSZPHDSA-N Oleuropein Chemical compound O([C@@H]1OC=C([C@H](C1=CC)CC(=O)OCCC=1C=C(O)C(O)=CC=1)C(=O)OC)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O RFWGABANNQMHMZ-HYYSZPHDSA-N 0.000 description 1
- 206010031096 Oropharyngeal cancer Diseases 0.000 description 1
- 206010057444 Oropharyngeal neoplasm Diseases 0.000 description 1
- 206010070905 Ovarian cancer stage I Diseases 0.000 description 1
- 239000012826 P38 inhibitor Substances 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 102100035593 POU domain, class 2, transcription factor 1 Human genes 0.000 description 1
- 101710084414 POU domain, class 2, transcription factor 1 Proteins 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 206010033701 Papillary thyroid cancer Diseases 0.000 description 1
- 208000003937 Paranasal Sinus Neoplasms Diseases 0.000 description 1
- UIMHJAOZYISGTJ-UHFFFAOYSA-N Pathenolide Natural products CC1=C/CCC2(C)OC2C3CC(=O)C(=C)C3CC1 UIMHJAOZYISGTJ-UHFFFAOYSA-N 0.000 description 1
- 206010034133 Pathogen resistance Diseases 0.000 description 1
- 241001440127 Phyllodes Species 0.000 description 1
- 208000002163 Phyllodes Tumor Diseases 0.000 description 1
- 206010071776 Phyllodes tumour Diseases 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 101710179684 Poly [ADP-ribose] polymerase Proteins 0.000 description 1
- 229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 description 1
- HCBIBCJNVBAKAB-UHFFFAOYSA-N Procaine hydrochloride Chemical compound Cl.CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 HCBIBCJNVBAKAB-UHFFFAOYSA-N 0.000 description 1
- 102100040120 Prominin-1 Human genes 0.000 description 1
- 238000003559 RNA-seq method Methods 0.000 description 1
- 206010063837 Reperfusion injury Diseases 0.000 description 1
- NTGIIKCGBNGQAR-UHFFFAOYSA-N Rheoemodin Natural products C1=C(O)C=C2C(=O)C3=CC(O)=CC(O)=C3C(=O)C2=C1O NTGIIKCGBNGQAR-UHFFFAOYSA-N 0.000 description 1
- 208000004337 Salivary Gland Neoplasms Diseases 0.000 description 1
- 206010061934 Salivary gland cancer Diseases 0.000 description 1
- 208000000097 Sertoli-Leydig cell tumor Diseases 0.000 description 1
- 206010041329 Somatostatinoma Diseases 0.000 description 1
- 208000036765 Squamous cell carcinoma of the esophagus Diseases 0.000 description 1
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 1
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical class [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
- 102000008221 Superoxide Dismutase-1 Human genes 0.000 description 1
- 108010021188 Superoxide Dismutase-1 Proteins 0.000 description 1
- 230000006052 T cell proliferation Effects 0.000 description 1
- IECRXMSGDFIOEY-UHFFFAOYSA-N Tangeretin Natural products COC=1C(OC)=C(OC)C(OC)=C(C(C=2)=O)C=1OC=2C1=CC=C(O)C=C1 IECRXMSGDFIOEY-UHFFFAOYSA-N 0.000 description 1
- HYXITZLLTYIPOF-UHFFFAOYSA-N Tanshinone II Natural products O=C1C(=O)C2=C3CCCC(C)(C)C3=CC=C2C2=C1C(C)=CO2 HYXITZLLTYIPOF-UHFFFAOYSA-N 0.000 description 1
- CBPNZQVSJQDFBE-FUXHJELOSA-N Temsirolimus Chemical compound C1C[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 CBPNZQVSJQDFBE-FUXHJELOSA-N 0.000 description 1
- FOCVUCIESVLUNU-UHFFFAOYSA-N Thiotepa Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 description 1
- 102100031294 Thymic stromal lymphopoietin Human genes 0.000 description 1
- 208000033781 Thyroid carcinoma Diseases 0.000 description 1
- 201000000170 Thyroid lymphoma Diseases 0.000 description 1
- 101710183280 Topoisomerase Proteins 0.000 description 1
- 108700019146 Transgenes Proteins 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 description 1
- PLKUTZNSKRWCCA-NQWUONRPSA-O Tulipanin Natural products O(C[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](Oc2c(-c3cc(O)c(O)c(O)c3)[o+]c3c(c(O)cc(O)c3)c2)O1)[C@H]1[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O1 PLKUTZNSKRWCCA-NQWUONRPSA-O 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102100040247 Tumor necrosis factor Human genes 0.000 description 1
- 102100033728 Tumor necrosis factor receptor superfamily member 18 Human genes 0.000 description 1
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 1
- CFQULUVMLGZVAF-OYJDLGDISA-N U0126.EtOH Chemical compound CCO.C=1C=CC=C(N)C=1SC(\N)=C(/C#N)\C(\C#N)=C(/N)SC1=CC=CC=C1N CFQULUVMLGZVAF-OYJDLGDISA-N 0.000 description 1
- 208000009311 VIPoma Diseases 0.000 description 1
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- OGNYUTNQZVRGMN-UHFFFAOYSA-N ZM447439 Chemical compound N1=CN=C2C=C(OCCCN3CCOCC3)C(OC)=CC2=C1NC(C=C1)=CC=C1NC(=O)C1=CC=CC=C1 OGNYUTNQZVRGMN-UHFFFAOYSA-N 0.000 description 1
- ZSTCHQOKNUXHLZ-PIRIXANTSA-L [(1r,2r)-2-azanidylcyclohexyl]azanide;oxalate;pentyl n-[1-[(2r,3r,4s,5r)-3,4-dihydroxy-5-methyloxolan-2-yl]-5-fluoro-2-oxopyrimidin-4-yl]carbamate;platinum(4+) Chemical compound [Pt+4].[O-]C(=O)C([O-])=O.[NH-][C@@H]1CCCC[C@H]1[NH-].C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 ZSTCHQOKNUXHLZ-PIRIXANTSA-L 0.000 description 1
- YODABPUZPVYDEF-CIBWSIAMSA-O [(2r,3s,4s,5r,6s)-3,4,5-trihydroxy-6-[4-[[(2r,3s,4s,5r,6s)-3,4,5-trihydroxy-6-[5-hydroxy-2-(3,4,5-trihydroxyphenyl)-3-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-[[(2r,3r,4r,5r,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxymethyl]oxan-2-yl]oxychromenylium-7-yl]oxyox Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OC=2C(=[O+]C3=CC(O[C@H]4[C@@H]([C@@H](O)[C@H](O)[C@@H](COC(=O)C=5C=CC(O[C@H]6[C@@H]([C@@H](O)[C@H](O)[C@@H](COC(=O)C=7C=CC(O)=CC=7)O6)O)=CC=5)O4)O)=CC(O)=C3C=2)C=2C=C(O)C(O)=C(O)C=2)O1 YODABPUZPVYDEF-CIBWSIAMSA-O 0.000 description 1
- OUUYNFWYLXMNQZ-HNPHZNNWSA-N [(2s,3r,4s,5r,6s)-4,5-dihydroxy-2-methyl-6-[[(2r,3s,4s,5r,6s)-3,4,5-trihydroxy-6-[7-hydroxy-5-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-2-(3,4,5-trihydroxyphenyl)chromenylium-3-yl]oxyoxan-2-yl]methoxy]oxan-3-yl] (e)-3-(4-hydroxyphe Chemical compound [Cl-].O([C@@H]1O[C@@H]([C@H]([C@H](O)[C@H]1O)O)CO[C@H]1O[C@H]([C@@H]([C@@H](O)[C@H]1O)OC(=O)\C=C\C=1C=CC(O)=CC=1)C)C(C(=[O+]C1=CC(O)=C2)C=3C=C(O)C(O)=C(O)C=3)=CC1=C2O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O OUUYNFWYLXMNQZ-HNPHZNNWSA-N 0.000 description 1
- 210000003815 abdominal wall Anatomy 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 208000037844 advanced solid tumor Diseases 0.000 description 1
- 229960000548 alemtuzumab Drugs 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- NBZANZVJRKXVBH-ITUXNECMSA-N all-trans-alpha-cryptoxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C(=CCCC2(C)C)C NBZANZVJRKXVBH-ITUXNECMSA-N 0.000 description 1
- UZFLPKAIBPNNCA-BQYQJAHWSA-N alpha-ionone Chemical compound CC(=O)\C=C\C1C(C)=CCCC1(C)C UZFLPKAIBPNNCA-BQYQJAHWSA-N 0.000 description 1
- 201000007434 ampulla of Vater carcinoma Diseases 0.000 description 1
- XCPGHVQEEXUHNC-UHFFFAOYSA-N amsacrine Chemical compound COC1=CC(NS(C)(=O)=O)=CC=C1NC1=C(C=CC=C2)C2=NC2=CC=CC=C12 XCPGHVQEEXUHNC-UHFFFAOYSA-N 0.000 description 1
- 229960001220 amsacrine Drugs 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000002280 anti-androgenic effect Effects 0.000 description 1
- 230000003432 anti-folate effect Effects 0.000 description 1
- 229940044684 anti-microtubule agent Drugs 0.000 description 1
- 230000000118 anti-neoplastic effect Effects 0.000 description 1
- 230000000561 anti-psychotic effect Effects 0.000 description 1
- 239000000051 antiandrogen Substances 0.000 description 1
- 238000009175 antibody therapy Methods 0.000 description 1
- 229940127074 antifolate Drugs 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 229940045686 antimetabolites antineoplastic purine analogs Drugs 0.000 description 1
- 229940045688 antineoplastic antimetabolites pyrimidine analogues Drugs 0.000 description 1
- KZNIFHPLKGYRTM-UHFFFAOYSA-N apigenin Chemical compound C1=CC(O)=CC=C1C1=CC(=O)C2=C(O)C=C(O)C=C2O1 KZNIFHPLKGYRTM-UHFFFAOYSA-N 0.000 description 1
- 229940117893 apigenin Drugs 0.000 description 1
- XADJWCRESPGUTB-UHFFFAOYSA-N apigenin Natural products C1=CC(O)=CC=C1C1=CC(=O)C2=CC(O)=C(O)C=C2O1 XADJWCRESPGUTB-UHFFFAOYSA-N 0.000 description 1
- 235000008714 apigenin Nutrition 0.000 description 1
- 238000003782 apoptosis assay Methods 0.000 description 1
- FIHJKUPKCHIPAT-AHIGJZGOSA-N artesunate Chemical compound C([C@](OO1)(C)O2)C[C@H]3[C@H](C)CC[C@@H]4[C@@]31[C@@H]2O[C@@H](OC(=O)CCC(O)=O)[C@@H]4C FIHJKUPKCHIPAT-AHIGJZGOSA-N 0.000 description 1
- 229960004991 artesunate Drugs 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- KLNFSAOEKUDMFA-UHFFFAOYSA-N azanide;2-hydroxyacetic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OCC(O)=O KLNFSAOEKUDMFA-UHFFFAOYSA-N 0.000 description 1
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 229950005645 barasertib Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 208000012999 benign epithelial neoplasm Diseases 0.000 description 1
- YBHILYKTIRIUTE-UHFFFAOYSA-N berberine Chemical compound C1=C2CC[N+]3=CC4=C(OC)C(OC)=CC=C4C=C3C2=CC2=C1OCO2 YBHILYKTIRIUTE-UHFFFAOYSA-N 0.000 description 1
- 229940093265 berberine Drugs 0.000 description 1
- QISXPYZVZJBNDM-UHFFFAOYSA-N berberine Natural products COc1ccc2C=C3N(Cc2c1OC)C=Cc4cc5OCOc5cc34 QISXPYZVZJBNDM-UHFFFAOYSA-N 0.000 description 1
- DMASLKHVQRHNES-FKKUPVFPSA-N beta-cryptoxanthin Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C DMASLKHVQRHNES-FKKUPVFPSA-N 0.000 description 1
- DMASLKHVQRHNES-ITUXNECMSA-N beta-cryptoxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2=C(C)CCCC2(C)C DMASLKHVQRHNES-ITUXNECMSA-N 0.000 description 1
- 235000002360 beta-cryptoxanthin Nutrition 0.000 description 1
- 239000011774 beta-cryptoxanthin Substances 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 201000009613 breast lymphoma Diseases 0.000 description 1
- 229960002092 busulfan Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- 229940112129 campath Drugs 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 238000002619 cancer immunotherapy Methods 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 208000011825 carcinoma of the ampulla of vater Diseases 0.000 description 1
- 229960005243 carmustine Drugs 0.000 description 1
- 230000012820 cell cycle checkpoint Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000002771 cell marker Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- HZASIAXCPXTISQ-NVXWUHKLSA-N chembl1236782 Chemical compound C=12C=C(OC)C(OC)=CC2=NC(C=2C(=CC=C(F)C=2)O)=NC=1N[C@@H]1CNC[C@H]1C(C)(C)O HZASIAXCPXTISQ-NVXWUHKLSA-N 0.000 description 1
- 239000013043 chemical agent Substances 0.000 description 1
- 238000009104 chemotherapy regimen Methods 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 229960004630 chlorambucil Drugs 0.000 description 1
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 1
- ACSIXWWBWUQEHA-UHFFFAOYSA-N clodronic acid Chemical compound OP(O)(=O)C(Cl)(Cl)P(O)(O)=O ACSIXWWBWUQEHA-UHFFFAOYSA-N 0.000 description 1
- 229960002286 clodronic acid Drugs 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 238000011970 concomitant therapy Methods 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 210000001608 connective tissue cell Anatomy 0.000 description 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000001351 cycling effect Effects 0.000 description 1
- 229960000684 cytarabine Drugs 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 229960003901 dacarbazine Drugs 0.000 description 1
- 229960000975 daunorubicin Drugs 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 108010025838 dectin 1 Proteins 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 235000007242 delphinidin Nutrition 0.000 description 1
- XENHPQQLDPAYIJ-PEVLUNPASA-O delphinidin 3-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC2=C(O)C=C(O)C=C2[O+]=C1C1=CC(O)=C(O)C(O)=C1 XENHPQQLDPAYIJ-PEVLUNPASA-O 0.000 description 1
- FFNDMZIBVDSQFI-UHFFFAOYSA-N delphinidin chloride Chemical compound [Cl-].[O+]=1C2=CC(O)=CC(O)=C2C=C(O)C=1C1=CC(O)=C(O)C(O)=C1 FFNDMZIBVDSQFI-UHFFFAOYSA-N 0.000 description 1
- ZJWIIMLSNZOCBP-BTTVDUMLSA-N delphinidin-3-glucoside Chemical compound [Cl-].O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC2=C(O)C=C(O)C=C2[O+]=C1C1=CC(O)=C(O)C(O)=C1 ZJWIIMLSNZOCBP-BTTVDUMLSA-N 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 229950002389 diaziquone Drugs 0.000 description 1
- 208000015799 differentiated thyroid carcinoma Diseases 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- RHMXXJGYXNZAPX-UHFFFAOYSA-N emodin Chemical compound C1=C(O)C=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O RHMXXJGYXNZAPX-UHFFFAOYSA-N 0.000 description 1
- VASFLQKDXBAWEL-UHFFFAOYSA-N emodin Natural products OC1=C(OC2=C(C=CC(=C2C1=O)O)O)C1=CC=C(C=C1)O VASFLQKDXBAWEL-UHFFFAOYSA-N 0.000 description 1
- 208000001991 endodermal sinus tumor Diseases 0.000 description 1
- 229960001904 epirubicin Drugs 0.000 description 1
- 208000028653 esophageal adenocarcinoma Diseases 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 208000007276 esophageal squamous cell carcinoma Diseases 0.000 description 1
- 229960005420 etoposide Drugs 0.000 description 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
- 229960000752 etoposide phosphate Drugs 0.000 description 1
- LIQODXNTTZAGID-OCBXBXKTSA-N etoposide phosphate Chemical compound COC1=C(OP(O)(O)=O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 LIQODXNTTZAGID-OCBXBXKTSA-N 0.000 description 1
- 229960005167 everolimus Drugs 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 229960000961 floxuridine Drugs 0.000 description 1
- ODKNJVUHOIMIIZ-RRKCRQDMSA-N floxuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ODKNJVUHOIMIIZ-RRKCRQDMSA-N 0.000 description 1
- 229960000390 fludarabine Drugs 0.000 description 1
- 229960005304 fludarabine phosphate Drugs 0.000 description 1
- 150000005699 fluoropyrimidines Chemical class 0.000 description 1
- 229940124307 fluoroquinolone Drugs 0.000 description 1
- 239000004052 folic acid antagonist Substances 0.000 description 1
- 230000003325 follicular Effects 0.000 description 1
- YAKWPXVTIGTRJH-UHFFFAOYSA-N fotemustine Chemical compound CCOP(=O)(OCC)C(C)NC(=O)N(CCCl)N=O YAKWPXVTIGTRJH-UHFFFAOYSA-N 0.000 description 1
- 229960004783 fotemustine Drugs 0.000 description 1
- 239000000446 fuel Substances 0.000 description 1
- 201000010175 gallbladder cancer Diseases 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 201000011587 gastric lymphoma Diseases 0.000 description 1
- 201000000052 gastrinoma Diseases 0.000 description 1
- 229960005144 gemcitabine hydrochloride Drugs 0.000 description 1
- 229940045109 genistein Drugs 0.000 description 1
- TZBJGXHYKVUXJN-UHFFFAOYSA-N genistein Natural products C1=CC(O)=CC=C1C1=COC2=CC(O)=CC(O)=C2C1=O TZBJGXHYKVUXJN-UHFFFAOYSA-N 0.000 description 1
- 235000006539 genistein Nutrition 0.000 description 1
- ZCOLJUOHXJRHDI-CMWLGVBASA-N genistein 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 ZCOLJUOHXJRHDI-CMWLGVBASA-N 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 208000006359 hepatoblastoma Diseases 0.000 description 1
- GLDSKRNGVVYJAB-DQSJHHFOSA-N hesperadin Chemical compound C12=CC(NS(=O)(=O)CC)=CC=C2NC(=O)\C1=C(C=1C=CC=CC=1)/NC(C=C1)=CC=C1CN1CCCCC1 GLDSKRNGVVYJAB-DQSJHHFOSA-N 0.000 description 1
- 108091008039 hormone receptors Proteins 0.000 description 1
- IWBJJCOKGLUQIZ-HQKKAZOISA-N hyperforin Chemical compound OC1=C(CC=C(C)C)C(=O)[C@@]2(CC=C(C)C)C[C@H](CC=C(C)C)[C@](CCC=C(C)C)(C)[C@]1(C(=O)C(C)C)C2=O IWBJJCOKGLUQIZ-HQKKAZOISA-N 0.000 description 1
- QOVWXXKVLJOKNW-UHFFFAOYSA-N hyperforin Natural products CC(C)C(=O)C12CC(CC=C(C)C)(CC(CC=C(C)C)C1CCC=C(C)C)C(=C(CC=C(C)C)C2=O)O QOVWXXKVLJOKNW-UHFFFAOYSA-N 0.000 description 1
- 229960000908 idarubicin Drugs 0.000 description 1
- 229960001101 ifosfamide Drugs 0.000 description 1
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000005965 immune activity Effects 0.000 description 1
- 230000005746 immune checkpoint blockade Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- FMFIFGLHVOZDEL-UHFFFAOYSA-N indotecan Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2C=2C(=O)C3=CC=4OCOC=4C=C3C=2N1CCCN1CCOCC1 FMFIFGLHVOZDEL-UHFFFAOYSA-N 0.000 description 1
- 210000004263 induced pluripotent stem cell Anatomy 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 206010022498 insulinoma Diseases 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000004073 interleukin-2 production Effects 0.000 description 1
- 230000010039 intracellular degradation Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 206010073095 invasive ductal breast carcinoma Diseases 0.000 description 1
- 208000012947 ischemia reperfusion injury Diseases 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 210000001931 lesser pelvis Anatomy 0.000 description 1
- 238000009092 lines of therapy Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- XGZVUEUWXADBQD-UHFFFAOYSA-L lithium carbonate Chemical compound [Li+].[Li+].[O-]C([O-])=O XGZVUEUWXADBQD-UHFFFAOYSA-L 0.000 description 1
- 229910052808 lithium carbonate Inorganic materials 0.000 description 1
- 229940087762 lithium orotate Drugs 0.000 description 1
- INHCSSUBVCNVSK-UHFFFAOYSA-L lithium sulfate Inorganic materials [Li+].[Li+].[O-]S([O-])(=O)=O INHCSSUBVCNVSK-UHFFFAOYSA-L 0.000 description 1
- 229960002247 lomustine Drugs 0.000 description 1
- 208000016992 lung adenocarcinoma in situ Diseases 0.000 description 1
- 201000005296 lung carcinoma Diseases 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 208000026037 malignant tumor of neck Diseases 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 229960004961 mechlorethamine Drugs 0.000 description 1
- HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical compound ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 1
- 208000030163 medullary breast carcinoma Diseases 0.000 description 1
- 208000023356 medullary thyroid gland carcinoma Diseases 0.000 description 1
- 229960001924 melphalan Drugs 0.000 description 1
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 1
- 229960001428 mercaptopurine Drugs 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 1
- 229960003105 metformin Drugs 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 208000024191 minimally invasive lung adenocarcinoma Diseases 0.000 description 1
- 229960001156 mitoxantrone Drugs 0.000 description 1
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 1
- QXYYYPFGTSJXNS-UHFFFAOYSA-N mitozolomide Chemical compound N1=NN(CCCl)C(=O)N2C1=C(C(=O)N)N=C2 QXYYYPFGTSJXNS-UHFFFAOYSA-N 0.000 description 1
- 229950005967 mitozolomide Drugs 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000003990 molecular pathway Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 208000004707 mucinous cystadenoma Diseases 0.000 description 1
- 238000011228 multimodal treatment Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 210000004985 myeloid-derived suppressor cell Anatomy 0.000 description 1
- 210000000107 myocyte Anatomy 0.000 description 1
- ISGGVCWFTPTHIX-UHFFFAOYSA-N n'-(2-hydroxy-3-piperidin-1-ylpropoxy)pyridine-3-carboximidamide;dihydrochloride Chemical compound Cl.Cl.C1CCCCN1CC(O)CONC(=N)C1=CC=CN=C1 ISGGVCWFTPTHIX-UHFFFAOYSA-N 0.000 description 1
- OBWNXGOQPLDDPS-UHFFFAOYSA-N n-(2,6-diethylphenyl)-3-[[4-(4-methylpiperazin-1-yl)benzoyl]amino]-4,6-dihydro-1h-pyrrolo[3,4-c]pyrazole-5-carboxamide Chemical compound CCC1=CC=CC(CC)=C1NC(=O)N1CC(C(NC(=O)C=2C=CC(=CC=2)N2CCN(C)CC2)=NN2)=C2C1 OBWNXGOQPLDDPS-UHFFFAOYSA-N 0.000 description 1
- NPRJSFWNFTXXQC-GWGOZDFZSA-N n-[(e,2r,3s)-1,3-dihydroxyoctadec-4-en-2-yl]hexanamide Chemical compound CCCCCCCCCCCCC\C=C\[C@H](O)[C@@H](CO)NC(=O)CCCCC NPRJSFWNFTXXQC-GWGOZDFZSA-N 0.000 description 1
- RTDCVLCTBQDLBW-UHFFFAOYSA-N n-[4-[[4-[[5-tert-butyl-2-(4-methylphenyl)pyrazol-3-yl]carbamoylamino]naphthalen-1-yl]oxymethyl]pyridin-2-yl]-2-methoxyacetamide Chemical compound C1=NC(NC(=O)COC)=CC(COC=2C3=CC=CC=C3C(NC(=O)NC=3N(N=C(C=3)C(C)(C)C)C=3C=CC(C)=CC=3)=CC=2)=C1 RTDCVLCTBQDLBW-UHFFFAOYSA-N 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- JLYAXFNOILIKPP-KXQOOQHDSA-N navitoclax Chemical compound C([C@@H](NC1=CC=C(C=C1S(=O)(=O)C(F)(F)F)S(=O)(=O)NC(=O)C1=CC=C(C=C1)N1CCN(CC1)CC1=C(CCC(C1)(C)C)C=1C=CC(Cl)=CC=1)CSC=1C=CC=CC=1)CN1CCOCC1 JLYAXFNOILIKPP-KXQOOQHDSA-N 0.000 description 1
- 229950007221 nedaplatin Drugs 0.000 description 1
- 238000009099 neoadjuvant therapy Methods 0.000 description 1
- 210000000441 neoplastic stem cell Anatomy 0.000 description 1
- 230000000955 neuroendocrine Effects 0.000 description 1
- 230000000720 neurosecretory effect Effects 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 229960005554 obatoclax mesylate Drugs 0.000 description 1
- RFWGABANNQMHMZ-CARRXEGNSA-N oleuropein Natural products COC(=O)C1=CO[C@@H](O[C@H]2O[C@@H](CO)[C@H](O)[C@@H](O)[C@@H]2O)C(=CC)[C@H]1CC(=O)OCCc3ccc(O)c(O)c3 RFWGABANNQMHMZ-CARRXEGNSA-N 0.000 description 1
- 235000011576 oleuropein Nutrition 0.000 description 1
- 210000002747 omentum Anatomy 0.000 description 1
- 201000006958 oropharynx cancer Diseases 0.000 description 1
- PXQPEWDEAKTCGB-UHFFFAOYSA-N orotic acid Chemical compound OC(=O)C1=CC(=O)NC(=O)N1 PXQPEWDEAKTCGB-UHFFFAOYSA-N 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- 208000011937 ovarian epithelial tumor Diseases 0.000 description 1
- 208000021284 ovarian germ cell tumor Diseases 0.000 description 1
- 210000003101 oviduct Anatomy 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 208000002820 pancreatoblastoma Diseases 0.000 description 1
- 201000010198 papillary carcinoma Diseases 0.000 description 1
- 201000007052 paranasal sinus cancer Diseases 0.000 description 1
- 208000012111 paraneoplastic syndrome Diseases 0.000 description 1
- 210000004197 pelvis Anatomy 0.000 description 1
- 229960005079 pemetrexed Drugs 0.000 description 1
- QOFFJEBXNKRSPX-ZDUSSCGKSA-N pemetrexed Chemical compound C1=N[C]2NC(N)=NC(=O)C2=C1CCC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 QOFFJEBXNKRSPX-ZDUSSCGKSA-N 0.000 description 1
- 229960002340 pentostatin Drugs 0.000 description 1
- FPVKHBSQESCIEP-JQCXWYLXSA-N pentostatin Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC[C@H]2O)=C2N=C1 FPVKHBSQESCIEP-JQCXWYLXSA-N 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 210000003200 peritoneal cavity Anatomy 0.000 description 1
- 210000004303 peritoneum Anatomy 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 229940038309 personalized vaccine Drugs 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical group [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- PKUBGLYEOAJPEG-UHFFFAOYSA-N physcion Natural products C1=C(C)C=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O PKUBGLYEOAJPEG-UHFFFAOYSA-N 0.000 description 1
- 229950005566 picoplatin Drugs 0.000 description 1
- IIMIOEBMYPRQGU-UHFFFAOYSA-L picoplatin Chemical compound N.[Cl-].[Cl-].[Pt+2].CC1=CC=CC=N1 IIMIOEBMYPRQGU-UHFFFAOYSA-L 0.000 description 1
- 210000004910 pleural fluid Anatomy 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 239000000186 progesterone Substances 0.000 description 1
- 229960003387 progesterone Drugs 0.000 description 1
- 230000005522 programmed cell death Effects 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 201000001514 prostate carcinoma Diseases 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 239000003196 psychodysleptic agent Substances 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 1
- 230000007420 reactivation Effects 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 208000010639 renal pelvis urothelial carcinoma Diseases 0.000 description 1
- 230000010410 reperfusion Effects 0.000 description 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 1
- 229960005399 satraplatin Drugs 0.000 description 1
- 190014017285 satraplatin Chemical compound 0.000 description 1
- CYOHGALHFOKKQC-UHFFFAOYSA-N selumetinib Chemical compound OCCONC(=O)C=1C=C2N(C)C=NC2=C(F)C=1NC1=CC=C(Br)C=C1Cl CYOHGALHFOKKQC-UHFFFAOYSA-N 0.000 description 1
- 229960003440 semustine Drugs 0.000 description 1
- FVLVBPDQNARYJU-UHFFFAOYSA-N semustine Chemical compound CC1CCC(NC(=O)N(CCCl)N=O)CC1 FVLVBPDQNARYJU-UHFFFAOYSA-N 0.000 description 1
- 229960002930 sirolimus Drugs 0.000 description 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- AZEZEAABTDXEHR-UHFFFAOYSA-M sodium;1,6,6-trimethyl-10,11-dioxo-8,9-dihydro-7h-naphtho[1,2-g][1]benzofuran-2-sulfonate Chemical compound [Na+].C12=CC=C(C(CCC3)(C)C)C3=C2C(=O)C(=O)C2=C1OC(S([O-])(=O)=O)=C2C AZEZEAABTDXEHR-UHFFFAOYSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000009168 stem cell therapy Methods 0.000 description 1
- 238000009580 stem-cell therapy Methods 0.000 description 1
- 229960001052 streptozocin Drugs 0.000 description 1
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 1
- 210000002536 stromal cell Anatomy 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- AIGAZQPHXLWMOJ-UHFFFAOYSA-N tanshinone IIA Natural products C1=CC2=C(C)C=CC=C2C(C(=O)C2=O)=C1C1=C2C(C)=CO1 AIGAZQPHXLWMOJ-UHFFFAOYSA-N 0.000 description 1
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 description 1
- 229960000235 temsirolimus Drugs 0.000 description 1
- QFJCIRLUMZQUOT-UHFFFAOYSA-N temsirolimus Natural products C1CC(O)C(OC)CC1CC(C)C1OC(=O)C2CCCCN2C(=O)C(=O)C(O)(O2)C(C)CCC2CC(OC)C(C)=CC=CC=CC(C)CC(C)C(=O)C(OC)C(O)C(C)=CC(C)C(=O)C1 QFJCIRLUMZQUOT-UHFFFAOYSA-N 0.000 description 1
- NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 1
- 229960001278 teniposide Drugs 0.000 description 1
- RBTVSNLYYIMMKS-UHFFFAOYSA-N tert-butyl 3-aminoazetidine-1-carboxylate;hydrochloride Chemical compound Cl.CC(C)(C)OC(=O)N1CC(N)C1 RBTVSNLYYIMMKS-UHFFFAOYSA-N 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 229960001196 thiotepa Drugs 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 208000030901 thyroid gland follicular carcinoma Diseases 0.000 description 1
- 208000030045 thyroid gland papillary carcinoma Diseases 0.000 description 1
- 208000019179 thyroid gland undifferentiated (anaplastic) carcinoma Diseases 0.000 description 1
- 201000009657 thyroid sarcoma Diseases 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 229960000303 topotecan Drugs 0.000 description 1
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 208000022679 triple-negative breast carcinoma Diseases 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 210000003741 urothelium Anatomy 0.000 description 1
- GCILEJUNEYIABW-UHFFFAOYSA-N v5t7s4hp8a Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2C=2C(=O)C3=CC=4OCOC=4C=C3C=2N1CCCN1C=CN=C1 GCILEJUNEYIABW-UHFFFAOYSA-N 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 229960000653 valrubicin Drugs 0.000 description 1
- ZOCKGBMQLCSHFP-KQRAQHLDSA-N valrubicin Chemical compound O([C@H]1C[C@](CC2=C(O)C=3C(=O)C4=CC=CC(OC)=C4C(=O)C=3C(O)=C21)(O)C(=O)COC(=O)CCCC)[C@H]1C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O1 ZOCKGBMQLCSHFP-KQRAQHLDSA-N 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- 229960004355 vindesine Drugs 0.000 description 1
- UGGWPQSBPIFKDZ-KOTLKJBCSA-N vindesine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(N)=O)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 UGGWPQSBPIFKDZ-KOTLKJBCSA-N 0.000 description 1
- 229960000922 vinflunine Drugs 0.000 description 1
- NMDYYWFGPIMTKO-HBVLKOHWSA-N vinflunine Chemical compound C([C@@](C1=C(C2=CC=CC=C2N1)C1)(C2=C(OC)C=C3N(C)[C@@H]4[C@@]5(C3=C2)CCN2CC=C[C@]([C@@H]52)([C@H]([C@]4(O)C(=O)OC)OC(C)=O)CC)C(=O)OC)[C@H]2C[C@@H](C(C)(F)F)CN1C2 NMDYYWFGPIMTKO-HBVLKOHWSA-N 0.000 description 1
- 229960002066 vinorelbine Drugs 0.000 description 1
- GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 description 1
- APEJHGBNAYVBDY-UHFFFAOYSA-N violdelphin Natural products CC1OC(OCC2OC(OC3=Cc4c(O)cc(OC5OC(COC(=O)c6ccc(OC7OC(COC(=O)c8ccc(O)cc8)C(O)C(O)C7O)cc6)C(O)C(O)C5O)cc4OC3c9cc(O)c(O)c(O)c9)C(O)C(O)C2O)C(O)C(O)C1O APEJHGBNAYVBDY-UHFFFAOYSA-N 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 238000007482 whole exome sequencing Methods 0.000 description 1
- 229940053867 xeloda Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2086—IL-13 to IL-16
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Definitions
- the present disclosure relates to a method of treating cancer, use of medicaments in a staged combination therapy for the treatment of cancer (also referred to herein as multimodal cancer therapy), and use of a medicament or medicaments in the manufacture of a multimodal therapy for the treatment of cancer, for example linked with dynamic input of tumor status, to optimise intervention and timing.
- the treatment of cancer is still a huge challenge and burden to society.
- the present inventor believes that the effectiveness of cancer therapy can be greatly increased by employing a multimodal method of treatment. That is conscious choice of sequence and the timing of multiple treatments to achieve improved outcomes, for patients.
- Cancer cells are highly adapted to corrupting and hijacking many natural biological processes that exist in the body. Cancers are sometimes based on mutations and modifications of cells and thus can readily change and adapt. Given this the present inventor believes that is unlikely that one or two modes of treatment will be effective for the treatment of the majority of cancers.
- the inventor has designed a new method to treat cancer, which involves a radical resetting of the immune system, which will be much more efficacious than just using simple steps, such as immune check point inhibitors or combinations thereof.
- the method of present disclosure can be considered a "reboot" of the immune system, which after treatment is then able to fight the cancer.
- the present disclosure provides a method of treating cancer comprising the steps;
- the treatment schedule of the present disclosure is a paradigm shift in cancer treatment, because at the present time standard of care cancer treatment generally only involves one or two of the above steps.
- cancer therapy regimes are a combination or cocktail of the therapeutic agents from the outset, and cancer adjuvant therapy is known (i.e. chemotherapy or radiation therapy after surgery to excise a tumor) subsequent cancer therapies are not employed until the first line or second therapy has failed.
- cancer adjuvant therapy i.e. chemotherapy or radiation therapy after surgery to excise a tumor
- the multimodal therapy of the present disclosure is not the same as simply trying different treatments after the failure of a treatment. Instead it involves pro- actively employing multiples modes of treatment, in particular in the order specified herein.
- the method comprises the further step of tumour surveillance.
- the therapeutic steps are taken in fast succession, in particular while surveying and reading "efficacy", for example by studying effects on immune parameters and/or variables showing circulating tumor components.
- Efficacy here is not employed in the strict technical sense but simply to effects more generically.
- the present multimodal treatment comprises multiple treatment steps, which are employed at specific times, for example over a period of 1 to 12 months, such as 1 to 2 months, 1 to 3 months, 1 to 4 months, 1 to 5 months, 1 to 6 months, 1 to 7 months, 1 to 8 months, 1 to 9 months, 1 to 10 months or 1 to 11 months.
- the "subsequent" therapies are not employed because a therapy has failed i.e. the further therapy is not started because there is resistance to "first line or second line” therapy.
- step b) follows step a) or step al).
- step c) follows step b).
- step d) follows step c).
- step e) follows step d).
- one or more treatment steps may overlap or be at the same time.
- step a) and al) overlap or are at the same time. In one embodiment step a) and b) overlap or are at the same time. In one embodiment step al) and b) overlap or are at the same time. In one embodiment step b) and c) overlap or are at the same time. In one embodiment step c) and d) overlap or are at the same time. In one embodiment step d) and e) overlap or are at the same time.
- step a), al) and b) overlap or are at the same time. In one embodiment step a), b) and c) overlap or are at the same time. In one embodiment step al), b) and c) overlap or are at the same time. In one embodiment step b), c) and d) overlap or are at the same time. In one embodiment step c), d) and e) overlap or are at the same time.
- step a), al), b) and c) overlap or are at the same time. In one embodiment step a), b), c) and d) overlap or are at the same time. In one embodiment step al), b), c) and d) overlap or are at the same time. In one embodiment step b), c), d) and e) overlap or are at the same time.
- step a), b), c), d) and e) overlap or are at the same time.
- step al), b), c), d) and e) overlap or are at the same time
- one or more of the steps do not overlap, for example 2, 3, 4 or all of the step do not overlap.
- step b) and d) do not overlap and are not at the same time.
- step e) does not overlap with step c).
- the method comprises a pre-step of surgery, for example to remove tumour mass and/or lymph nodes and the like.
- the method comprises irradiation.
- step a) is a treatment selected from the group comprising irradiation, chemotherapy, anti-proliferation pathway therapy (for example anti- oestrogen, anti-androgen, anti-HER, anti-BCR/ABL, anti-VEGF, anti-PDGF, anti-BRAF antibody molecule [including a bispecific antibody, full-length or an antibody binding fragment], with or without combining with the appropriate chemotherapy) and a combination of two or more of the same.
- anti-proliferation pathway therapy for example anti- oestrogen, anti-androgen, anti-HER, anti-BCR/ABL, anti-VEGF, anti-PDGF, anti-BRAF antibody molecule [including a bispecific antibody, full-length or an antibody binding fragment], with or without combining with the appropriate chemotherapy
- At least one agent employed in step a) is an antiproliferative agent, for example selected from the group 25-hydroxcholesterol, 3-hydroxtyrosol, 7 ⁇ - hydroxycholestrol, aloe-emodin, apigenin, artesunate, berberine, caffeine power (C0750), dichloromethylenediphosphonic acid (for example as a salt, such as a disodium salt), emodin, HA 14-1, hyperforin, N-acetyl-D-sphingosine, N-hexanoyl-D-sphingosine, oleuropein, pathenolide, tangeretin, tanshinone IIA, ⁇ -cryptoxanthine, ⁇ -cryptoxanthin, ⁇ -lonone, trans-cinnamaldehyde and combinations thereof.
- an antiproliferative agent for example selected from the group 25-hydroxcholesterol, 3-hydroxtyrosol
- agents that can be employed alone or in a combination in step a) include high doses of vitamin Bl, parp inhibitors, a gene product of NME2, myrtillin (delphinidin-3-O-glucoside), tulipanin (delphinidin-3-O-rutinoside), violdelphin (delphinidin 3-rutinoside-7-0-(6-0-(4-(6-0-(4-hydroxybenzoyl) -p-D-glucosyl)oxy benzoyiJ-p-D-glucoside), nasunin (delphinidin-3-(p-coumaroylrutinoside)-5-glucoside) and combinations of two or more of the same.
- therapy employed in step a) is Varlitinib [(i?)-N4-[3-Chloro- 4-(thiazol-2-ylmethoxy)-phenyl]-N6-(4-methyl-4, 5,-dihydro-oxazol-2-yl)-quinazoline- 4,6-diamine] or a pharmaceutically acceptable salt thereof, which may be employed alone or in a combination therapy.
- the Varlitinib is administered at a dose in the range lOOmg to 900mg on each occasion, in particular 200 mg, 300mg, 400mg or 500mg each dose, such as 400mg, for example administered once or twice daily, such as twice daily.
- the therapy of step a) comprises a DHODH inhibitor, such as 2-(3,5-difluoro-3'-methoxybiphenyl-4-ylamino)nicotinic acid or a pharmaceutically acceptable salt thereof.
- a DHODH inhibitor such as 2-(3,5-difluoro-3'-methoxybiphenyl-4-ylamino)nicotinic acid or a pharmaceutically acceptable salt thereof.
- CEP-9722 a PARP-1 and PARP-2 inhibitor
- INO-1001 (3-aminobenzamide) a potent inhibitor of PARP (with IC50 of ⁇ 50 nM in CHO cells and a mediator of oxidant- induced myocyte dysfunction during reperfusion)
- BGB-290 a PARP-1 and PARP-2 inhibitor BGP-15 a PARP inhibitor (which has been (structure not shown); shown to protect against ischemia- reperfusion injury);
- E7016 (previously known as GPI-21016) a PARP inhibitor (undergoing Phase I trials in combination with temozolomide for advanced solid tumours and gliomas);
- ABT-737 a PARP-1 and PARP-2 inhibitor
- the therapy in step al), i.e. the decluttering of immune cells is performed by administering a compound, such as a CXCR2 antagonist, an anti-GCF, cyclophosphamide and/or irradiation, and a combination of two or more of the same.
- a compound such as a CXCR2 antagonist, an anti-GCF, cyclophosphamide and/or irradiation, and a combination of two or more of the same.
- decluttering refers to neutralisation of immune cells. This neutralisation may, for example include reduction in number of immune cells. Generally speaking, decluttering results in a reduction in overall number of immune cells, but may also encompass total depletion, including local and systemic depletion.
- decluttering of immune cells is performed by removing specific immune cell populations, for example using medication and/or techniques such as a dialysis.
- the immune cells that are "decluttered" are selected from a lymphocyte (such as a T lymphocyte, such as a T cell or a NKT cell), a B cell, a natural killer cell and a combination of two or more of the same.
- a lymphocyte such as a T lymphocyte, such as a T cell or a NKT cell
- B cell such as a B cell
- natural killer cell such as a B cell
- a combination of two or more of the same are selected from a lymphocyte (such as a T lymphocyte, such as a T cell or a NKT cell), a B cell, a natural killer cell and a combination of two or more of the same.
- the immune cells which are decluttered are tumor associated macrophages.
- Tumor associated macrophages can be decluttered by NKT cells engineered to encode a cytokine, for example as disclosed in WO2013/040371, incorporated herein by reference.
- the immune cell which is decluttered is a lymphocyte, for example a NK cell or a T lymphocyte, such as a T cell or a NKT cell.
- a lymphocyte for example a NK cell or a T lymphocyte, such as a T cell or a NKT cell.
- the immune cells that are decluttered are B cells.
- the immune cell that is decluttered is a natural killer cell.
- NK cells can be targeted by monoclonal antibodies or binding fragments specific to CD56.
- Mature T lymphocytes can be removed by medicaments such as alemtuzumab.
- Immune cells with surface expression of CD52 can be removed by Campath.
- the CXCR2 antagonist is selected from an antibody or binding fragment thereof, MK-7123, SB265610, SB 225002:
- GSK1325756 GSK1325756, AZD5069, and combinations thereof.
- the CXCR2 antagonist is SCH-527123.
- the decluttering step al) is performed by employing anti- neutrophil antibodies.
- the step al) is performed using a G-CSF antibody, for example CSL324, which is a humanized G-CSFR antibody.
- the debulking in step b) is surgery to reduce a tumor mass.
- the surgery is followed by chemotherapy and/or (in particular or) irradiation therapy.
- Debulking refers to a reduction in the total mass of a tumor. This includes breaking a tumor mass into smaller fragments as well as shrinking the tumor mass. Methods of reducing a tumor mass include cutting (excising), ablating (including cryoablation, liquid nitrogen treatment of topical cancer cells and combinations of two or more of the same.
- the debulking in step b) is performed by administering chemotherapy selected from alkylating agents, antimetabolites, anthracyclines, plant alkaloids, topoisomerase inhibitors, and other antitumour agents, such as doxorubicin, 5-fluorouracil (5-FU), paclitaxel, gemcitabine, capecitabine, irinotecan, and platins such as cisplatin and oxaliplatin.
- chemotherapy selected from alkylating agents, antimetabolites, anthracyclines, plant alkaloids, topoisomerase inhibitors, and other antitumour agents, such as doxorubicin, 5-fluorouracil (5-FU), paclitaxel, gemcitabine, capecitabine, irinotecan, and platins such as cisplatin and oxaliplatin.
- the debulking in step b) is selected from treatment with an oncolytic virus, an antibody drug conjugate and a combination thereof.
- the oncolytic virus is a virus selected from an adenovirus, herpes simplex virus, reovirus, measles virus, Newcastle disease virus, Seneca Valley virus, Vesicular stomatitis virus, polio virus, ECHO enterovirus, Coxsackie virus, and vaccinia virus.
- the oncolytic virus is selected from Enadenotucirev, talimogene laherparepvec, RIGVIR, Ad5-yCD/mutTKSR39rep-hIL12, CavatakTM, CG0070, DNX-2401, G207, HF10, Imlygic®, JX-594, MG1-MA3, MV-NIS, OBP-301, Reolysin®, Toca 511.
- the antibody drug conjugate is selected from the group comprising AGS-15E, AGS-16C3F, AGS-22M6E, AMG-172, AMG-595, ASG-5ME, brentuximab vedotin, DEDN-6526A, DMUC-5754A, gemtuzumab ozogamicin, glembatumumab vedotin, GSK2857916, hRS7-SN-38, IMGN-242, IMGN-289, IMGN-388, IMGN-529, IMGN-633, IMGN-853, Indatuximab, indatuximab ravtansine, Inotuzumab ozogamicin, lorvotuzumab mertansine, MEDI-547, milatuzumab doxorubicin, MLN- 0264, MLN-2704, PF-06263507, pinatuzumab vedo
- step b) comprises administering varlitinib or a salt thereof, as a monotherapy or as part of a combination therapy, for example as disclosed elsewhere herein.
- step b) comprises administering a DHODH inhibitor, such as as 2-(3,5-difluoro-3'-methoxybiphenyl-4-ylamino)nicotinic acid or a pharmaceutically acceptable salt thereof.
- a DHODH inhibitor such as as 2-(3,5-difluoro-3'-methoxybiphenyl-4-ylamino)nicotinic acid or a pharmaceutically acceptable salt thereof.
- activating the immune cells in step c) comprises administering a RON inhibitor, an AXL kinase inhibitor, a MER kinase agonist, a cytokine (such as IL-13, IL-15, IL-4 or IL-2), a tumour vaccine for example comprising a tumour antigen and adjuvant, a dendritic cell vaccine and a combination of two or more of the same.
- a RON inhibitor an AXL kinase inhibitor
- a MER kinase agonist such as IL-13, IL-15, IL-4 or IL-2
- a cytokine such as IL-13, IL-15, IL-4 or IL-2
- a tumour vaccine for example comprising a tumour antigen and adjuvant, a dendritic cell vaccine and a combination of two or more of the same.
- activating immune cells refers to the functional activation of the immune cells, for example the activation of T cells by stimilulation with antigens (including where the antigen is provided on antigen presenting cells), and the activation of B cells to produce tumor specific antibodies. Activating may also include the recruitment of immune cells to the tumor site. Use of appropriate cytokines can stimulate and/or activate immune cells.
- the RON inhibitor is N-(4-(2-Amino-3-chloropyridin-4- yloxy)-3-fluorophenyl)-4-ethoxy-l-(4-fluorophenyl)-2-oxo-l,2-dihydropyridine-3- carboxamide disclosed in WO 2008/058229.
- activating the immune cells in step c) comprises administering one or more check-point inhibitors.
- V155991 and V158411 are CHKl and CHK2 inhibitors,:
- MK-8776 is a selective CHKl inhibitor (with CHIR124 is CHKl inhibitor (is a novel an IC50 of 3 nM in a cell-free assay.
- the and potent inhibitor with IC50 of 0.3 molecule shows 500-fold selectivity against nM in a cell-free assay. It shows 2,000- CHK2); fold selectivity against CHK2 and 500 to
- GDC-0425 is a selective CHKl a natural product derived from sponges that inhibitor;
- KU55933 is a potent and selective KU59403 is an ATM inhibitor; ATM inhibitor vis-a-vie DNA-PK
- VE-822 is a selective ATR inhibitor
- NU6027 is a potent ATR inhibitor; with a Ki of 0.2 nM and an about 150
- PD-321852 is a CHKl and WEEl PD-407824 is a CHKl and WEEl inhibitor;
- PV1019 is a CHK2 inhibitor
- CCT241533 is a CHK2 inhibitor with about 63
- the check-point inhibitor is a PD-1 or PD-L1 inhibitor.
- the checkpoint inhibitor is a combination of 2 or several immune checkpoint inhibitors such as PD-1 plus CTL4, or PD-1 plus LAG3 (or TIM3 or GITR).
- step d) i.e. increasing antigen presentation and/or enhancing T cell response, comprises administering a therapy selected from the group comprising a T cell therapy (for example where T cells are activated in vitro to generate CTLs specific to an antigen), a cell therapy comprising engineered chimeric receptors, a PD1 inhibitor, a PD-L1 inhibitors, a CTLA4 inhibitor, a LAG3 inhibitor and a combination of two or more of the same.
- a therapy selected from the group comprising a T cell therapy (for example where T cells are activated in vitro to generate CTLs specific to an antigen), a cell therapy comprising engineered chimeric receptors, a PD1 inhibitor, a PD-L1 inhibitors, a CTLA4 inhibitor, a LAG3 inhibitor and a combination of two or more of the same.
- Increasing antigen presentation refers to the enhancement of the presentation of antigens to antigen presenting cells, for example by using a combination of treatments to make tumors necrotic, thereby providing a lot of potential antigenic material for presentation by antigen presenting cells.
- Other examples of increasing antigen presentation include enhancing the ability of dendritic cells and macrophages to phagocytose tumor and present tumor antigen; and blocking or inhibiting do-not-eat- me signals (CD47) on tumour cells that prevent phagocytosis of tumour cells.
- onclotytic viruses carrying a transgene can be used to infect the cancer cell and express the "protein or peptide" encoded on the cancer cells surface to increase antigen expression.
- Antigen in this context simply means a target for therapy or immune cells, in particular a target for immunotherapy.
- step d) comprises administering a therapy selected from the group comprising an oncolytic virus, a DLL inhibitor, ADH-1 molecular targeting therapy and combinations of two or more of the same
- the oncolytic virus is a virus selected from an adenovirus, herpes simplex virus, reovirus, measles virus, Newcastle disease virus, Seneca Valley virus, Vesicular stomatitis virus, polio virus, ECHO enterovirus, Coxsackie virus, and vaccinia virus, such as Enadenotucirev, talimogene laherparepvec, RIGVIR, Ad5-yCD/mutTKSR39rep-hIL12, CavatakTM, CG0070, DNX-2401, G207, HF10, Imlygic®, JX-594, MG1-MA3, MV-NIS, OBP-301, Reolysin®, or Toca 511.
- the oncolytic virus is a virus selected from an a
- Residual tumor cells refers to tumor cells that remain after the previous therapy, for exampleat the primary tumor site or in the vicinity, including circulating tumor cells, dormant cancer cells, cancer stems cells and combinations of the two or more of the sameThe goal of this step is to eradicate any remaining traces of cancer cells and minimise recurrence of the cancer.
- step e), i.e. clearing residual tumor cells comprises targeting cancer stem cells.
- the cancer stem cell therapy comprises targeting one or surface markers, for example with one or more monoclonal antibodies.
- the marker is selected from CD133, CD44, CD24, ESA, CD34 + CD38, and CD47.
- step e) comprises an agent, such as an antibody or binding fragment thereof, specific to TRAIL or NF-aB.
- step e) comprises an agent, such as an antibody or binding fragment thereof, specific to a cell marker Epcam, CD 133, CD44, CD24, ESA, CD34 + /CD38- and CD47.
- an agent such as an antibody or binding fragment thereof, specific to a cell marker Epcam, CD 133, CD44, CD24, ESA, CD34 + /CD38- and CD47.
- the cell markers are targeted by a chimeric antigen receptor.
- antibody or antibody binding fragment is in the format of an antibody drug conjugate.
- Multimodal or stage cancer therapy refers to discrete phases of therapy, for example each phase lasting in the region of 1 week to 6 months, such as 2 weeks to 1 month, 2 weeks to 2 months, 2 weeks to 3 months, 2 weeks to 4 months or 2 weeks to 5 months.
- the therapies may overlap but generally will not simply be a combination therapy.
- Combination therapy as employed herein is two or more active agents both administered over the same period of treatment.
- Neutrophils are key for angiogenesis, which turns cancers to fast growth via the so called angiogenic shift (7)
- TAMs Tumor associated Macrophages
- Macrophage type 2 is the most prevalent TAM and is not effective in antigen presentation (11)
- Dendritic cells capture antigens from tumour and migrate into the draining lymph nodes for presentation.
- the antigens can be presented with MHC class I and class II molecules.
- Tumours interfere with DC maturation through IL-10 and TSLP.
- the DCs are skewed towards a Th2 lineage which promotes tumour development.
- pDCs are also inhibited due to ligation of ILT7 with BST2 on tumour cells.
- the inhibited pDCs induce CD4+ T cells to differentiate to become immunosuppressive.
- GM-CSF in combination with other chemokines, can induce differentiation of inflammatory DCs that in turn will activate T cell functions.
- chemokines can induce differentiation of inflammatory DCs that in turn will activate T cell functions.
- Antibody therapy for engagement of surface molecules on DCs such as dectinl, DCSIGN/CD209 and CD40 putatively polarize DCs towards the proinflammatory phenotype. (19, 20, 21)
- a specific example of cancer metabolism inhibitor would be DHODH inhibitors that inhibit de novo synthesis of pyrimidines. This inhibition will specifically inhibit rapidly dividing cells. DHODH inhibition will also lead to induction of p53 and resulting apoptosis once a threshold of p53 levels is breached. (39)
- Neo-antigen presentation can also be greatly enhanced by blocking or inhibiting do-not-eat-me signals (CD47) on tumour cells that prevent phagocytosis of tumour cells.
- ICI immune checkpoint inhibitor
- ICIs Single or combinations or sequences of ICIs can be used and have shown additive effects in the clinic (25) b.
- These ICI therapies are not limited to T cell mediators and may also affect DCs, NK, NKT cells. They are a combination of antagonists to inhibitory signals and agonists to activation signals on the immune cells. (25)
- CTC Circulating tumour cells
- CSC Cancer Stem Cells
- DCC dormant cancer cells
- CSCs The phenotype of CSCs will differ depending on the cellular context.
- therapies against CSC have also shown efficacy, in reducing tumour recurrence and demonstrating long-term efficacy. (29, 30, 31, 32)
- Tumors signal via exosomes in the circulation to seeding areas about status and to steer grafting probabilities (34)
- Thrombocytes carry RNA and other tumor markers that tell status in tumor (35)
- Tumors recruit a number of cells and they are either supporting cells, or just bystanders, which are likely to physically block access to the cancer. It may also be that these supporting or bystander cells, feed of fuel the cancer cell growth. Therefore we hypothesise therapy should focus on removing these before shifting to changing the macrophage and dendritic cell infiltration.
- the immunostimulation by the means of making antigens available en masse, to the macrophages and the dendritic cells, should occur after the macrophages and the dendritic cells have been activated, and should precede application of the immune checkpoint inhibitors.
- Killing circulating tumor cells and cancer stem cells and dormant cancer cells is described as the last step. However this step can be applied at initiation and/or during the subsequent steps, and may be repeated together with immune reactivation at subsequent sessions.
- the timely feedback of the status of the tumor is important, since this multi-stage immuno, pathway and tumor escape/survival directed therapy needs to be steered and directed.
- daily measures of anti-tumour activity may enable one to be able to direct the therapy better (i.e. understanding when the neutrophils are down and depleted, and when the myeloid derived suppressor cells have been turned off, and when the macrophages have turned to Ml phenotype and how the immune checkpoint inhibition is successful in attacking the tumor).
- the detection of circulating tumor cells and RNA and DNA products from the tumor provides an indication whether the strategies to kill cancer stem cells have been successful.
- the method is different from other methods in that it foresees usage of key therapies for a limited period of time, for a therapy period of less than 2 months is envisioned for one or more stages. This therapy in parts or in full may need to be repeated at a later stage, potentially with changes that may take instruction from the ongoing immune and cancer diagnostics.
- a 2 week period of proliferation and nutrient/metabolic inhibition may be sufficient before taking down neutrophils and debulking of tumor.
- This step may take a week, followed by macrophage/dendritic cell type change (3-7 days), and then turning on the antigen production and presentation (1 to 2 weeks) before turning on the immune defense with T-cells and NK cells via the immune checkpoint inhibitors for at least 2 weeks.
- the killing of circulating and dormant cancer cells should be started, along with attempts to eradicate cancer stem cells.
- This new method represents a way to declare total war against the cancer and is believed to cause maximal effect in the shortest period of time, while keeping side effects to a minimum. It also is a new way to try to learn as much possible about the specific cancer and to be able to adapt therapy to achieve best effect and avoid side effects.
- the method should be meaningful both in early cancer (e.g. neo-adjuvant setting pre surgery) as well as a treatment alternative later in the cancer development.
- Treatment of cancer refers to administration of the combination therapy of the present disclosure for the purpose of reducing symptoms, ameliorating symptoms, slowing progressing (including spreading) of the cancer or a form thereof (such as metastatic cancer), stopping progression (including spreading) of the cancer or a form thereof (such as metastatic cancer), shrinking tumors, reducing metastases, reducing or eliminating certain populations of cancer cells, for example cancer stem cell populations, sending the cancer into remission, maintaining the cancer in remission, prophylactic treatment of cancer, curing cancer or a combination of one or more the same, as appropriate.
- Treatment of cancer as employed herein also refers to administration of the combination therapy of the present disclosure for the purpose of enhancing concomitant anti-cancer therapy, and for the purpose (at least in part) to reduce side effects and/or reducing the dose required of concomitant anti-cancer therapy.
- Lithium compound as employed herein refers to an active agent employed in therapy comprising the alkali metal lithium, for example lithium salts comprising a counter-ion such as selected from the group comprising aspartate, bromide, chloride, citrate, lithium carbonate, lithium sulfate and orotate.
- a counter-ion such as selected from the group comprising aspartate, bromide, chloride, citrate, lithium carbonate, lithium sulfate and orotate.
- Lithium salts are well established treatments for mood disorders.
- the main side effects are taste derangement, tremor and kidney side effects.
- these side effects are much less toxic than those encountered by patients receiving normal traditional cancer therapy, and the doses employed for cancer therapy may be lower than those employed for the treatment of mood disorders, especially when the lithium is employed in combination of disulfiram.
- the patient receiving the combination therapy of the present disclosure is monitored for plasma levels of lithium, for example when the treatment is started and/or on a monthly, three monthly, six monthly or annual basis.
- the dose of lithium employed is a dose that does not elicit side effects in the majority of patients.
- the majority of patients as employed herein refers to wherein at 51% of patients who receive that dose do not encounter therapy limiting side effects or only encounter minor side effects associated with the lithium such as 55, 60, 65, 70, 75, 80, 85, 90, 95 or 100% of patients do not encounter therapy limiting side effects.
- the lithium acts in cancer cells (for example cancer cells which are differentiated, i.e. non-cancer-stem-cells) at least via inhibiting the enzyme glycogen synthase kinase-3 (GSK-3), which is linked to the insulin and the Wnt pathways.
- GSK-3 glycogen synthase kinase-3
- the inhibition of GSK-3 may be associated with antiproliferative effects.
- lithium may also be linked to hormone receptors such as estrogen and androgen.
- other effects of lithium may be exerted on bone marrow and on adaptive and innate immune defenses which are not necessarily associated to the GSK3 mediated effects.
- lithium seems to increase the proliferation and self-renewal of stem cells, including cancer stem cells. That could be seen as a negative in terms of cancer therapy. However, in this instance it may be positive because it prevents the cancer cells evading treatment.
- lithium driving proliferation and self-renewal prevents the cancer cells becoming dormant.
- the latter is thought to be a mechanism for cancer cell resistance.
- preventing the option for the cancer cells to become dormant may enhance immediate efficacy of cancer therapy and may allow more or all of the cancer cell populations present to be treated. This in turn may improve the effectiveness of the cancer therapy and/or reduce the risk for cancer relapse.
- self-renewal may also mean that the effectiveness of concomitant therapies (such as traditional cancer therapies or therapies directed to cancerous at renewal mechanisms) may have an increased therapeutic window or have a therapeutic window which is shifted towards more "selectively" effecting cancer cells (or certain types of cancer cells, such as cancer stem cells).
- concomitant therapies such as traditional cancer therapies or therapies directed to cancerous at renewal mechanisms
- Another mechanism of lithium efficacy may be on the bone marrow and the T- cells, which through the inhibition of GSK3 may become more effective, for example providing prolonged T cell proliferation and increased IL-2 production.
- immune-stimulatory effects provided by employing the combination therapy of the present disclosure which renders the patient more receptive to therapy, for example in the form of immune-oncology compounds.
- Immune-oncology compounds also referred to as cancer immune therapy herein refers to therapies that target tumor associated antigens (TAAs) and stimulate immune responses to the cancer.
- TAAs tumor associated antigens
- lithium and disulfiram may work additively or in synergy, to decrease the survival of cancer cells, such as cancer stem cells.
- Disulfiram inhibits the aldehyde dehydrogenase, which is a key marker for cancer stem cells, and is a key enzyme for defense against reactive oxygen species (ROS), which may otherwise harm the cancer stem cell.
- ROS reactive oxygen species
- disulfiram may cause cancer stem cell reduction, for example via accumulation of reactive oxygen species leading to necrosis, apoptosis or autophagy thereby increasing death of cancer stem cells.
- Necrosis as employed herein refers to cell death through injury or damage to the cell.
- Apoptosis as employed herein refers to hastening programmed cell death, which is sometimes referred to as cell assisted suicide.
- Autophagy as employed herein refers to a complex process of intracellular degradation, which may deliver nutrients and/or energy to other cells.
- the combination therapy of the present disclosure makes it difficult for cancer cells to stay in quiescent dormant mode, for example by provoking self-renewal stimulated by the lithium part of the combined therapy. This renders the cancer stem cells vulnerable to cancer treatments, either via the disulfiram part or by other anti-cancer therapeutics.
- ROS reactive oxygen species
- Reactive oxygen species refers to peroxides, superoxides, hydroxyl radicals, singlet oxygen and the like.
- ROS reactive oxygen species
- DSF Disulfiram
- aldehyde dehydrogenase aldehyde dehydrogenase
- its' inhibition causes upstream accumulation of ethanol aldehyde which is linked to physical discomfort.
- Aldehyde dehydrogenase is also a marker of cancer stem cells and the present inventors believe that disulfiram via inhibition of aldehyde dehydrogenase increases the concentration of reactive oxygen species. This increased concentration of reactive oxygen species in turn damages the cancer stem cells. Thus is hypothesized that DSF suppresses self-renewal capability mainly through the activation of reactive oxygen species (ROS)-p38 MAPK pathway.
- ROS reactive oxygen species
- TNF-alpha TNF-alpha
- vascular endothelial growth factor TNF-alpha
- MMP-2 and MMP-9 from cultured macrophages, which may contribute to the overall effectiveness of the combination therapy.
- effects of lithium on the bone marrow and on the immune system may add to the breadth of potential positives of the therapy of the present disclosure.
- the combination therapy of the present disclosure has beneficial effects in protecting non-cancerous tissue from the toxic effect of cancer therapy that may be employed in combination with the therapy comprising disulfiram and a lithium compound.
- Combination treatment refers to a treatment wherein the duration of time when the patient is on or taking the medicament comprising a lithium compound is also the time when the patient is taking or is administered a medicament comprising the disulfiram (i.e. treatment regimens for lithium and disulfiram at least overlap).
- a lithium compound and a disulfiram are administered or taken in the same 7 days period. In one embodiment the disulfiram is administered or taken on the same day as the lithium compound.
- the combination therapy of the present disclosure is employed as adjuvant therapy, for example post-surgery or post-chemotherapy.
- the combination therapy of the present disclosure is employed as neo-adjuvant therapy.
- the combination treatment of the present disclosure may be employed in combination with one or more further cancer treatments, for example
- the therapy may reduce the side effects of such and may allow usage of higher and more effective doses of other cancer therapies to be employed and tolerated.
- a suitable dose may be chosen by the practitioner based on the nature of the cancer being treated.
- Chemotherapeutic agent as employed herein is intended to refer to specific antineoplastic chemical agents or drugs that are selectively destructive to malignant cells and tissues. Chemotherapeutic agent and chemotherapy or cytotoxic agent are employed interchangeably herein unless the context indicates otherwise. Examples inlcude alkylating agents, antimetabolites, anthracyclines, plant alkaloids, topoisomerase inhibitors, and other antitumour agents. Other examples of chemotherapy include doxorubicin, 5-fluorouracil (5-FU), paclitaxel, capecitabine, irinotecan, and platins such as cisplatin and oxaliplatin.
- 5-fluorouracil 5-FU
- paclitaxel paclitaxel
- capecitabine paclitaxel
- irinotecan irinotecan
- platins such as cisplatin and oxaliplatin.
- alkylating agents which may be employed in the method of the present disclosure include an nitrogen mustards alkylating agent, nitrosoureas, tetrazines, aziridines, platins and derivatives, and non-classical alkylating agents.
- platinum containing chemotherapeutic agent also referred to as platins
- chemotherapeutic agent such as cisplatin, carboplatin, oxaliplatin, satraplatin, picoplatin, nedaplatin, triplatin and lipoplatin (a liposomal version of cisplatin), in particular cisplatin, carboplatin and oxaliplatin.
- the dose for cisplatin ranges from about 20 to about 270 mg/m 2 depending on the exact cancer. Often the dose is in the range about 70 to about 100mg/m 2 .
- the dose for cisplatin ranges from about 20 to about 270 mg/m 2 depending on the exact cancer. Often the dose is in the range about 70 to about 100mg/m 2 .
- hemotherapeutic agent is a topoisomerase inhibitor.
- Nitrogen mustards include mechlorethamine, cyclophosphamide, melphalan, chlorambucil, ifosfamide and busulfan.
- Nitrosoureas include N-Nitroso-N-methylurea (MNU), carmustine (BCNU), lomustine (CCNU) and semustine (MeCCNU), fotemustine and streptozotocin.
- Tetrazines include dacarbazine, mitozolomide and temozolomide.
- Aziridines include thiotepa, mytomycin and diaziquone (AZQ).
- antimetabolites examples include anti-folates (for example methotrexate and pemetrexed), purine analogues (for example thiopurines, such as azathiopurine, mercaptopurine, thiopurine, fludarabine (including the phosphate form), pentostatin and cladribine), pyrimidine analogues (for example fluoropyrimidines, such as 5-fluorouracil and prodrugs thereof such as capecitabine [Xeloda®]), floxuridine, gemcitabine, cytarabine, decitabine, raltitrexed(tomudex) hydrochloride, cladribine and 6-azauracil.
- anti-folates for example methotrexate and pemetrexed
- purine analogues for example thiopurines, such as azathiopurine, mercaptopurine, thiopurine, fludarabine (including the phosphate form),
- anthracyclines examples include daunorubicin (Daunomycin), daunorubicin (liposomal), doxorubicin (Adriamycin), doxorubicin (liposomal), epirubicin, idarubicin, valrubicin currenlty used only to treat bladder cancer and mitoxantrone an anthracycline analog, in particular doxorubicin.
- anti-microtubule agents examples include vinca alkaloids and taxanes.
- Vinca alkaloids include completely natural chemicals for example vincristine and vinblastine and also semi-synthetic vinca alkaloids, for example vinorelbine, vindesine, and vinflunine.
- Taxanes include paclitaxel, docetaxel, abraxane, carbazitaxel and derivatives of thereof.
- Derivatives of taxanes as employed herein includes reformulations of taxanes like taxol, for example in a micelluar formulaitons, derivatives also include chemical derivatives wherein synthetic chemistry is employed to modify a starting material which is a taxane.
- Topoisomerase inhibitors which may be employed in a method of the present disclosure include type I topoisomerase inhibitors, type II topoisomerase inhibitors and type II topoisomerase poisons.
- Type I inhibitors include topotecan, irinotecan, indotecan and indimitecan.
- Type II inhibitors include genistein and ICRF 193 which has the following structure:
- Type II poisons include amsacrine, etoposide, etoposide phosphate, teniposide and doxorubicin and fluoroquinolones.
- he chemotherapeutic agent is a parp inhibitor, in particular as disclosed herein.
- the combination therapy is administered with or following a treatment regime comprising a platinum containing chemotherapeutic agent, for example cisplatin, carboplatin or oxaliplatin.
- a combination of chemotherapeutic agents employed is, for example a platin and 5-FU or a prodrug thereof, for example cisplatin or oxaplatin and capecitabine or gemcitabine, such as FOLFOX.
- the chemotherapy comprises a combination of chemotherapy agents, in particular cytotoxic chemotherapeutic agents.
- the chemotherapy combination comprises a platin, such as cisplatin and fluorouracil or capecitabine.
- the chemotherapy combination in capecitabine and oxaliplatin in capecitabine and oxaliplatin (Xelox).
- the chemotherapy is a combination of folinic acid and 5-FU, optionally in combination with oxaliplatin.
- the chemotherapy is a combination of folinic acid, 5-FU and irinotecan (FOLFIRI), optionally in combination with oxaliplatin (FOLFIRINOX).
- the regimen consists of: irinotecan (180 mg/m 2 IV over 90 minutes) concurrently with folinic acid (400 mg/m 2 [or 2 x 250 mg/m 2 ] IV over 120 minutes); followed by fluorouracil (400-500 mg/m 2 IV bolus) then fluorouracil (2400-3000 mg/m 2 intravenous infusion over 46 hours). This cycle is typically repeated every two weeks.
- the dosages shown above may vary from cycle to cycle.
- the combination employs a microtubule inhibitor, for example vincristine sulphate, epothilone A, N-[2-[(4-Hydroxyphenyl)amino]-3- pyridinyl]-4-methoxybenzenesulfonamide (ABT-751), ataxol derived chemotherapeutic agent, for example paclitaxel, abraxane, or docetaxel or a combination thereof.
- a microtubule inhibitor for example vincristine sulphate, epothilone A, N-[2-[(4-Hydroxyphenyl)amino]-3- pyridinyl]-4-methoxybenzenesulfonamide (ABT-751), ataxol derived chemotherapeutic agent, for example paclitaxel, abraxane, or docetaxel or a combination thereof.
- the combination employs an mTor inhibitor.
- mTor inhibitors include: everolimus (RADOOl), WYE-354, KU-0063794, papamycin (Sirolimus), Temsirolimus, Deforolimus(MK-8669), AZD8055 and BEZ235(NVP-
- the chemotherapy combination employs a microtubule inhibitor, for example vincristine sulphate, epothilone A, N-[2-[(4- Hydroxyphenyl)amino]-3-pyridinyl]-4-methoxybenzenesulfonamide (ABT-751), a taxol derived chemotherapeutic agent, for example paclitaxel, abraxane, or docetaxel or a combination thereof.
- a microtubule inhibitor for example vincristine sulphate, epothilone A, N-[2-[(4- Hydroxyphenyl)amino]-3-pyridinyl]-4-methoxybenzenesulfonamide (ABT-751), a taxol derived chemotherapeutic agent, for example paclitaxel, abraxane, or docetaxel or a combination thereof.
- a microtubule inhibitor for example vincristine sulphate, epothilone A,
- the chemotherapy combination employs a MEK inhibitor.
- MEK inhibitors include: AS703026, CI-1040 (PD184352), AZD6244 (Selumetinib), PD318088, PD0325901, AZD8330, PD98059, U0126-EtOH, BIX 02189 or BIX 02188.
- the chemotherapy combination employs an AKT inhibitor.
- AKT inhibitors include: MK-2206 and AT7867.
- the combination employs an aurora kinase inhibitor.
- aurora kinase inhibitors include: Aurora A Inhibitor I, VX-680, AZD1152- HQPA (Barasertib), SNS-314 Mesylate, PHA-680632, ZM-447439, CCT129202 and Hesperadin.
- the chemotherapy combination employs a p38 inhibitor, for example as disclosed in WO2010/038086, such as N-[4-( ⁇ 4-[3-(3-tert-Butyl-l-p-tolyl- lH-pyrazol-5-yl)ureido]naphthalen-l-yloxy ⁇ methyl)pyridin-2-yl]-2-methoxyacetamide.
- a p38 inhibitor for example as disclosed in WO2010/038086, such as N-[4-( ⁇ 4-[3-(3-tert-Butyl-l-p-tolyl- lH-pyrazol-5-yl)ureido]naphthalen-l-yloxy ⁇ methyl)pyridin-2-yl]-2-methoxyacetamide.
- the combination employs a Bcl-2 inhibitor.
- Bcl- 2 inhibitors include: obatoclax mesylate, ABT-737, ABT-263(navitoclax) and TW-37.
- the chemotherapy combination comprises an antimetabolite such as capecitabine (xeloda), fludarabine phosphate, fludarabine (fludara), decitabine, raltitrexed (tomudex), gemcitabine hydrochloride and cladribine.
- an antimetabolite such as capecitabine (xeloda), fludarabine phosphate, fludarabine (fludara), decitabine, raltitrexed (tomudex), gemcitabine hydrochloride and cladribine.
- the chemotherapy combination comprises ganciclovir, which may assist in controlling immune responses and/or tumour vasculation.
- the gastric cancer is selected from the group comprising adenocarcinoma of the stomach, squamous cell carcinomas, lymphoma of the stomach, gastric stromal tumour, and neuroendocrine tumours.
- the liver cancer is, for example selected from the group hepatocellular carcinoma, cholangiocarcinoma, angiosarcoma, and hepatoblastoma, in particular hepatocellular carcinoma.
- the primary liver cancer is stage 1, 2, 3 or 4.
- the liver cancer is secondary or metastasized liver cancer.
- Prostate cancer refers to cancer of the prostate, for example ductal adenocarcinoma, transitional cell (urothelial cancer), squamous cell cancer, carcinoid of the prostate, small cell cancer or sarcoma and sarcomatoid cancer.
- Pancreatic cancer as employed herein includes exocrine cancers (including rare forms thereof such as cystitic tumours, and cancer of the acinar cells), endocrine pancreatic tumours (including gastrinomas, insulinomas, somatostatinomas, VIPomas, glucagonomas), pancreatoblastoma, sarcomas of the pancreas and lymphoma.
- Biliary tract cancer refers to cholangiocarcinoma (intrahepatic, extrahepatic), gall bladder cancer and ampullary carcinoma.
- Colorectal cancer refers to cancer or the colon and/or rectum and includes squamous cell cancers, carcinoid tumours, sarcomas and lymphomas.
- Breast cancer refers to cancer of the breast and includes ductal carcinoma in situ, lobular carcinoma in situ, invasive ductal breast cancer, invasive lobular breast cancer, invasive breast cancer, Paget's disease, angiosarcoma of the breast and rare types of breast cancer such as medullary breast cancer, mucinous breast cancer, tubular breast cancer, adenoid cystic carcinoma of the breast metaplastic breast cancer, basal type breast cancer and papillary breast cancer.
- Lung cancers are classified according to histological type and are categorized by the size and appearance of the malignant cells seen by a histopathologist under a microscope.
- two broad classes are distinguished: non-small cell lung carcinoma and small cell lung carcinoma.
- the epithelial cancer is lung cancer, for example small-cell lung cancer (SCLC) and non-small-cell lung cancer (NSCLC).
- SCLC small-cell lung cancer
- NSCLC non-small-cell lung cancer
- Non-small-cell lung carcinoma The three main subtypes of NSCLC are adenocarcinoma, squamous-cell carcinoma and large-cell carcinoma.
- adenocarcinoma Nearly 40% of lung cancers are adenocarcinoma, which usually originates in peripheral lung tissue.
- a subtype of adenocarcinoma, the bronchioloalveolar carcinoma, is more common in female never-smokers, and may be associated with a better long term survival.
- Squamous-cell carcinoma accounts for about 30% of lung cancers. They typically occur close to large airways. A hollow cavity and associated cell death are commonly found at the center of the tumor. About 9% of lung cancers are large-cell carcinoma. These are so named because the cancer cells are large, with excess cytoplasm, large nuclei and conspicuous nucleoli.
- SCLC Small-cell lung carcinoma-In small-cell lung carcinoma
- the cells contain dense neurosecretory granules (vesicles containing neuroendocrine hormones), which give this tumor an endocrine/paraneoplastic syndrome association.
- These cancers grow quickly and spread early in the course of the disease. Sixty to seventy percent have metastatic disease at presentation.
- the cancer is non-small lung carcinoma.
- the cancer is liver cancer, for example a liver metastasis from a primary cancer, for example colon cancer, which has spread to the liver.
- the liver cancer is HCC hepatocellular carcinoma.
- renal cancer for example renal cell carcinoma and/or urothelial cell carcinoma.
- Other examples of renal cancer include squamous cell carcinoma, juxtaglomerular cell tumor (reninoma), angiomyolipoma, renal oncocytoma, Bellini duct carcinoma, clear-cell sarcoma of the kidney, mesoblastic nephroma, Wilms' tumor, mixed epithelial stromal tumor, clear cell adenocarcinoma, transitional cell carcinoma, inverted papilloma, renal lymphoma, teratoma, carcinosarcoma, and carcinoid tumor of the renal pelvis.
- reninoma juxtaglomerular cell tumor
- angiomyolipoma renal oncocytoma
- Bellini duct carcinoma clear-cell sarcoma of the kidney
- mesoblastic nephroma Wilms' tumor
- mixed epithelial stromal tumor mixed epithelial stromal tumor
- the cancer is bladder cancer, for example is any of several types of malignancy arising from the epithelial lining (i.e. the urothelium) of the urinary bladder.
- the epithelial lining i.e. the urothelium
- the bladder cancers are transitional cell carcinoma.
- the other 10% are squamous cell carcinoma, adenocarcinoma, sarcoma, small cell carcinoma, and secondary deposits from cancers elsewhere in the body.
- the staging of this cancer is given below.
- the current disclosure extends to any stage of bladder cancer.
- Cancerous ovarian tumours can start from three common cell types:
- Germ Cells - cells that are destined to form eggs • Stromal Cells - Cells that release hormones and connect the different structures of the ovaries
- the present disclosure relates to treatment of ovarian cancer from any source, for example as described herein, in particular epithelium cells.
- Epithelial ovarian carcinomas account for 85 to 90 percent of all cancers of the ovaries.
- Epithelial ovarian tumors develop from the cells that cover the outer surface of the ovary. Most epithelial ovarian tumors are benign (noncancerous). There are several types of benign epithelial tumors, including serous adenomas, mucinous adenomas, and Brenner tumors. Cancerous epithelial tumors are carcinomas - meaning they begin in the tissue that lines the ovaries. These are the most common and most dangerous of all types of ovarian cancers. Unfortunately, almost 70 percent of women with the common epithelial ovarian cancer are not diagnosed until the disease is advanced in stage.
- LMP tumors tumors of low malignant potential
- Germ Cell Tumors Ovarian germ cell tumors develop from the cells that produce the ova or eggs. Most germ cell tumors are benign (non-cancerous), although some are cancerous and may be life threatening. The most common germ cell malignancies are maturing teratomas, dysgerminomas, and endodermal sinus tumors. Germ cell malignancies occur most often in teenagers and women in their twenties. Today, 90 percent of patients with ovarian germ cell malignancies can be cured and their fertility preserved.
- Stromal Tumors - Ovarian stromal tumors are a rare class of tumors that develop from connective tissue cells that hold the ovary together and those that produce the female hormones, estrogen and progesterone. The most common types are granulosa- theca tumors and Sertoli-Leydig cell tumors. These tumors are quite rare and are usually considered low-grade cancers, with approximately 70 percent presenting as Stage I disease (cancer is limited to one or both ovaries).
- Primary Peritoneal Carcinoma The removal of one's ovaries eliminates the risk for ovarian cancer, but not the risk for a less common cancer called Primary Peritoneal Carcinoma.
- Primary Peritoneal Carcinoma is closely rated to epithelial ovarian cancer (most common type). It develops in cells from the peritoneum (abdominal lining) and looks the same under a microscope. It is similar in symptoms, spread and treatment. Stages of Ovarian Cancer
- stage of a tumor can be determined during surgery, when the doctor can tell if the cancer has spread outside the ovaries.
- the treatment plan and prognosis (the probable course and outcome) will be determined by the stage of cancer.
- Stage I - Growth of the cancer is limited to the ovary or ovaries.
- Stage IA - Growth is limited to one ovary and the tumor is confined to the inside of the ovary. There is no cancer on the outer surface of the ovary. There are no ascites present containing malignant cells. The capsule is intact.
- Stage IB - Growth is limited to both ovaries without any tumor on their outer surfaces. There are no ascites present containing malignant cells. The capsule is intact.
- Stage IC The tumor is classified as either Stage IA or IB and one or more of the following are present: (1) tumor is present on the outer surface of one or both ovaries;
- Stage II - Growth of the cancer involves one or both ovaries with pelvic extension.
- Stage IIA - The cancer has extended to and/or involves the uterus or the fallopian tubes, or both.
- Stage IIB - The cancer has extended to other pelvic organs.
- Stage IIC The tumor is classified as either Stage IIA or IIB and one or more of the following are present: (1) tumor is present on the outer surface of one or both ovaries; (2) the capsule has ruptured; and (3) there are ascites containing malignant cells or with positive peritoneal washings.
- Stage III - Growth of the cancer involves one or both ovaries, and one or both of the following are present: (1) the cancer has spread beyond the pelvis to the lining of the abdomen; and (2) the cancer has spread to lymph nodes.
- the tumor is limited to the true pelvis but with histologically proven malignant extension to the small bowel or omentum.
- Stage IIIA - During the staging operation, the practitioner can see cancer involving one or both of the ovaries, but no cancer is grossly visible in the abdomen and it has not spread to lymph nodes. However, when biopsies are checked under a microscope, very small deposits of cancer are found in the abdominal peritoneal surfaces.
- Stage IIIB The tumor is in one or both ovaries, and deposits of cancer are present in the abdomen that are large enough for the surgeon to see but not exceeding 2 cm in diameter. The cancer has not spread to the lymph nodes.
- Stage IIIC The tumor is in one or both ovaries, and one or both of the following is present: (1) the cancer has spread to lymph nodes; and/or (2) the deposits of cancer exceed 2 cm in diameter and are found in the abdomen.
- Stage IV This is the most advanced stage of ovarian cancer. Growth of the cancer involves one or both ovaries and distant metastases (spread of the cancer to organs located outside of the peritoneal cavity) have occurred. Finding ovarian cancer cells in pleural fluid (from the cavity which surrounds the lungs) is also evidence of stage IV disease.
- the ovarian cancer is: type I, for example IA, IB or IC; type II, for example IIA, IIB or IIC; type III, for example IIIA, IIIB or III C; or type IV.
- the breast cancer is one selected from the group comprising ductal carcinoma in situ, lobular carcinoma in situ, invasive breast cancer, invasive lobular breast cancer, Paget's disease, angiosarcoma of the breast, medulllary breast cancer, mucinous breast cancer, tubular breast cancer, adenoid cystic carcinoma of the breast, metaplastic breast cancer, lymphoma of the breast, basal type breast cancer, phyllodes or cystosarcoma phyllodes and papillary breast cancer.
- the prostate cancer is selected from the group comprising ductal adenocarcinoma, transitional cell (urothelial) cancer, squamous cell cancer, carcinoid, small cell cancer, sarcomas and sarcomatoid cancers.
- the prostate cancer is selected from the group comprising ductal adenocarcinoma, transitional cell (urothelial) cancer, squamous cell cancer, carcinoid, small cell cancer, sarcomas and sarcomatoid cancers and a combination of two or more of the same.
- Thyroid cancer refers to cancer of the thyroid originating from follicular or parafollicular thyroid cells and includes papillary thyroid cancer (75% to 85% of cases); follicular thyroid cancer (10% to 20% of cases); medullary thyroid cancer (5% to 8% of cases)- cancer of the parafollicular cells, often part of multiple endocrine neoplasia type 2; poorly differentiated thyroid cancer; anaplastic thyroid cancer (less than 5% of cases) is not responsive to treatment and can cause pressure symptoms, thyroid lymphoma, squamous cell thyroid carcinoma, sarcoma of thyroid.
- Renal cancer refers to cancer of the kidney, for example renal cell carcinoma and transitional cell carcinoma of the renal pelvis, such as squamous cell carcinoma, juxtaglomerular cell tumor (reninoma), angiomyolipoma, renal oncocytoma, bellini duct carcinoma, clear-cell sarcoma of the kidney, mesoblastic nephroma, Wilms' tumor, mixed epithelial stromal tumor, clear cell adenocarcinoma, transitional cell carcinoma, inverted papilloma, renal lymphoma, teratoma, carcinosarcoma; carcinoid tumor of the renal pelvis.
- reninoma juxtaglomerular cell tumor
- angiomyolipoma angiomyolipoma
- renal oncocytoma bellini duct carcinoma
- clear-cell sarcoma of the kidney mesoblastic nephroma, Wilms' tumor, mixed epithelial stromal tumor
- Bladder cancer as employed herein refers to cancer of the bladder including transitional cell bladder cancer, carcinoma in situ, papillary cancer and rarer types of bladder cancer such as squamous cell cancer, adenocarcinoma and a combination of two or more of the same.
- Esophageal cancer as employed herein refers to cancer of the oesphagus including esophageal squamous-cell carcinomas, esophageal adenocarcinomas, and variants of squamous-cell carcinoma, and non-epithelial tumors, such as leiomyosarcoma, malignant melanoma, rhabdomyosarcoma, lymphoma, among others and a combination of two or more of the same.
- Head and neck cancer refers to cancer of the neck and/or head, including mouth cancer, nasopharyngeal cancer, oropharyngeal cancer, paranasal sinus cancer, salivary gland cancer and a combination of two or more of the same.
- the chemotherapy combination comprises ganciclovir, which may assist in controlling immune responses and/or tumour vasculation.
- Embodiments of the invention may be combined. Embodiments are described herein as comprising certain features/elements. The disclosure also extends to separate embodiments consisting or consisting essentially of said features/elements.
- the IL-6-STAT3 axis mediates a reciprocal crosstalk between cancer-derived mesenchymal stem cells and neutrophils to synergistically prompt gastric cancer progression Q Zhu,l,4 X Zhang,l,4,* L Zhang,l W Li,2 H Wu,2 X Yuan,l F Mao,l M Wang.1 W Zhu,l H Qian,l and W Xul,3,*
- Macrophage plasticity and polarization in vivo Veritas. Sica Al, Mantovani A.
- TNF skews monocyte differentiation from macrophages to dendritic cells. Chomarat P 1 , Dantin C, Bennett L, Banchereau J, Palucka AK.
- T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions.
- Lithium an anti-psychotic drug, greatly enhances the generation of induced pluripotent stem cells; Quan Wang,l Xinxiu Xu,2 Jun Li,3 Jing Liu,4 Haifeng Gu,l Ru Zhang,2 Jiekai Chen,4 Yin Kuang,5 Jian Fei,5 Cong Jiang,6 Ping Wang,6 Duanqing Pei,4 Sheng Ding,3 and Xin Xiel,2,*
- FIG. 2 Schematic diagram showing multimodal cancer treatment according to the present method
- Example 1 Protocol for treating a cholangiocarcinoma patient Example 1 Protocol for treating a cholangiocarcinoma patient.
- a pre-step as much cancerous tissue as possible is removed by surgery.
- the patient is then given a dose of 300-400mg bidaily of varlitinib together with a chemotoxic agent (eg capecitabine or gemcitabine) for 12-28 days.
- a chemotoxic agent eg capecitabine or gemcitabine
- AZD5069 is given as a monotherapy or concomitantly with a T-cell stimulator for 4 to 6 weeks. After completing the latter 4, 5 or 6 cycles of chemotherapy comprising gemcitabine and cisplatin are given.
- treatment with permbrolizumab is given at 2 mg/Kg or 200mg every 3 weeks for 3, 6, 9, 12, 15 or 18 weeks.
- the final stage of the therapy is one cycle of antibody drug conjugate, wherein the antibody is specific to Epcam, potentially in combination with an immune-oncology (IO) agent such as pemrolizumab.
- IO immune-oncology
- a pre-step as much cancerous tissue as possible is removed by surgery.
- the patient is then given a dose of 300-400mg bidaily of varlitinib together with a chemotoxic agent (eg capecitabine or gemcitabine) for 12-28 days.
- a chemotoxic agent eg capecitabine or gemcitabine
- AZD5069 is given as a monotherapy for 4 to 6 weeks. After completing the latter 4, 5 or 6 cycles of chemotherapy comprising 5-FU and leucovorin are given.
- treatment with permbrolizumab is given at 2 mg/Kg or 200mg every 3 weeks for 3, 6, 9, 12, 15 or 18 weeks.
- the final stage of the therapy is one cycle of antibody drug conjugate, wherein the antibody is specific to Epcam, potentially in combination with an 10 agent such as pemrolizumab.
- Example 3 Protocol for treating a cholangiocarcinoma patient
- AZD5069 eg capecitabine or gemcitabine
- AZD5069 is given as a monotherapy for 4 to 6 weeks. After completing the latter 4, 5 or 6 cycles of
- an IO agent such as pemrolizumab.
- treatment with permbrolizumab is given at 2 mg/Kg or 200mg every 3 weeks for 3, 6, 9, 12, 15 or 18 weeks.
- the final stage of the therapy targeted radiation therapy in combination with a PARP inhibitor potentially in combination with an 10 agent such as pemrolizumab.
- Example 4 Protocol for treating a cholangiocarcinoma patient
- AZD5069 e.g. capecitabine or gemcitabine
- AZD5069 is given as a monotherapy for 4 to 6 weeks. After completing the latter 4, 5 or 6 cycles of
- treatment with permbrolizumab is given at 2 mg/Kg or 200mg every 3 weeks for 3, 6, 9, 12, 15 or 18 weeks.
- the final stage of the therapy targeted radiation therapy in combination with a PARP inhibitor potentially in combination with an 10 agent such as pemrolizumab.
Abstract
Disclosed herein is a method of treating cancer, comprising: a) reducing or stopping cancer proliferation, b) debulking tumour mass, c) activating immune cells, d) increasing antigen presentation and/or enhancing T cell response, and e) clearing residual tumour cells.
Description
METHOD OF TREATING CANCER
The present disclosure relates to a method of treating cancer, use of medicaments in a staged combination therapy for the treatment of cancer (also referred to herein as multimodal cancer therapy), and use of a medicament or medicaments in the manufacture of a multimodal therapy for the treatment of cancer, for example linked with dynamic input of tumor status, to optimise intervention and timing.
BACKGROUND
The treatment of cancer is still a huge challenge and burden to society. The present inventor believes that the effectiveness of cancer therapy can be greatly increased by employing a multimodal method of treatment. That is conscious choice of sequence and the timing of multiple treatments to achieve improved outcomes, for patients.
The involvement of the immune system in defense against cancer growth has been evident for a long time but with the emergence of the immune check-point inhibitor therapies (for example, PD-1, PDL-1, CTLA4) the understanding of the field has rapidly expanded. It is clear that tumors attract immune cells. However, it is also clear that many of these cells that are effective against viral and bacterial infections, offer little effect against cancer, and may even be counterproductive and cancer supporting.
It is now thought that tumor associated macrophages actually feed and protect the cancer cells. Stroma, containing immune cells, builds up around cancer cells and creates a protected environment where the cancer flourishes.
Cancer cells are highly adapted to corrupting and hijacking many natural biological processes that exist in the body. Cancers are sometimes based on mutations and modifications of cells and thus can readily change and adapt. Given this the present inventor believes that is unlikely that one or two modes of treatment will be effective for the treatment of the majority of cancers.
Therefore, the inventor has designed a new method to treat cancer, which involves a radical resetting of the immune system, which will be much more efficacious than just using simple steps, such as immune check point inhibitors or combinations thereof.
In some ways, the method of present disclosure can be considered a "reboot" of the immune system, which after treatment is then able to fight the cancer.
SUMMARY OF THE DISCLOSURE
Thus, the present disclosure provides a method of treating cancer comprising the steps;
a) reducing or stopping cancer proliferation,
al) declutter of tumor infiltrating immune cells,
b) debulking tumour mass, and/or increasing antigen presentation,
c) activating immune cells,
d) increasing antigen presentation and/or enhancing T cell response, and e) clearing residual tumor cells.
The treatment schedule of the present disclosure is a paradigm shift in cancer treatment, because at the present time standard of care cancer treatment generally only involves one or two of the above steps.
Whilst some cancer therapy regimes (like chemotherapy regimens) are a combination or cocktail of the therapeutic agents from the outset, and cancer adjuvant therapy is known (i.e. chemotherapy or radiation therapy after surgery to excise a tumor) subsequent cancer therapies are not employed until the first line or second therapy has failed.
The multimodal therapy of the present disclosure is not the same as simply trying different treatments after the failure of a treatment. Instead it involves pro- actively employing multiples modes of treatment, in particular in the order specified herein.
In one embodiment the method comprises the further step of tumour surveillance.
In one embodiment the therapeutic steps are taken in fast succession, in particular while surveying and reading "efficacy", for example by studying effects on immune parameters and/or variables showing circulating tumor components. Efficacy here is not employed in the strict technical sense but simply to effects more generically.
The fast delivery of a sequence of therapies and the elected timing of the next treatment step may be important to reset the immune system while stopping further cancer growth. Thus in one embodiment the present multimodal treatment comprises multiple treatment steps, which are employed at specific times, for example over a period of 1 to 12 months, such as 1 to 2 months, 1 to 3 months, 1 to 4 months, 1 to 5 months, 1 to 6 months, 1 to 7 months, 1 to 8 months, 1 to 9 months, 1 to 10 months or 1 to 11 months.
This fast succession of different modes of treatment is highly advantageous because it minimises the time available for the cancer cells to "regroup" and develop strategies to make them resistant to treatment.
In one embodiment the "subsequent" therapies are not employed because a therapy has failed i.e. the further therapy is not started because there is resistance to "first line or second line" therapy.
In one embodiment step b) follows step a) or step al). In one embodiment step c) follows step b). In one embodiment step d) follows step c). In one embodiment step e) follows step d).
In one embodiment one or more treatment steps may overlap or be at the same time.
In one embodiment step a) and al) overlap or are at the same time. In one embodiment step a) and b) overlap or are at the same time. In one embodiment step al) and b) overlap or are at the same time. In one embodiment step b) and c) overlap or are at the same time. In one embodiment step c) and d) overlap or are at the same time. In one embodiment step d) and e) overlap or are at the same time.
In one embodiment step a), al) and b) overlap or are at the same time. In one embodiment step a), b) and c) overlap or are at the same time. In one embodiment step al), b) and c) overlap or are at the same time. In one embodiment step b), c) and d) overlap or are at the same time. In one embodiment step c), d) and e) overlap or are at the same time.
In one embodiment step a), al), b) and c) overlap or are at the same time. In one embodiment step a), b), c) and d) overlap or are at the same time. In one embodiment step al), b), c) and d) overlap or are at the same time. In one embodiment step b), c), d) and e) overlap or are at the same time.
In one embodiment step a), b), c), d) and e) overlap or are at the same time. In one embodiment step al), b), c), d) and e) overlap or are at the same time
In one embodiment one or more of the steps do not overlap, for example 2, 3, 4 or all of the step do not overlap.
In one embodiment step b) and d) do not overlap and are not at the same time.
In one embodiment step e) does not overlap with step c).
In one embodiment the method comprises a pre-step of surgery, for example to remove tumour mass and/or lymph nodes and the like.
In one embodiment the method comprises irradiation.
In one embodiment step a) is a treatment selected from the group comprising irradiation, chemotherapy, anti-proliferation pathway therapy (for example anti- oestrogen, anti-androgen, anti-HER, anti-BCR/ABL, anti-VEGF, anti-PDGF, anti-BRAF antibody molecule [including a bispecific antibody, full-length or an antibody binding fragment], with or without combining with the appropriate chemotherapy) and a combination of two or more of the same.
In one embodiment at least one agent employed in step a) is an antiproliferative agent, for example selected from the group 25-hydroxcholesterol, 3-hydroxtyrosol, 7β- hydroxycholestrol, aloe-emodin, apigenin, artesunate, berberine, caffeine power (C0750), dichloromethylenediphosphonic acid (for example as a salt, such as a disodium salt), emodin, HA 14-1, hyperforin, N-acetyl-D-sphingosine, N-hexanoyl-D-sphingosine, oleuropein, pathenolide, tangeretin, tanshinone IIA, β-cryptoxanthine, β-cryptoxanthin, β-lonone, trans-cinnamaldehyde and combinations thereof.
Other agents that can be employed alone or in a combination in step a) include high doses of vitamin Bl, parp inhibitors, a gene product of NME2, myrtillin (delphinidin-3-O-glucoside), tulipanin (delphinidin-3-O-rutinoside), violdelphin (delphinidin 3-rutinoside-7-0-(6-0-(4-(6-0-(4-hydroxybenzoyl) -p-D-glucosyl)oxy benzoyiJ-p-D-glucoside), nasunin (delphinidin-3-(p-coumaroylrutinoside)-5-glucoside) and combinations of two or more of the same.
In one embodiment therapy employed in step a) is Varlitinib [(i?)-N4-[3-Chloro- 4-(thiazol-2-ylmethoxy)-phenyl]-N6-(4-methyl-4, 5,-dihydro-oxazol-2-yl)-quinazoline- 4,6-diamine] or a pharmaceutically acceptable salt thereof, which may be employed alone or in a combination therapy.
The Varlitinib, is administered at a dose in the range lOOmg to 900mg on each occasion, in particular 200 mg, 300mg, 400mg or 500mg each dose, such as 400mg, for example administered once or twice daily, such as twice daily.
In one embodiment the therapy of step a) comprises a DHODH inhibitor, such as 2-(3,5-difluoro-3'-methoxybiphenyl-4-ylamino)nicotinic acid or a pharmaceutically acceptable salt thereof.
In one embodiment the PARP inhibitor one or more compounds independently selected from of the followin :
Phase III trials for ovarian, breast and evaluated in Phase III studies for breast, other solid cancers); pancreatic, non-small cell lung cancer, lymphoma and multiple myeloma);
CEP-9722 a PARP-1 and PARP-2 inhibitor; INO-1001 (3-aminobenzamide) a potent inhibitor of PARP (with IC50 of <50 nM in CHO cells and a mediator of oxidant- induced myocyte dysfunction during reperfusion)
BGB-290 a PARP-1 and PARP-2 inhibitor BGP-15 a PARP inhibitor (which has been (structure not shown); shown to protect against ischemia- reperfusion injury);
H
E7016 (previously known as GPI-21016) a PARP inhibitor (undergoing Phase I trials in combination with temozolomide for advanced solid tumours and gliomas);
MP-124 a PARP-1 inhibitor (structure not shown);
ABT-737 a PARP-1 and PARP-2 inhibitor,
or a pharmaceutically acceptable salt or solvate of any one of the same.
In one embodiment the therapy in step al), i.e. the decluttering of immune cells, is performed by administering a compound, such as a CXCR2 antagonist, an anti-GCF, cyclophosphamide and/or irradiation, and a combination of two or more of the same.
As used herein, decluttering refers to neutralisation of immune cells. This neutralisation may, for example include reduction in number of immune cells. Generally speaking, decluttering results in a reduction in overall number of immune cells, but may also encompass total depletion, including local and systemic depletion.
In one embodiment decluttering of immune cells is performed by removing specific immune cell populations, for example using medication and/or techniques such as a dialysis.
In one embodiment the immune cells that are "decluttered" are selected from a lymphocyte (such as a T lymphocyte, such as a T cell or a NKT cell), a B cell, a natural killer cell and a combination of two or more of the same.
In one embodiment the immune cells which are decluttered are tumor associated macrophages. Tumor associated macrophages can be decluttered by NKT cells engineered to encode a cytokine, for example as disclosed in WO2013/040371, incorporated herein by reference.
In one embodiment the immune cell, which is decluttered is a lymphocyte, for example a NK cell or a T lymphocyte, such as a T cell or a NKT cell.
In one embodiment the immune cells that are decluttered are B cells.
In one embodiment the immune cell that is decluttered is a natural killer cell. NK cells can be targeted by monoclonal antibodies or binding fragments specific to CD56.
Mature T lymphocytes can be removed by medicaments such as alemtuzumab. Immune cells with surface expression of CD52 can be removed by Campath. In one embodiment the CXCR2 antagonist is selected from an antibody or binding fragment thereof, MK-7123, SB265610, SB 225002:
GSK1325756, AZD5069, and combinations thereof.
In one embodiment the CXCR2 antagonist is SCH-527123.
In one embodiment the decluttering step al) is performed by employing anti- neutrophil antibodies.
In one embodiment the step al) is performed using a G-CSF antibody, for example CSL324, which is a humanized G-CSFR antibody.
In one embodiment the debulking in step b) is surgery to reduce a tumor mass. In one embodiment the surgery is followed by chemotherapy and/or (in particular or) irradiation therapy.
Debulking as employed herein refers to a reduction in the total mass of a tumor. This includes breaking a tumor mass into smaller fragments as well as shrinking the tumor mass. Methods of reducing a tumor mass include cutting (excising), ablating (including cryoablation, liquid nitrogen treatment of topical cancer cells and combinations of two or more of the same.
In one embodiment the debulking in step b) is performed by administering chemotherapy selected from alkylating agents, antimetabolites, anthracyclines, plant alkaloids, topoisomerase inhibitors, and other antitumour agents, such as doxorubicin, 5-fluorouracil (5-FU), paclitaxel, gemcitabine, capecitabine, irinotecan, and platins such as cisplatin and oxaliplatin.
In one embodiment the debulking in step b) is selected from treatment with an oncolytic virus, an antibody drug conjugate and a combination thereof.
In one embodiment the oncolytic virus is a virus selected from an adenovirus, herpes simplex virus, reovirus, measles virus, Newcastle disease virus, Seneca Valley virus, Vesicular stomatitis virus, polio virus, ECHO enterovirus, Coxsackie virus, and vaccinia virus.
In one embodiment the oncolytic virus is selected from Enadenotucirev, talimogene laherparepvec, RIGVIR, Ad5-yCD/mutTKSR39rep-hIL12, Cavatak™, CG0070, DNX-2401, G207, HF10, Imlygic®, JX-594, MG1-MA3, MV-NIS, OBP-301, Reolysin®, Toca 511.
In one embodiment the antibody drug conjugate (ADCC) is selected from the group comprising AGS-15E, AGS-16C3F, AGS-22M6E, AMG-172, AMG-595, ASG-5ME, brentuximab vedotin, DEDN-6526A, DMUC-5754A, gemtuzumab ozogamicin, glembatumumab vedotin, GSK2857916, hRS7-SN-38, IMGN-242, IMGN-289, IMGN-388, IMGN-529, IMGN-633, IMGN-853, Indatuximab, indatuximab ravtansine, Inotuzumab
ozogamicin, lorvotuzumab mertansine, MEDI-547, milatuzumab doxorubicin, MLN- 0264, MLN-2704, PF-06263507, pinatuzumab vedotin, polatuzumab, PSMA-ADC, RG- 7450, RG-7599, SAR-3419, SAR-566658, SC16LD6.6, SGN-15, SGN-19A, SGN-CD33A, SGN-LIV1A, trastuzumab emtansine and combinations thereof.
In one embodiment step b) comprises administering varlitinib or a salt thereof, as a monotherapy or as part of a combination therapy, for example as disclosed elsewhere herein.
In one embodiment step b) comprises administering a DHODH inhibitor, such as as 2-(3,5-difluoro-3'-methoxybiphenyl-4-ylamino)nicotinic acid or a pharmaceutically acceptable salt thereof.
In one embodiment activating the immune cells in step c) comprises administering a RON inhibitor, an AXL kinase inhibitor, a MER kinase agonist, a cytokine (such as IL-13, IL-15, IL-4 or IL-2), a tumour vaccine for example comprising a tumour antigen and adjuvant, a dendritic cell vaccine and a combination of two or more of the same.
As used herein activating immune cells refers to the functional activation of the immune cells, for example the activation of T cells by stimilulation with antigens (including where the antigen is provided on antigen presenting cells), and the activation of B cells to produce tumor specific antibodies. Activating may also include the recruitment of immune cells to the tumor site. Use of appropriate cytokines can stimulate and/or activate immune cells.
In one embodiment the RON inhibitor is N-(4-(2-Amino-3-chloropyridin-4- yloxy)-3-fluorophenyl)-4-ethoxy-l-(4-fluorophenyl)-2-oxo-l,2-dihydropyridine-3- carboxamide disclosed in WO 2008/058229.
In one embodiment activating the immune cells in step c) comprises administering one or more check-point inhibitors.
In one embodiment the checkpoint inhibitor is one or more compounds
422, V155991 and V158411 are CHKl and CHK2 inhibitors,:
VEfe00£5$992,
Γ':
Gero pHHS (610) f 79
VsSuas sre tse average of si tsasi St !tii«¾itsfis ± SO
potent CHKl
MK-8776 is a selective CHKl inhibitor (with CHIR124 is CHKl inhibitor (is a novel an IC50 of 3 nM in a cell-free assay. The and potent inhibitor with IC50 of 0.3 molecule shows 500-fold selectivity against nM in a cell-free assay. It shows 2,000- CHK2); fold selectivity against CHK2 and 500 to
K2/4
Debromohymenialdisine (SKF 108753) is GDC-0425 is a selective CHKl a natural product derived from sponges that inhibitor;
KU55933 is a potent and selective KU59403 is an ATM inhibitor; ATM inhibitor vis-a-vie DNA-PK
VE-822 is a selective ATR inhibitor NU6027 is a potent ATR inhibitor; with a Ki of 0.2 nM and an about 150
PD-321852 is a CHKl and WEEl PD-407824 is a CHKl and WEEl inhibitor;
PV1019 is a CHK2 inhibitor; CCT241533 is a CHK2 inhibitor with about 63
In one embodiment the check-point inhibitor is a PD-1 or PD-L1 inhibitor.
In one embodiment the checkpoint inhibitor is a combination of 2 or several immune checkpoint inhibitors such as PD-1 plus CTL4, or PD-1 plus LAG3 (or TIM3 or GITR).
In one embodiment step d), i.e. increasing antigen presentation and/or enhancing T cell response, comprises administering a therapy selected from the group comprising a T cell therapy (for example where T cells are activated in vitro to generate CTLs specific to an antigen), a cell therapy comprising engineered chimeric receptors, a PD1 inhibitor, a PD-L1 inhibitors, a CTLA4 inhibitor, a LAG3 inhibitor and a combination of two or more of the same.
Increasing antigen presentation as used herein refers to the enhancement of the presentation of antigens to antigen presenting cells, for example by using a combination of treatments to make tumors necrotic, thereby providing a lot of potential antigenic material for presentation by antigen presenting cells. Other examples of increasing
antigen presentation include enhancing the ability of dendritic cells and macrophages to phagocytose tumor and present tumor antigen; and blocking or inhibiting do-not-eat- me signals (CD47) on tumour cells that prevent phagocytosis of tumour cells.
Alternatively or in addition onclotytic viruses carrying a transgene can be used to infect the cancer cell and express the "protein or peptide" encoded on the cancer cells surface to increase antigen expression. Antigen in this context simply means a target for therapy or immune cells, in particular a target for immunotherapy.
In one embodiment step d) comprises administering a therapy selected from the group comprising an oncolytic virus, a DLL inhibitor, ADH-1 molecular targeting therapy and combinations of two or more of the same, for example the oncolytic virus is a virus selected from an adenovirus, herpes simplex virus, reovirus, measles virus, Newcastle disease virus, Seneca Valley virus, Vesicular stomatitis virus, polio virus, ECHO enterovirus, Coxsackie virus, and vaccinia virus, such as Enadenotucirev, talimogene laherparepvec, RIGVIR, Ad5-yCD/mutTKSR39rep-hIL12, Cavatak™, CG0070, DNX-2401, G207, HF10, Imlygic®, JX-594, MG1-MA3, MV-NIS, OBP-301, Reolysin®, or Toca 511.
Residual tumor cells as used herein refers to tumor cells that remain after the previous therapy, for exampleat the primary tumor site or in the vicinity, including circulating tumor cells, dormant cancer cells, cancer stems cells and combinations of the two or more of the sameThe goal of this step is to eradicate any remaining traces of cancer cells and minimise recurrence of the cancer.
In one embodiment step e), i.e. clearing residual tumor cells comprises targeting cancer stem cells.
In one embodiment the cancer stem cell therapy comprises targeting one or surface markers, for example with one or more monoclonal antibodies. In one embodiment the marker is selected from CD133, CD44, CD24, ESA, CD34 + CD38, and CD47.
In one embodiment step e) comprises an agent, such as an antibody or binding fragment thereof, specific to TRAIL or NF-aB.
In one embodiment step e) comprises an agent, such as an antibody or binding fragment thereof, specific to a cell marker Epcam, CD 133, CD44, CD24, ESA, CD34+/CD38- and CD47.
In one embodiment the cell markers are targeted by a chimeric antigen receptor.
In one antibody or antibody binding fragment is in the format of an antibody drug conjugate.
DETAILED DISCLOSURE
Multimodal or stage cancer therapy as employed herein refers to discrete phases of therapy, for example each phase lasting in the region of 1 week to 6 months, such as
2 weeks to 1 month, 2 weeks to 2 months, 2 weeks to 3 months, 2 weeks to 4 months or 2 weeks to 5 months. The therapies may overlap but generally will not simply be a combination therapy.
Combination therapy as employed herein is two or more active agents both administered over the same period of treatment.
The theory behind the method of the present disclosure is as follows:
1. Stop cancer continuing growing via use of cell cycle inhibitors and proliferation pathway inhibitors, and nutrient pump/metabolic inhibitors, to decrease growth of tumor burden:
a. Cancers use de-breaking of cell cycle to go on fast growth (1)
b. Proliferation pathway inhibitors and metabolic inhibitors can slow cancer growth (2)
2. Remove Neutrophils and Tregs and de-clog cancer (remove non-functional immune cells and other cancer supportive elements) to make it accessible to immune therapy and to stop building of cancer tissue
a. Mesenchymal stem cells and Neutrophils are steered by cancer G-CSF (2) b. Mesenchymal stem cell (MSC) are attracted to early stage tumor (2) c. MCS steer Neutrophils via G-CSF to become tumor supportive (2)
d. Inhibitors of G-CSF slow cancer (3)
e. Tumors with higher blood Neutrophil to Lymphocyte ratio have worse prognosis (4)
f. Patients who become neutropenic during chemotherapy have better prognosis (5)
g. Neutrophils steer dendritic cells and Tregs (6)
h. Neutrophils are key for angiogenesis, which turns cancers to fast growth via the so called angiogenic shift (7)
i. Tumor associated Macrophages (TAMs) support tumor growth (8)
j. Removing Neutrophils using an antibody, increases survival in PDX model (9) k. In order for allogenic T-cell transplantation to work, best results are achieved by combination of cyclophosphamide and radiation to remove Tregs and other immune cells (10)
3. Then shift dendritic cells and macrophages to macrophage type 1, the inflammatory kind
a. Macrophage type 2 is the most prevalent TAM and is not effective in antigen presentation (11)
b. Intervention with inhibitor of RON kinase shifts macrophages to Type 1 and increase efficacy of PD-1 therapy (12)
c. Potential steering of M2 macrophage to Ml subtype with inhibition of IL-4 and 1L-13 since these gluococorticoid hormones have been shown to induce M2 Macrophage phenotype. (12)
d. Dendritic cells capture antigens from tumour and migrate into the draining lymph nodes for presentation. The antigens can be presented with MHC class I and class II molecules. (13)
e. Tumours interfere with DC maturation through IL-10 and TSLP. The DCs are skewed towards a Th2 lineage which promotes tumour development. (14) f. pDCs are also inhibited due to ligation of ILT7 with BST2 on tumour cells.
The inhibited pDCs induce CD4+ T cells to differentiate to become immunosuppressive. (15)
g. GM-CSF, in combination with other chemokines, can induce differentiation of inflammatory DCs that in turn will activate T cell functions. (16, 17, 18) h. Antibody therapy for engagement of surface molecules on DCs such as dectinl, DCSIGN/CD209 and CD40 putatively polarize DCs towards the proinflammatory phenotype. (19, 20, 21)
Secure major antigen presentation to make dendritic cells and macrophages phagocytose tumor and present tumor antigen
a. Use either of a series of technologies (radiation, chemo, oncolytic virus, cancer vaccine, toxin loaded antibodies, cancer metabolism inhibitors or nutrient pump inhibitors or other) to make tumor necrotic and allow APCs lots of material to present. (40)
b. A specific example of cancer metabolism inhibitor would be DHODH inhibitors that inhibit de novo synthesis of pyrimidines. This inhibition will specifically inhibit rapidly dividing cells. DHODH inhibition will also lead to induction of p53 and resulting apoptosis once a threshold of p53 levels is breached. (39)
c. With findings that the neoantigen repertoire for tumours vary greatly across tumours, exome sequencing for tumours can yield personalized vaccine targets based on predicted MHC binding capacity. (22, 23)
d. Neo-antigen presentation can also be greatly enhanced by blocking or inhibiting do-not-eat-me signals (CD47) on tumour cells that prevent phagocytosis of tumour cells. (24)
Use immune checkpoint inhibitor (ICI) to enhance T-cell response (or use highly targeted CAR-T construct to seek out and destroy tumor tissue
a. Single or combinations or sequences of ICIs can be used and have shown additive effects in the clinic (25)
b. These ICI therapies are not limited to T cell mediators and may also affect DCs, NK, NKT cells. They are a combination of antagonists to inhibitory signals and agonists to activation signals on the immune cells. (25)
6. Eradicate remnant tumor by using either of the following technologies to specifically kill Circulating tumour cells (CTC) and Cancer Stem Cells (CSC) dormant cancer cells (DCC)
a. Oncolytic virus kills CTC (26)
b. Inhibition of ALDH by eg. disulfiram increases reactive oxygen species (ROS) and kills CSC (27)
c. Inhibition of NANOG indirectly through HIFla inhibition by eg. disulfiram may inhibit CSCs (28)
d. The phenotype of CSCs will differ depending on the cellular context. In well- validated systems, such as breast and hemaotopoietic cancers, therapies against CSC have also shown efficacy, in reducing tumour recurrence and demonstrating long-term efficacy. (29, 30, 31, 32)
e. Starting proliferation of dormant cells by eg. Lithium turns DCCs non- dormant and accessible for killing via eg. chemo, irradiation or other means. Chemotherapy and irradiation methods may only impact cycling cells. By driving cells out of GO into the cell cycle - you would be able to trigger apoptosis at cell cycle checkpoint. (33)
7. Use fast dynamic diagnostics to follow immune status in the tumor and direct therapy
a. Tumors signal via exosomes in the circulation to seeding areas about status and to steer grafting probabilities (34)
b. Thrombocytes carry RNA and other tumor markers that tell status in tumor (35)
c. Survey both CTC and circulating immune cell subsets to gain an idea about heightened nature of immune system in response to tumour, as well as, resolution of immune response. (36)
d. This is particularly important as several immune checkpoint therapies have demonstrated pseudo-progression, increase in tumour size via RECIST due to immune cell infiltration and inflammation. The anti-tumour effect is only visible after several weeks. Hence it would be critical to have a dynamic marker of immune activity that can be read out at earlier timepoints. (37) e. Use combination of RNA, DNA, cell and immune diagnostics to determine response to therapy and best next steps (38)
Tumors recruit a number of cells and they are either supporting cells, or just bystanders, which are likely to physically block access to the cancer. It may also be that
these supporting or bystander cells, feed of fuel the cancer cell growth. Therefore we hypothesise therapy should focus on removing these before shifting to changing the macrophage and dendritic cell infiltration.
In turn changing the macrophage and dendritic cell set up is important to perform before applying ICIs since these activated Ml and active dendritic cells can provide immunogenic material to the T-cells.
Generally it is useful in the present method that the immunostimulation, by the means of making antigens available en masse, to the macrophages and the dendritic cells, should occur after the macrophages and the dendritic cells have been activated, and should precede application of the immune checkpoint inhibitors.
Killing circulating tumor cells and cancer stem cells and dormant cancer cells is described as the last step. However this step can be applied at initiation and/or during the subsequent steps, and may be repeated together with immune reactivation at subsequent sessions.
The timely feedback of the status of the tumor is important, since this multi-stage immuno, pathway and tumor escape/survival directed therapy needs to be steered and directed. For example daily measures of anti-tumour activity may enable one to be able to direct the therapy better (i.e. understanding when the neutrophils are down and depleted, and when the myeloid derived suppressor cells have been turned off, and when the macrophages have turned to Ml phenotype and how the immune checkpoint inhibition is successful in attacking the tumor).
Additionally, the detection of circulating tumor cells and RNA and DNA products from the tumor provides an indication whether the strategies to kill cancer stem cells have been successful.
Furthermore, the diagnosis of autoimmune reactions early allowing early intervention will be key, since several of the immunostimulation combos and efforts will elicit autoimmune reactions that need to be staved off quickly. The learning from this monitoring is likely to be important since individuals' response to these combined therapies may be highly specific both in kind, quality, quantity and timing.
The method is different from other methods in that it foresees usage of key therapies for a limited period of time, for a therapy period of less than 2 months is envisioned for one or more stages. This therapy in parts or in full may need to be repeated at a later stage, potentially with changes that may take instruction from the ongoing immune and cancer diagnostics.
In one embodiment we expect that a 2 week period of proliferation and nutrient/metabolic inhibition may be sufficient before taking down neutrophils and debulking of tumor. This step may take a week, followed by macrophage/dendritic cell type change (3-7 days), and then turning on the antigen production and presentation (1
to 2 weeks) before turning on the immune defense with T-cells and NK cells via the immune checkpoint inhibitors for at least 2 weeks. During the latter period, if not before, the killing of circulating and dormant cancer cells should be started, along with attempts to eradicate cancer stem cells.
This new method represents a way to declare total war against the cancer and is believed to cause maximal effect in the shortest period of time, while keeping side effects to a minimum. It also is a new way to try to learn as much possible about the specific cancer and to be able to adapt therapy to achieve best effect and avoid side effects.
The method should be meaningful both in early cancer (e.g. neo-adjuvant setting pre surgery) as well as a treatment alternative later in the cancer development.
The tumor mass and whether or not mass metastasis has occurred will be key factors whether or not the therapy will be effective. However, given the reported cases of durable responses in melanoma with immune checkpoint inhibitors, even after many lines of therapy, make it possible to believe in efficacy even at protracted and far progressed disease.
Treatment of cancer as employed herein refers to administration of the combination therapy of the present disclosure for the purpose of reducing symptoms, ameliorating symptoms, slowing progressing (including spreading) of the cancer or a form thereof (such as metastatic cancer), stopping progression (including spreading) of the cancer or a form thereof (such as metastatic cancer), shrinking tumors, reducing metastases, reducing or eliminating certain populations of cancer cells, for example cancer stem cell populations, sending the cancer into remission, maintaining the cancer in remission, prophylactic treatment of cancer, curing cancer or a combination of one or more the same, as appropriate.
Treatment of cancer as employed herein also refers to administration of the combination therapy of the present disclosure for the purpose of enhancing concomitant anti-cancer therapy, and for the purpose (at least in part) to reduce side effects and/or reducing the dose required of concomitant anti-cancer therapy.
Lithium compound as employed herein refers to an active agent employed in therapy comprising the alkali metal lithium, for example lithium salts comprising a counter-ion such as selected from the group comprising aspartate, bromide, chloride, citrate, lithium carbonate, lithium sulfate and orotate.
Lithium salts are well established treatments for mood disorders. The main side effects are taste derangement, tremor and kidney side effects. However, these side effects are much less toxic than those encountered by patients receiving normal traditional cancer therapy, and the doses employed for cancer therapy may be lower
than those employed for the treatment of mood disorders, especially when the lithium is employed in combination of disulfiram.
It is common clinical practice to monitor plasma levels of lithium, so that the likelihood of toxicity is reduced. Therefore, in one embodiment the patient receiving the combination therapy of the present disclosure is monitored for plasma levels of lithium, for example when the treatment is started and/or on a monthly, three monthly, six monthly or annual basis.
Thus in one embodiment the dose of lithium employed is a dose that does not elicit side effects in the majority of patients.
The majority of patients as employed herein refers to wherein at 51% of patients who receive that dose do not encounter therapy limiting side effects or only encounter minor side effects associated with the lithium such as 55, 60, 65, 70, 75, 80, 85, 90, 95 or 100% of patients do not encounter therapy limiting side effects.
Minor side effects as employed herein are effects that a negligible i.e. that do not significantly impact on the patients' quality of life and thus at most are slightly inconvenient.
It is believed by the present inventors that the lithium acts in cancer cells (for example cancer cells which are differentiated, i.e. non-cancer-stem-cells) at least via inhibiting the enzyme glycogen synthase kinase-3 (GSK-3), which is linked to the insulin and the Wnt pathways. The inhibition of GSK-3 may be associated with antiproliferative effects. However, lithium may also be linked to hormone receptors such as estrogen and androgen. Thus other effects of lithium may be exerted on bone marrow and on adaptive and innate immune defenses which are not necessarily associated to the GSK3 mediated effects.
Paradoxically, lithium seems to increase the proliferation and self-renewal of stem cells, including cancer stem cells. That could be seen as a negative in terms of cancer therapy. However, in this instance it may be positive because it prevents the cancer cells evading treatment.
Thus lithium driving proliferation and self-renewal prevents the cancer cells becoming dormant. The latter is thought to be a mechanism for cancer cell resistance. Thus preventing the option for the cancer cells to become dormant may enhance immediate efficacy of cancer therapy and may allow more or all of the cancer cell populations present to be treated. This in turn may improve the effectiveness of the cancer therapy and/or reduce the risk for cancer relapse.
Furthermore, self-renewal may also mean that the effectiveness of concomitant therapies (such as traditional cancer therapies or therapies directed to cancerous at renewal mechanisms) may have an increased therapeutic window or have a therapeutic
window which is shifted towards more "selectively" effecting cancer cells (or certain types of cancer cells, such as cancer stem cells).
Another mechanism of lithium efficacy may be on the bone marrow and the T- cells, which through the inhibition of GSK3 may become more effective, for example providing prolonged T cell proliferation and increased IL-2 production. Thus, there may be immune-stimulatory effects provided by employing the combination therapy of the present disclosure which renders the patient more receptive to therapy, for example in the form of immune-oncology compounds.
Immune-oncology compounds also referred to as cancer immune therapy herein refers to therapies that target tumor associated antigens (TAAs) and stimulate immune responses to the cancer.
Thus lithium and disulfiram may work additively or in synergy, to decrease the survival of cancer cells, such as cancer stem cells.
Disulfiram inhibits the aldehyde dehydrogenase, which is a key marker for cancer stem cells, and is a key enzyme for defense against reactive oxygen species (ROS), which may otherwise harm the cancer stem cell. Thus disulfiram may cause cancer stem cell reduction, for example via accumulation of reactive oxygen species leading to necrosis, apoptosis or autophagy thereby increasing death of cancer stem cells.
Necrosis as employed herein refers to cell death through injury or damage to the cell.
Apoptosis as employed herein refers to hastening programmed cell death, which is sometimes referred to as cell assisted suicide.
Autophagy as employed herein refers to a complex process of intracellular degradation, which may deliver nutrients and/or energy to other cells.
We hypothesize that the combination therapy of the present disclosure makes it difficult for cancer cells to stay in quiescent dormant mode, for example by provoking self-renewal stimulated by the lithium part of the combined therapy. This renders the cancer stem cells vulnerable to cancer treatments, either via the disulfiram part or by other anti-cancer therapeutics.
However, if the cancer cells manage to stay in quiescent dormant mode the disulfiram part of the therapy may be deleterious to them through, for example the accumulation of reactive oxygen species (ROS).
Reactive oxygen species (ROS) as employed herein refers to peroxides, superoxides, hydroxyl radicals, singlet oxygen and the like. The accumulation of reactive oxygen specifies causes significant damage to cell structure, which ultimately is likely to cause cell death.
Disulfiram (DSF) is a widely used anti addiction medicine (ethanol addiction). Its main target is aldehyde dehydrogenase, and its' inhibition causes upstream accumulation of ethanol aldehyde which is linked to physical discomfort.
Aldehyde dehydrogenase is also a marker of cancer stem cells and the present inventors believe that disulfiram via inhibition of aldehyde dehydrogenase increases the concentration of reactive oxygen species. This increased concentration of reactive oxygen species in turn damages the cancer stem cells. Thus is hypothesized that DSF suppresses self-renewal capability mainly through the activation of reactive oxygen species (ROS)-p38 MAPK pathway.
In addition disulfiram, via inhibition of SOD-1, is thought to inhibit the release of
TNF-alpha, vascular endothelial growth factor, and MMP-2 and MMP-9 from cultured macrophages, which may contribute to the overall effectiveness of the combination therapy.
It is believed that by attacking cancers cell via two independent pathways, using well tolerated drugs, and particularly the ability to target cancer stems cells will lead to significant improvements of cancer treatment.
In addition, effects of lithium on the bone marrow and on the immune system may add to the breadth of potential positives of the therapy of the present disclosure.
Furthermore it may be that the combination therapy of the present disclosure has beneficial effects in protecting non-cancerous tissue from the toxic effect of cancer therapy that may be employed in combination with the therapy comprising disulfiram and a lithium compound.
Combination treatment as employed herein refers to a treatment wherein the duration of time when the patient is on or taking the medicament comprising a lithium compound is also the time when the patient is taking or is administered a medicament comprising the disulfiram (i.e. treatment regimens for lithium and disulfiram at least overlap).
In one embodiment a lithium compound and a disulfiram are administered or taken in the same 7 days period. In one embodiment the disulfiram is administered or taken on the same day as the lithium compound.
In one embodiment the combination therapy of the present disclosure is employed as adjuvant therapy, for example post-surgery or post-chemotherapy.
In one embodiment the combination therapy of the present disclosure is employed as neo-adjuvant therapy.
The combination treatment of the present disclosure may be employed in combination with one or more further cancer treatments, for example
• concomitant with chemotherapy (including where chemotherapy follows radiation therapy), or
• concomitantly with radiation therapy (including where radiation therapy follows chemotherapy)
• concomitant with chemotherapy and radiation therapy
• concomitant with immune-modulating agents such as PD-1 inhibitors and IDOl- inhibitors and agents active on the macrophage type shift (type 2 to type 1 shift)
In one embodiment the therapy may reduce the side effects of such and may allow usage of higher and more effective doses of other cancer therapies to be employed and tolerated.
A suitable dose may be chosen by the practitioner based on the nature of the cancer being treated.
Chemotherapeutic agent as employed herein is intended to refer to specific antineoplastic chemical agents or drugs that are selectively destructive to malignant cells and tissues. Chemotherapeutic agent and chemotherapy or cytotoxic agent are employed interchangeably herein unless the context indicates otherwise. Examples inlcude alkylating agents, antimetabolites, anthracyclines, plant alkaloids, topoisomerase inhibitors, and other antitumour agents. Other examples of chemotherapy include doxorubicin, 5-fluorouracil (5-FU), paclitaxel, capecitabine, irinotecan, and platins such as cisplatin and oxaliplatin.
Examples of alkylating agents, which may be employed in the method of the present disclosure include an nitrogen mustards alkylating agent, nitrosoureas, tetrazines, aziridines, platins and derivatives, and non-classical alkylating agents.
Examples of a platinum containing chemotherapeutic agent (also referred to as platins), such as cisplatin, carboplatin, oxaliplatin, satraplatin, picoplatin, nedaplatin, triplatin and lipoplatin (a liposomal version of cisplatin), in particular cisplatin, carboplatin and oxaliplatin.
The dose for cisplatin ranges from about 20 to about 270 mg/m2 depending on the exact cancer. Often the dose is in the range about 70 to about 100mg/m2.
The dose for cisplatin ranges from about 20 to about 270 mg/m2 depending on the exact cancer. Often the dose is in the range about 70 to about 100mg/m2.hemotherapeutic agent is a topoisomerase inhibitor.
Nitrogen mustards include mechlorethamine, cyclophosphamide, melphalan, chlorambucil, ifosfamide and busulfan. Nitrosoureas include N-Nitroso-N-methylurea (MNU), carmustine (BCNU), lomustine (CCNU) and semustine (MeCCNU), fotemustine and streptozotocin. Tetrazines include dacarbazine, mitozolomide and temozolomide.
Aziridines include thiotepa, mytomycin and diaziquone (AZQ).
Examples of antimetabolites, which may be employed in the method of the present disclosure, include anti-folates (for example methotrexate and pemetrexed), purine analogues (for example thiopurines, such as azathiopurine, mercaptopurine,
thiopurine, fludarabine (including the phosphate form), pentostatin and cladribine), pyrimidine analogues (for example fluoropyrimidines, such as 5-fluorouracil and prodrugs thereof such as capecitabine [Xeloda®]), floxuridine, gemcitabine, cytarabine, decitabine, raltitrexed(tomudex) hydrochloride, cladribine and 6-azauracil.
Examples of anthracyclines, which may be employed in the method of the present disclosure, include daunorubicin (Daunomycin), daunorubicin (liposomal), doxorubicin (Adriamycin), doxorubicin (liposomal), epirubicin, idarubicin, valrubicin currenlty used only to treat bladder cancer and mitoxantrone an anthracycline analog, in particular doxorubicin.
Examples of anti-microtubule agents, which may be employed in the method of the present disclosure, include include vinca alkaloids and taxanes.
Vinca alkaloids include completely natural chemicals for example vincristine and vinblastine and also semi-synthetic vinca alkaloids, for example vinorelbine, vindesine, and vinflunine.
Taxanes include paclitaxel, docetaxel, abraxane, carbazitaxel and derivatives of thereof. Derivatives of taxanes as employed herein includes reformulations of taxanes like taxol, for example in a micelluar formulaitons, derivatives also include chemical derivatives wherein synthetic chemistry is employed to modify a starting material which is a taxane.
Topoisomerase inhibitors, which may be employed in a method of the present disclosure include type I topoisomerase inhibitors, type II topoisomerase inhibitors and type II topoisomerase poisons. Type I inhibitors include topotecan, irinotecan, indotecan and indimitecan. Type II inhibitors include genistein and ICRF 193 which has the following structure:
Type II poisons include amsacrine, etoposide, etoposide phosphate, teniposide and doxorubicin and fluoroquinolones.
In one embodiment he chemotherapeutic agent is a parp inhibitor, in particular as disclosed herein.
In one embodiment the combination therapy is administered with or following a treatment regime comprising a platinum containing chemotherapeutic agent, for example cisplatin, carboplatin or oxaliplatin.
In one embodiment a combination of chemotherapeutic agents employed is, for example a platin and 5-FU or a prodrug thereof, for example cisplatin or oxaplatin and capecitabine or gemcitabine, such as FOLFOX.
In one embodiment the chemotherapy comprises a combination of chemotherapy agents, in particular cytotoxic chemotherapeutic agents.
In one embodiment the chemotherapy combination comprises a platin, such as cisplatin and fluorouracil or capecitabine.
In one embodiment the chemotherapy combination in capecitabine and oxaliplatin (Xelox).
In one embodiment the chemotherapy is a combination of folinic acid and 5-FU, optionally in combination with oxaliplatin.
In one embodiment the chemotherapy is a combination of folinic acid, 5-FU and irinotecan (FOLFIRI), optionally in combination with oxaliplatin (FOLFIRINOX). The regimen consists of: irinotecan (180 mg/m2 IV over 90 minutes) concurrently with folinic acid (400 mg/m2 [or 2 x 250 mg/m2] IV over 120 minutes); followed by fluorouracil (400-500 mg/m2 IV bolus) then fluorouracil (2400-3000 mg/m2 intravenous infusion over 46 hours). This cycle is typically repeated every two weeks.
The dosages shown above may vary from cycle to cycle.
In one embodiment the combination employs a microtubule inhibitor, for example vincristine sulphate, epothilone A, N-[2-[(4-Hydroxyphenyl)amino]-3- pyridinyl]-4-methoxybenzenesulfonamide (ABT-751), ataxol derived chemotherapeutic agent, for example paclitaxel, abraxane, or docetaxel or a combination thereof.
In one embodiment the combination employs an mTor inhibitor. Examples of mTor inhibitors include: everolimus (RADOOl), WYE-354, KU-0063794, papamycin (Sirolimus), Temsirolimus, Deforolimus(MK-8669), AZD8055 and BEZ235(NVP-
BEZ235).
In one embodiment the chemotherapy combination employs a microtubule inhibitor, for example vincristine sulphate, epothilone A, N-[2-[(4- Hydroxyphenyl)amino]-3-pyridinyl]-4-methoxybenzenesulfonamide (ABT-751), a taxol derived chemotherapeutic agent, for example paclitaxel, abraxane, or docetaxel or a combination thereof.
In one embodiment the chemotherapy combination employs a MEK inhibitor. Examples of MEK inhibitors include: AS703026, CI-1040 (PD184352), AZD6244 (Selumetinib), PD318088, PD0325901, AZD8330, PD98059, U0126-EtOH, BIX 02189 or BIX 02188.
In one embodiment the chemotherapy combination employs an AKT inhibitor. Examples of AKT inhibitors include: MK-2206 and AT7867.
In one embodiment the combination employs an aurora kinase inhibitor. Examples of aurora kinase inhibitors include: Aurora A Inhibitor I, VX-680, AZD1152- HQPA (Barasertib), SNS-314 Mesylate, PHA-680632, ZM-447439, CCT129202 and Hesperadin.
In one embodiment the chemotherapy combination employs a p38 inhibitor, for example as disclosed in WO2010/038086, such as N-[4-({4-[3-(3-tert-Butyl-l-p-tolyl- lH-pyrazol-5-yl)ureido]naphthalen-l-yloxy}methyl)pyridin-2-yl]-2-methoxyacetamide.
In one embodiment the combination employs a Bcl-2 inhibitor. Examples of Bcl- 2 inhibitors include: obatoclax mesylate, ABT-737, ABT-263(navitoclax) and TW-37.
In one embodiment the chemotherapy combination comprises an antimetabolite such as capecitabine (xeloda), fludarabine phosphate, fludarabine (fludara), decitabine, raltitrexed (tomudex), gemcitabine hydrochloride and cladribine.
In one embodiment the chemotherapy combination comprises ganciclovir, which may assist in controlling immune responses and/or tumour vasculation.
Cancer Types In more Detail
In one embodiment the gastric cancer is selected from the group comprising adenocarcinoma of the stomach, squamous cell carcinomas, lymphoma of the stomach, gastric stromal tumour, and neuroendocrine tumours.
In one embodiment the liver cancer is, for example selected from the group hepatocellular carcinoma, cholangiocarcinoma, angiosarcoma, and hepatoblastoma, in particular hepatocellular carcinoma. In one embodiment the primary liver cancer is stage 1, 2, 3 or 4. In one embodiment the liver cancer is secondary or metastasized liver cancer.
Prostate cancer as employed herein refers to cancer of the prostate, for example ductal adenocarcinoma, transitional cell (urothelial cancer), squamous cell cancer, carcinoid of the prostate, small cell cancer or sarcoma and sarcomatoid cancer.
Pancreatic cancer as employed herein includes exocrine cancers (including rare forms thereof such as cystitic tumours, and cancer of the acinar cells), endocrine pancreatic tumours (including gastrinomas, insulinomas, somatostatinomas, VIPomas, glucagonomas), pancreatoblastoma, sarcomas of the pancreas and lymphoma.
Biliary tract cancer as employed herein refers to cholangiocarcinoma (intrahepatic, extrahepatic), gall bladder cancer and ampullary carcinoma.
Colorectal cancer as employed herein refers to cancer or the colon and/or rectum and includes squamous cell cancers, carcinoid tumours, sarcomas and lymphomas.
Breast cancer as employed herein refers to cancer of the breast and includes ductal carcinoma in situ, lobular carcinoma in situ, invasive ductal breast cancer, invasive lobular breast cancer, invasive breast cancer, Paget's disease, angiosarcoma of
the breast and rare types of breast cancer such as medullary breast cancer, mucinous breast cancer, tubular breast cancer, adenoid cystic carcinoma of the breast metaplastic breast cancer, basal type breast cancer and papillary breast cancer.
Lung cancers are classified according to histological type and are categorized by the size and appearance of the malignant cells seen by a histopathologist under a microscope. For therapeutic purpose, two broad classes are distinguished: non-small cell lung carcinoma and small cell lung carcinoma.
In one embodiment the epithelial cancer is lung cancer, for example small-cell lung cancer (SCLC) and non-small-cell lung cancer (NSCLC).
Non-small-cell lung carcinoma-The three main subtypes of NSCLC are adenocarcinoma, squamous-cell carcinoma and large-cell carcinoma.
Nearly 40% of lung cancers are adenocarcinoma, which usually originates in peripheral lung tissue. A subtype of adenocarcinoma, the bronchioloalveolar carcinoma, is more common in female never-smokers, and may be associated with a better long term survival.
Squamous-cell carcinoma accounts for about 30% of lung cancers. They typically occur close to large airways. A hollow cavity and associated cell death are commonly found at the center of the tumor. About 9% of lung cancers are large-cell carcinoma. These are so named because the cancer cells are large, with excess cytoplasm, large nuclei and conspicuous nucleoli.
Small-cell lung carcinoma-In small-cell lung carcinoma (SCLC), the cells contain dense neurosecretory granules (vesicles containing neuroendocrine hormones), which give this tumor an endocrine/paraneoplastic syndrome association. Most cases arise in the larger airways (primary and secondary bronchi). These cancers grow quickly and spread early in the course of the disease. Sixty to seventy percent have metastatic disease at presentation.
In one embodiment the cancer is non-small lung carcinoma.
In one embodiment the cancer is liver cancer, for example a liver metastasis from a primary cancer, for example colon cancer, which has spread to the liver. In one embodiment the liver cancer is HCC hepatocellular carcinoma.
In one embodiment there is provided treatment of renal cancer, for example renal cell carcinoma and/or urothelial cell carcinoma. Other examples of renal cancer include squamous cell carcinoma, juxtaglomerular cell tumor (reninoma), angiomyolipoma, renal oncocytoma, Bellini duct carcinoma, clear-cell sarcoma of the kidney, mesoblastic nephroma, Wilms' tumor, mixed epithelial stromal tumor, clear cell adenocarcinoma, transitional cell carcinoma, inverted papilloma, renal lymphoma, teratoma, carcinosarcoma, and carcinoid tumor of the renal pelvis.
In one embodiment the cancer is bladder cancer, for example is any of several types of malignancy arising from the epithelial lining (i.e. the urothelium) of the urinary bladder. About 90% of bladder cancers are transitional cell carcinoma. The other 10% are squamous cell carcinoma, adenocarcinoma, sarcoma, small cell carcinoma, and secondary deposits from cancers elsewhere in the body. The staging of this cancer is given below.
T (Primary tumour)
• TX Primary tumour cannot be assessed
• TO No evidence of primary tumour
· Ta Non-invasive papillary carcinoma
• Tis Carcinoma in situ ('flat tumour')
• Tl Tumour invades subepithelial connective tissue
• T2a Tumour invades superficial muscle (inner half)
• T2b Tumour invades deep muscle (outer half)
· T3 Tumour invades perivesical tissue:
• T3a Microscopically
• T3b Macroscopically (extravesical mass)
• T4a Tumour invades prostate, uterus or vagina
• T4b Tumour invades pelvic wall or abdominal wall
N (Lymph nodes)
• NX Regional lymph nodes cannot be assessed
• NO No regional lymph node metastasis
• Nl Metastasis in a single lymph node 2 cm or less in greatest dimension
• N2 Metastasis in a single lymph node more than 2 cm but not more than 5 cm in greatest dimension, or multiple lymph nodes, none more than 5 cm in greatest dimension
• N3 Metastasis in a lymph node more than 5 cm in greatest dimension
M (Distant metastasis)
• MX Distant metastasis cannot be assessed
· M0 No distant metastasis
• Ml Distant metastasis.
The current disclosure extends to any stage of bladder cancer.
There are more than 30 different types of ovarian cancer which are classified according to the type of cell from which they start. Cancerous ovarian tumours can start from three common cell types:
• Surface Epithelium - cells covering the lining of the ovaries
• Germ Cells - cells that are destined to form eggs
• Stromal Cells - Cells that release hormones and connect the different structures of the ovaries
The present disclosure relates to treatment of ovarian cancer from any source, for example as described herein, in particular epithelium cells. Epithelial ovarian carcinomas (EOCs) account for 85 to 90 percent of all cancers of the ovaries.
Common Epithelial Tumors - Epithelial ovarian tumors develop from the cells that cover the outer surface of the ovary. Most epithelial ovarian tumors are benign (noncancerous). There are several types of benign epithelial tumors, including serous adenomas, mucinous adenomas, and Brenner tumors. Cancerous epithelial tumors are carcinomas - meaning they begin in the tissue that lines the ovaries. These are the most common and most dangerous of all types of ovarian cancers. Unfortunately, almost 70 percent of women with the common epithelial ovarian cancer are not diagnosed until the disease is advanced in stage.
There are some ovarian epithelial tumors whose appearance under the microscope does not clearly identify them as cancerous. These are called borderline tumors or tumors of low malignant potential (LMP tumors). The method of the present disclosure includes treatment of the latter.
Germ Cell Tumors - Ovarian germ cell tumors develop from the cells that produce the ova or eggs. Most germ cell tumors are benign (non-cancerous), although some are cancerous and may be life threatening. The most common germ cell malignancies are maturing teratomas, dysgerminomas, and endodermal sinus tumors. Germ cell malignancies occur most often in teenagers and women in their twenties. Today, 90 percent of patients with ovarian germ cell malignancies can be cured and their fertility preserved.
Stromal Tumors - Ovarian stromal tumors are a rare class of tumors that develop from connective tissue cells that hold the ovary together and those that produce the female hormones, estrogen and progesterone. The most common types are granulosa- theca tumors and Sertoli-Leydig cell tumors. These tumors are quite rare and are usually considered low-grade cancers, with approximately 70 percent presenting as Stage I disease (cancer is limited to one or both ovaries).
Primary Peritoneal Carcinoma-The removal of one's ovaries eliminates the risk for ovarian cancer, but not the risk for a less common cancer called Primary Peritoneal Carcinoma. Primary Peritoneal Carcinoma is closely rated to epithelial ovarian cancer (most common type). It develops in cells from the peritoneum (abdominal lining) and looks the same under a microscope. It is similar in symptoms, spread and treatment. Stages of Ovarian Cancer
Once diagnosed with ovarian cancer, the stage of a tumor can be determined during surgery, when the doctor can tell if the cancer has spread outside the ovaries. There are
four stages of ovarian cancer - Stage I (early disease) to Stage IV (advanced disease). The treatment plan and prognosis (the probable course and outcome) will be determined by the stage of cancer.
Following is a description of the various stages of ovarian cancer:
Stage I - Growth of the cancer is limited to the ovary or ovaries.
Stage IA - Growth is limited to one ovary and the tumor is confined to the inside of the ovary. There is no cancer on the outer surface of the ovary. There are no ascites present containing malignant cells. The capsule is intact.
Stage IB - Growth is limited to both ovaries without any tumor on their outer surfaces. There are no ascites present containing malignant cells. The capsule is intact.
Stage IC - The tumor is classified as either Stage IA or IB and one or more of the following are present: (1) tumor is present on the outer surface of one or both ovaries;
(2) the capsule has ruptured; and (3) there are ascites containing malignant cells or with positive peritoneal washings.
Stage II - Growth of the cancer involves one or both ovaries with pelvic extension.
Stage IIA - The cancer has extended to and/or involves the uterus or the fallopian tubes, or both.
Stage IIB - The cancer has extended to other pelvic organs.
Stage IIC - The tumor is classified as either Stage IIA or IIB and one or more of the following are present: (1) tumor is present on the outer surface of one or both ovaries; (2) the capsule has ruptured; and (3) there are ascites containing malignant cells or with positive peritoneal washings.
Stage III - Growth of the cancer involves one or both ovaries, and one or both of the following are present: (1) the cancer has spread beyond the pelvis to the lining of the abdomen; and (2) the cancer has spread to lymph nodes. The tumor is limited to the true pelvis but with histologically proven malignant extension to the small bowel or omentum.
Stage IIIA - During the staging operation, the practitioner can see cancer involving one or both of the ovaries, but no cancer is grossly visible in the abdomen and it has not spread to lymph nodes. However, when biopsies are checked under a microscope, very small deposits of cancer are found in the abdominal peritoneal surfaces.
Stage IIIB - The tumor is in one or both ovaries, and deposits of cancer are present in the abdomen that are large enough for the surgeon to see but not exceeding 2 cm in diameter. The cancer has not spread to the lymph nodes.
Stage IIIC - The tumor is in one or both ovaries, and one or both of the following is present: (1) the cancer has spread to lymph nodes; and/or (2) the deposits of cancer exceed 2 cm in diameter and are found in the abdomen.
Stage IV - This is the most advanced stage of ovarian cancer. Growth of the cancer involves one or both ovaries and distant metastases (spread of the cancer to organs located outside of the peritoneal cavity) have occurred. Finding ovarian cancer cells in pleural fluid (from the cavity which surrounds the lungs) is also evidence of stage IV disease.
In one embodiment the ovarian cancer is: type I, for example IA, IB or IC; type II, for example IIA, IIB or IIC; type III, for example IIIA, IIIB or III C; or type IV.
In one embodiment the breast cancer is one selected from the group comprising ductal carcinoma in situ, lobular carcinoma in situ, invasive breast cancer, invasive lobular breast cancer, Paget's disease, angiosarcoma of the breast, medulllary breast cancer, mucinous breast cancer, tubular breast cancer, adenoid cystic carcinoma of the breast, metaplastic breast cancer, lymphoma of the breast, basal type breast cancer, phyllodes or cystosarcoma phyllodes and papillary breast cancer.
In one embodiment the prostate cancer is selected from the group comprising ductal adenocarcinoma, transitional cell (urothelial) cancer, squamous cell cancer, carcinoid, small cell cancer, sarcomas and sarcomatoid cancers.
In one embodiment the prostate cancer is selected from the group comprising ductal adenocarcinoma, transitional cell (urothelial) cancer, squamous cell cancer, carcinoid, small cell cancer, sarcomas and sarcomatoid cancers and a combination of two or more of the same.
Thyroid cancer as employed herein refers to cancer of the thyroid originating from follicular or parafollicular thyroid cells and includes papillary thyroid cancer (75% to 85% of cases); follicular thyroid cancer (10% to 20% of cases); medullary thyroid cancer (5% to 8% of cases)- cancer of the parafollicular cells, often part of multiple endocrine neoplasia type 2; poorly differentiated thyroid cancer; anaplastic thyroid cancer (less than 5% of cases) is not responsive to treatment and can cause pressure symptoms, thyroid lymphoma, squamous cell thyroid carcinoma, sarcoma of thyroid.
Renal cancer as employed herein refers to cancer of the kidney, for example renal cell carcinoma and transitional cell carcinoma of the renal pelvis, such as squamous cell carcinoma, juxtaglomerular cell tumor (reninoma), angiomyolipoma, renal oncocytoma, bellini duct carcinoma, clear-cell sarcoma of the kidney, mesoblastic nephroma, Wilms' tumor, mixed epithelial stromal tumor, clear cell adenocarcinoma, transitional cell carcinoma, inverted papilloma, renal lymphoma, teratoma, carcinosarcoma; carcinoid tumor of the renal pelvis.
Bladder cancer as employed herein refers to cancer of the bladder including transitional cell bladder cancer, carcinoma in situ, papillary cancer and rarer types of bladder cancer such as squamous cell cancer, adenocarcinoma and a combination of two or more of the same.
Esophageal cancer as employed herein refers to cancer of the oesphagus including esophageal squamous-cell carcinomas, esophageal adenocarcinomas, and variants of squamous-cell carcinoma, and non-epithelial tumors, such as leiomyosarcoma, malignant melanoma, rhabdomyosarcoma, lymphoma, among others and a combination of two or more of the same.
Head and neck cancer as employed herein refers to cancer of the neck and/or head, including mouth cancer, nasopharyngeal cancer, oropharyngeal cancer, paranasal sinus cancer, salivary gland cancer and a combination of two or more of the same.
In one embodiment the chemotherapy combination comprises ganciclovir, which may assist in controlling immune responses and/or tumour vasculation.
In the context of this specification "comprising" is to be interpreted as "including".
Aspects of the invention comprising certain elements are also intended to extend to alternative embodiments "consisting" or "consisting essentially" of the relevant elements.
Where technically appropriate, embodiments of the invention may be combined. Embodiments are described herein as comprising certain features/elements. The disclosure also extends to separate embodiments consisting or consisting essentially of said features/elements.
Technical references such as patents and applications are incorporated herein by reference.
Any embodiments specifically and explicitly recited herein may form the basis of a disclaimer either alone or in combination with one or more further embodiments. REFERENCES (all incorporated herein by reference)
1. Clin Lab. 2016;62(3) :409-16. SNP rsl059234 in CDKN1A Gene Correlates with
Prognosis in Resected Gastric Adenocarcinoma. Nie X, Wang X, Lin Y, Yu Y, Liu W, Xie F, Wang X, Tan J, Huang Q.
2. Proc Natl Acad Sci U S A. 2015 Feb 10; 112(6) : E566-E575. Invasive breast cancer reprograms early myeloid differentiation in the bone marrow to generate immunosuppressive neutrophils Amy-Jo Casbon,a Damien Reynaud,b Chanhyuk Park,a Emily Khuc,a Dennis D. Gan,a Koen Schepers,b Emmanuelle Passegue,b and Zena Werba,l
3. Oncoimmunology. 2015 Nov 24;5(3) :elll5177. eCollection 2016. G-CSF regulates macrophage phenotype and associates with poor overall survival in human triple- negative breast cancer. Hollmen Ml, Karaman SI, Schwager SI, Lisibach Al, Christiansen AJ1, Maksimow M2, Varga Z3, Jalkanen S2, Detmar Ml.
4 Semin Immunol. 2016 Apr 7. pii: S1044-5323(16)30004-5. Human neutrophils: Their role in cancer and relation to myeloid-derived suppressor cells. Moses Kl, Brandau S2.
5. Med Oncol. 2014 Jun;31(6):969. Neutrophil-lymphocyte ratio as a predictor of outcomes for patients with hepatocellular carcinoma undergoing TAE combined with Sorafenib. Wei Kl, Wang M, Zhang W, Mu H, Song TQ.
6. Cell Death Dis. 2014 Jun; 5(6): el295. The IL-6-STAT3 axis mediates a reciprocal crosstalk between cancer-derived mesenchymal stem cells and neutrophils to synergistically prompt gastric cancer progression Q Zhu,l,4 X Zhang,l,4,* L Zhang,l W Li,2 H Wu,2 X Yuan,l F Mao,l M Wang.1 W Zhu,l H Qian,l and W Xul,3,*
7. Proc Natl Acad Sci U S A. 2006 Aug l5; 103(33) : 12493-12498; Published online 2006 Aug 4. Infiltrating neutrophils mediate the initial angiogenic switch in a mouse model of multistage carcinogenesis Hiroaki Nozawa,*† Christopher Chiu,* and Douglas Hanahand:
8. Immunology, 2013 Oct; 5(1): 1075-87. Targeting tumor-infiltrating macrophages to combat cancer Roheena Z Panni,l David C Linehan,l,2 and David G
DeNardo*,2,3,4
9. J Exp Med. 1995;181:435-440. Inhibition of tumor growth by elimination of
granulocytes. Pekarek LA, Starr BA, Toledano AY, Schreiber H.
10. Curr Opin Immunol. 2009 Apr;21(2):233-40. Adoptive cell therapy for the
treatment of patients with metastatic melanoma. Rosenberg SA1, Dudley ME.
11. Gut. 2016 Mar 24. pii: gutjnl-2015-310049. Pharmacological macrophage inhibition decreases metastasis formation in a genetic model of pancreatic cancer. Griesmann HI, Drexel C2, Milosevic N2, Sipos B3, Rosendahl J 4, Gress TM2, Michl PI.
12. J Clin Invest. 2012 Mar;122(3):787-95. doi: 10.1172/JCI59643. Epub 2012 Mar 1.
Macrophage plasticity and polarization: in vivo Veritas. Sica Al, Mantovani A.
13. Annu Rev Immunol. 2000;18:767-811. Immunobiology of dendritic cells.
Banchereau Jl, Briere F, Caux C, Davoust J, Lebecque S, Liu YJ, Pulendran B, Palucka K.
14. J Exp Med. 2007 May 14;204(5):1037-47. Epub 2007 Apr 16. Breast cancer
instructs dendritic cells to prime interleukin 13-secreting CD4+ T cells that facilitate tumor development. Aspord CI, Pedroza-Gonzalez A, Gallegos M, Tindle S, Burton EC, Su D, Marches F, Banchereau J, Palucka AK.
15. J Exp Med. 2009 Jul 6;206(7):1603-14. Regulation of TLR7/9 responses in
plasmacytoid dendritic cells by BST2 and ILT7 receptor interaction. Cao Wl, Bover L, Cho M, Wen X, Hanabuchi S, Bao M, DB, Wang YH, Shaw JL, Du Q, Li C, Arai N, Yao
Z, Lanier LL, Liu YJ.
16. J Leukoc Biol. 1998 Sep;64(3):358-67. Interferon-alpha and granulocyte- macrophage colony-stimulating factor differentiate peripheral blood monocytes into potent antigen-presenting cells. Paquette RL1, Hsu NC, Kiertscher SM, Park AN, Tran L, Roth MD, Glaspy J A.
17. J Immunol.2003 Sep l;171(5):2262-9. TNF skews monocyte differentiation from macrophages to dendritic cells. Chomarat P1, Dantin C, Bennett L, Banchereau J, Palucka AK.
18. J Exp Med. 2001 Oct l;194(7):1013-20. Interleukin 15 skews monocyte
differentiation into dendritic cells with features of Langerhans cells.
Mohamadzadeh M1, Berard F, Essert G, Chalouni C, Pulendran B, Davoust J, Bridges
G, Palucka AK, Banchereau J.
19. PLoS One. 2010 Oct 18;5(10): el3418. Human dendritic cells activated via dectin-1 are efficient at priming Thl7, cytotoxic CD8 T and B cell responses. Agrawal S1, Gupta S, Agrawal A.
20. Blood. 2005 Aug 15;106(4):1278-85. Epub 2005 May 5. Effective induction of naive and recall T-cell responses by targeting antigen to human dendritic cells via ahumanized anti-DC-SIGN antibody. Tacken PJ1, de Vries IJ, Gijzen K, Joosten B, Wu D, Rother RP, Faas SJ, Punt CJ, Torensma R, Adema GJ, Figdor CG.
21. Nature. 1998 Jun 4;393(6684):480-3. T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Schoenberger SP1, Toes RE, van der Voort
EI, Offringa R, Melief CJ.
22. Oncoimmunology. 2014 Jun 25;3:e29311. eCollection 2014; Personal neoantigen cancer vaccines: The momentum builds. Fritsch EF1, Hacohen N2, Wu CJ3.
23. J Clin Invest. 2015 Sep;125(9):3413-21. Tumor neoantigens: building a framework for personalized cancer immunotherapy. Gubin MM, Artyomov MN Mardis ER,
Schreiber RD.
24. Proc Natl Acad Sci U S A. 2013 Jul 2;110(27):11103-8. Anti-CD47 antibody- mediated phagocytosis of cancer by macrophages primes an effective antitumor T- cellresponse. Tseng D1, Volkmer JP, Willingham SB, Contreras-Trujillo H, Fathman JW, Fernhoff NB, Seita J, Inlay MA, Weiskopf K, Miyanishi M, Weissman IL.
25. Nature Reviews Cancer, 12, 252-264 (April 2012). Doi: 10.1038/nrc3239; The
blockade of immune checkpoints in cancer immunotherapy. Drew M Pardoll
26. Nature review Drug Discovery, September 2015 Vol 14(9): 642-662. Cancer
immunotherapy Oncolytic viruses: a new class of immunotherapy drugs, Howard L. Kaufman, Frederick J Kohlhapp & Andrew Zloza
27. Br J Cancer. 2013 Oct l;109(7): 1876-85. Disulfiram targets cancer stem-like cells and reverses resistance and cross-resistance in acquired paclitaxel-resistant triple- negative breast cancer cells. Liu PI, Kumar IS, Brown S, Kannappan V, Tawari PE, Tang JZ, Jiang W, Armesilla AL, Darling JL, Wang W.
28. Acta Pharmacol Sin. 2013 Sep;34(9):1208-16. Disulfiram deregulates HIF-a
subunits and blunts tumor adaptation to hypoxia in hepatoma cells. Park HJ1, Kim MS, Cho K, Yun JH, Choi YJ, Cho CH.
29. J Cell Mol Med. 2013 Jan; 17(1): 30-54. Hypoxia-inducing factors as master
regulators of sternness properties and altered metabolism of cancer- and
metastasis-initiating cells Murielle Mimeault* and Surinder K Batra*
30. Cancer Res. 2009 Oct 1;69(19):7507-11. Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission. Hirsch HA1, Iliopoulos D, Tsichlis PN, Struhl K.
31. Nat Med. 2006 Oct;12(10):1167-74. Epub 2006 Sep 24. Targeting of CD44
eradicates human acute myeloid leukemic stem cells. Jin L1, Hope KJ, Zhai
Q, Smadja-Joffe F, Dick JE.
32. Cell Stem Cell. 2009 Jul 2;5(l):31-42. Monoclonal antibody-mediated targeting of CD123, IL-3 receptor alpha chain, eliminates human acute myeloid leukemic stem cells. Jin L1, Lee EM, Ramshaw HS, Busfield SJ, Peoppl AG, Wilkinson L, Guthridge MA, Thomas D, Barry EF, Boyd A, Gearing DP, Vairo G, Lopez AF, DickJE, Lock RB.
33. Cell Res. 2011 Oct; 21(10): 1424-1435. Lithium, an anti-psychotic drug, greatly enhances the generation of induced pluripotent stem cells; Quan Wang,l Xinxiu Xu,2 Jun Li,3 Jing Liu,4 Haifeng Gu,l Ru Zhang,2 Jiekai Chen,4 Yin Kuang,5 Jian Fei,5 Cong Jiang,6 Ping Wang,6 Duanqing Pei,4 Sheng Ding,3 and Xin Xiel,2,*
34. Cancer Metastasis Rev. 2013 Dec; 32(0): 10.1007/sl0555-013-9441-9. Exosomes in Cancer Development, Metastasis and Drug Resistance: A Comprehensive Review Asfar S. Azmi,l,* Bin Bao,l and Fazlul H. Sarkarl,2,*
35. Cancer Cell 2015 Nov 9; 28(5): 666-676. RNA-Seq of Tumor-Educated Platelets Enables Blood-Based Pan-Cancer, Multiclass, and Molecular Pathway Cancer Diagnostics, Myron G. Best, Nik Sol, Irsan Kooi, Jihane Tannous, Bart A. Westerman,
Francois Rustenburg, Pepijn Schellen, Heleen Verschueren, Edward Post, Jan Koster, Bauke Ylstra, Najim Ameziane, Josephine Dorsman, Egbert F. Smit, Henk M. Verheul, David P. Noske, Jaap C. Reijneveld, R. Jonas A. Nilsson, Bakhos A. Tannousl2, Pieter Wesselingl2, Thomas Wurdingerl2,
36. J Mol Diagn. 2015 May; 17(3): 209-224; Do Circulating Tumor Cells, Exosomes, and Circulating Tumor Nucleic Acids Have Clinical Utility? A Report of the Association
for Molecular Pathology Bert Gold,*†* Milena Cankovic,*:}: Larissa V. Furtado,*§ Frederick Meier,*:}: and Christopher D. Gocke*
37. J Clin Oncol. 2015 Nov 1; 33(31): 3541-3543; Pseudoprogression and Immune- Related Response in Solid Tumors. Chiou VL1, Burotto M2.
38. Oncoimmunology. 2015 Oct 29;5(3):el093277. Small cell lung cancer: Recruitment of macrophages by circulating tumor cells. Hamilton Gl, Rath B2, Klameth L2, Hochmair MJ3.
39. Oncogene, 2013 Mar 21: 32(12): 1570-1579; Inhibition of autophagy and tumor growth in colon cancer by miR-502, Haiyan Zhai, BO Song, Xiao Hu, Wei Zhu and Jingfang Ju
40. Semin Oncol. 2012, June; 39(3): 323-339; The tipping point for combination
therapy: cancer vaccines with radiation, chemotherapy or targeted small molecule inhibitors James W. Hodge, Andressa Ardiani, Benedetto Fasaci, Anna R. Kwilas and Sofia Gameiro
BRIEF DESCRIPTION OF FIGURES
Figure 1 Flow diagram showing process of the CIM-MIMEC method
Figure 2 Schematic diagram showing multimodal cancer treatment according to the present method
EXAMPLES
Example 1 Protocol for treating a cholangiocarcinoma patient.
As a pre-step as much cancerous tissue as possible is removed by surgery. The patient is then given a dose of 300-400mg bidaily of varlitinib together with a chemotoxic agent (eg capecitabine or gemcitabine) for 12-28 days. Following this, AZD5069 is given as a monotherapy or concomitantly with a T-cell stimulator for 4 to 6 weeks. After completing the latter 4, 5 or 6 cycles of chemotherapy comprising gemcitabine and cisplatin are given.
After chemotherapy is complete or concomitantly, treatment with permbrolizumab is given at 2 mg/Kg or 200mg every 3 weeks for 3, 6, 9, 12, 15 or 18 weeks.
The final stage of the therapy is one cycle of antibody drug conjugate, wherein the antibody is specific to Epcam, potentially in combination with an immune-oncology (IO) agent such as pemrolizumab.
Example 2 Protocol for treating a cholangiocarcinoma patient.
As a pre-step as much cancerous tissue as possible is removed by surgery. The patient is then given a dose of 300-400mg bidaily of varlitinib together with a chemotoxic agent (eg capecitabine or gemcitabine) for 12-28 days. Following this AZD5069 is given as a
monotherapy for 4 to 6 weeks. After completing the latter 4, 5 or 6 cycles of chemotherapy comprising 5-FU and leucovorin are given.
After or concomitantly chemotherapy is complete, treatment with permbrolizumab is given at 2 mg/Kg or 200mg every 3 weeks for 3, 6, 9, 12, 15 or 18 weeks.
The final stage of the therapy is one cycle of antibody drug conjugate, wherein the antibody is specific to Epcam, potentially in combination with an 10 agent such as pemrolizumab.
Example 3 Protocol for treating a cholangiocarcinoma patient.
As a pre-step as much cancerous tissue as possible is removed by surgery. The patient is then given a dose of 300-400mg bidaily of varlitinib together with a chemotoxic agent
(eg capecitabine or gemcitabine) for 12-28 days. Following this AZD5069 is given as a monotherapy for 4 to 6 weeks. After completing the latter 4, 5 or 6 cycles of
chemotherapy comprising gemcitabine and cisplatin are given potentially in
combination with an IO agent such as pemrolizumab.
After chemotherapy is complete or concomitantly, treatment with permbrolizumab is given at 2 mg/Kg or 200mg every 3 weeks for 3, 6, 9, 12, 15 or 18 weeks.
The final stage of the therapy targeted radiation therapy in combination with a PARP inhibitor, potentially in combination with an 10 agent such as pemrolizumab.
Example 4 Protocol for treating a cholangiocarcinoma patient.
As a pre-step as much cancerous tissue as possible is removed by surgery. The patient is then given a dose of 300-400mg bidaily of varlitinib together with a chemotoxic agent
(e.g. capecitabine or gemcitabine) for 12-28 days. Following this AZD5069 is given as a monotherapy for 4 to 6 weeks. After completing the latter 4, 5 or 6 cycles of
chemotherapy comprising 5-FU and leucovorin are given.
After chemotherapy is complete or concomitantly, treatment with permbrolizumab is given at 2 mg/Kg or 200mg every 3 weeks for 3, 6, 9, 12, 15 or 18 weeks.
The final stage of the therapy targeted radiation therapy in combination with a PARP inhibitor potentially in combination with an 10 agent such as pemrolizumab.
In all of these examples, a careful assessment of the immune status of the patient and the presence or absence of circulating tumor material like circulating tumor cells and circulating tumor DNA, is monitored on a weekly basis, and changes in the treatment regimen may be considered based on these findings.
Claims
1. A method of treating cancer comprising the steps;
a) reducing or stopping cancer proliferation,
b) debulking tumour mass,
c) activating immune cells,
d) increasing antigen presentation and/or enhancing T cell response, and
e) clear residual tumor cells.
2. A method according to claim 1, which comprises the further step of tumour
surveillance.
3. A method according to claim 1 or 2, wherein method comprises a pre-step of
surgery.
4. A method according to any one of claims 1 to 3, wherein step a) is selected from irradiation, chemotherapy, a CXCR2 antagonist and a combination of two or more the same.
5. A method according to claim 4, wherein the chemotherapy is selected from
alkylating agents, antimetabolites, anthracyclines, plant alkaloids, topoisomerase inhibitors, and other antitumour agents, such as doxorubicin, 5-fluorouracil (5-FU), paclitaxel, gemcitabine, capecitabine, irinotecan, and platins such as cisplatin and oxaliplatin.
6. A method according to claim 4 or 5, wherein the CXCR2 antagonist is selected from an antibody or binding fragment thereof, MK-7123, SB265610, SB 225002,
GSK1325756, AZD5069, and combinations thereof.
7. A method according to any one of claims 1 to 6, further comprising prior to step al) a step of decluttering of immune cells.
8. A method according to claim 7, wherein the decluttering is selected from treatment with a CXCR2 antagonist, an anti-GCF, cyclophosphamide, irradiation and a combination of two or more of the same.
9. A method according to claim 7 or 8, wherein the decluttering is performed by
removing specific immune cell populations, for example using medication and/or techniques such as dialysis.
10. A method according to claim 9, wherein the immune cell is selected from a
lymphocyte (such as a T cell or NKT cell), a B cell, a natural killer cell, a tumor associated macrophage, and a combination of two or more of the same, in particular a tumor associated macrophage.
12. A method according to any one of claims 1 to 11, wherein the debulking in step b) is selected from treatment with an oncolytic virus, an antibody drug conjugate and a combination thereof.
13. A method according to claim 12, wherein the oncolytic virus is a virus selected from an adenovirus, herpes simplex virus, reovirus, measles virus, Newcastle disease virus, Seneca Valley virus, Vesicular stomatitis virus, polio virus, ECHO enterovirus, Coxsackie virus, and vaccinia virus.
14. A method according to claim 13, wherein the oncolytic virus is selected from
Enadenotucirev, talimogene laherparepvec, RIGVIR, Ad5-yCD/mutTKSR39rep- hIL12, Cavatak™, CG0070, DNX-2401, G207, HF10, Imlygic®, JX-594, MG1-MA3, MV-NIS, OBP-301, Reolysin®, Toca 511.
15. A method according to claim 13 or 14, where the antibody drug conjugate (ADCC) is selected from the group comprising AGS-15E, AGS-16C3F, AGS-22M6E, AMG-172, AMG-595, ASG-5ME, brentuximab vedotin, DEDN-6526A, DMUC-5754A,
gemtuzumab ozogamicin, glembatumumab vedotin, GSK2857916, hRS7-SN-38, IMGN-242, IMGN-289, IMGN-388, IMGN-529, IMGN-633, IMGN-853, Indatuximab, indatuximab ravtansine, Inotuzumab ozogamicin, lorvotuzumab mertansine, MEDI- 547, milatuzumab doxorubicin, MLN-0264, MLN-2704, PF-06263507, pinatuzumab vedotin, polatuzumab, PSMA-ADC, RG-7450, RG-7599, SAR-3419, SAR-566658, SC16LD6.6, SGN-15, SGN-19A, SGN-CD33A, SGN-LIV1A, trastuzumab emtansine and combinations thereof.
16. A method according to any one of claims 1 to 15, wherein activating the immune cells in step c) comprises administering a RON inhibitor, an AXL kinase inhibitor, a MER kinase agonist, a cytokine (such as IL-13), a tumour vaccine for example comprising a tumour antigen and adjuvant, a dendritic cell vaccine and a
combination of two or more of the same.
17. A method according to claim 16, wherein the RON inhibitor is N-(4-(2-Amino-3- chloropyridin-4-yloxy]-3-fluorophenyl]-4-ethoxy-l-(4-fluorophenyl]-2-oxo-l,2- dihydropyridine-3-carboxamide disclosed in WO 2008/058229.
18. A method according to any one of claims 1 to 17, wherein activating the immune cells in step c) comprises administering a check-point inhibitor.
19. A method according to claim 18, wherein the check-point inhibitor is a PD-1 or PD- Ll inhibitor.
20. A method according to any one of claims 1 to 19, wherein step d) comprises
administering a therapy from the group comprising a T cell therapy (for example where T cells are activated in vitro to generate CTLs specific to an antigen), a cell therapy comprising engineered chimeric receptors, a PD1 inhibitor, a PD-L1
inhibitors, a CTLA4 inhibitor, a LAG3 inhibitor and a combination of two or more of the same.
21. A method according to any one of claims 1 to 20, wherein step e) comprises
administering a therapy selected from the group comprising an oncolytic virus, a DLL inhibitor, ADH-1 molecular targeting therapy and combinations of two or more of the same.
22. A method according to claim 21, wherein the oncolytic virus is a virus selected from an adenovirus, herpes simplex virus, reovirus, measles virus, Newcastle disease virus, Seneca Valley virus, Vesicular stomatitis virus, polio virus, ECHO enterovirus, Coxsackie virus, and vaccinia virus.
23. A method according to claim 22, wherein the oncolytic virus is selected from
Enadenotucirev, talimogene laherparepvec, RIGVIR, Ad5-yCD/mutTKSR39rep- hIL12, Cavatak™, CG0070, DNX-2401, G207, HF10, Imlygic®, JX-594, MG1-MA3, MV-NIS, OBP-301, Reolysin®, Toca 511.
24. A method according to any one of claims 1 to 23, wherein step e) comprises
targeting cancer stem cells.
25. A method according to claim 24, wherein the cancer stem cells are treated with a combination therapy comprising lithium and disulfiram.
26. A method according to any one of claims 1 to 25, wherein the cancer is an epithelial cancer.
27. A method according to claim 26, wherein the epithelial cancer is selected from liver cancer (such as hepatocellular carcinoma), biliary tract cancer, breast cancer (such as non-ER+ breast cancer, in particular double negative breast cancer ), prostate cancer, colorectal cancer, ovarian cancer, endometrial cancer, cervical cancer, lung cancer, gastric cancer, pancreatic, bone cancer, bladder cancer, head and neck cancer, thyroid cancer, skin cancer, renal cancer, and oesophagus cancer, for example gastric cancer.
28. A method according to claim 27, wherein the cancer is selected from the group comprising liver cancer (such as hepatocellular carcinoma), breast cancer, biliary duct cancer prostate cancer, colorectal cancer, bladder cancer, ovarian cancer, endometrial cancer, lung cancer, gastric cancer, oesophageal cancer, kidney cancer, head and neck cancers and combinations thereof.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1608918.7A GB201608918D0 (en) | 2016-05-20 | 2016-05-20 | Method |
GB1608918.7 | 2016-05-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2017200492A1 true WO2017200492A1 (en) | 2017-11-23 |
Family
ID=56369705
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/SG2017/050263 WO2017200492A1 (en) | 2016-05-20 | 2017-05-19 | Method of treating cancer |
Country Status (2)
Country | Link |
---|---|
GB (1) | GB201608918D0 (en) |
WO (1) | WO2017200492A1 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108543077A (en) * | 2018-04-10 | 2018-09-18 | 武汉迈德森医药科技股份有限公司 | A kind of mesoporous silica nano-particle and its preparation method and application of disulfiram monomer |
WO2019183455A1 (en) * | 2018-03-22 | 2019-09-26 | Windmil Therapeutics, Inc. | Prostate cancer specific marrow infiltrating lymphocytes and uses thereof |
CN110947004A (en) * | 2018-09-26 | 2020-04-03 | 江苏康缘药业股份有限公司 | Pharmaceutical composition, application thereof, sterile container and kit |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20190275092A1 (en) * | 2016-11-01 | 2019-09-12 | Dnatrix, Inc. | Combination therapy for treatment of brain cancers |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009083232A1 (en) * | 2007-12-28 | 2009-07-09 | Deutsches Krebsforschungszentrum | Parvovirus cancer therapy and combination with chemotherapy |
WO2010135242A1 (en) * | 2009-05-19 | 2010-11-25 | Eden Pharmaceuticals, Inc. | Combinations of immunostimulatory agents, oncolytic virus, and additional anticancer therapy |
WO2013112942A1 (en) * | 2012-01-25 | 2013-08-01 | Dna Trix, Inc. | Biomarkers and combination therapies using oncolytic virus and immunomodulation |
WO2014022138A2 (en) * | 2012-07-30 | 2014-02-06 | Alex Wah Hin Yeung | Live and in-vivo tumor specific cancer vaccine system developed by co-administration of either at least two or all three of the following components such as tumor cells, an oncolytic virus vector with transgenic expression of gm-csf and an immune checkpoint modulator |
WO2015027915A1 (en) * | 2013-09-02 | 2015-03-05 | 北京中康万达医药科技有限公司 | In-vivo individualized system immunological therapeutic method and device |
US20150086541A1 (en) * | 2013-09-21 | 2015-03-26 | Carlos Estuardo Aguilar-Cordova | Methods of Cytotoxic Gene Therapy To Treat Tumors |
WO2015061752A1 (en) * | 2013-10-25 | 2015-04-30 | Pharmacyclics, Inc. | Treatment using bruton's tyrosine kinase inhibitors and immunotherapy |
WO2015153514A1 (en) * | 2014-03-31 | 2015-10-08 | Genentech, Inc. | Combination therapy comprising anti-angiogenesis agents and ox40 binding agonists |
WO2016065330A1 (en) * | 2014-10-24 | 2016-04-28 | Aladar Szalay | Combination immunotherapy approach for treatment of cancer |
-
2016
- 2016-05-20 GB GBGB1608918.7A patent/GB201608918D0/en not_active Ceased
-
2017
- 2017-05-19 WO PCT/SG2017/050263 patent/WO2017200492A1/en active Application Filing
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009083232A1 (en) * | 2007-12-28 | 2009-07-09 | Deutsches Krebsforschungszentrum | Parvovirus cancer therapy and combination with chemotherapy |
WO2010135242A1 (en) * | 2009-05-19 | 2010-11-25 | Eden Pharmaceuticals, Inc. | Combinations of immunostimulatory agents, oncolytic virus, and additional anticancer therapy |
WO2013112942A1 (en) * | 2012-01-25 | 2013-08-01 | Dna Trix, Inc. | Biomarkers and combination therapies using oncolytic virus and immunomodulation |
WO2014022138A2 (en) * | 2012-07-30 | 2014-02-06 | Alex Wah Hin Yeung | Live and in-vivo tumor specific cancer vaccine system developed by co-administration of either at least two or all three of the following components such as tumor cells, an oncolytic virus vector with transgenic expression of gm-csf and an immune checkpoint modulator |
WO2015027915A1 (en) * | 2013-09-02 | 2015-03-05 | 北京中康万达医药科技有限公司 | In-vivo individualized system immunological therapeutic method and device |
US20150086541A1 (en) * | 2013-09-21 | 2015-03-26 | Carlos Estuardo Aguilar-Cordova | Methods of Cytotoxic Gene Therapy To Treat Tumors |
WO2015061752A1 (en) * | 2013-10-25 | 2015-04-30 | Pharmacyclics, Inc. | Treatment using bruton's tyrosine kinase inhibitors and immunotherapy |
WO2015153514A1 (en) * | 2014-03-31 | 2015-10-08 | Genentech, Inc. | Combination therapy comprising anti-angiogenesis agents and ox40 binding agonists |
WO2016065330A1 (en) * | 2014-10-24 | 2016-04-28 | Aladar Szalay | Combination immunotherapy approach for treatment of cancer |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019183455A1 (en) * | 2018-03-22 | 2019-09-26 | Windmil Therapeutics, Inc. | Prostate cancer specific marrow infiltrating lymphocytes and uses thereof |
CN112074280A (en) * | 2018-03-22 | 2020-12-11 | 温德弥尔治疗公司 | Prostate cancer specific marrow infiltrating lymphocytes and uses thereof |
CN108543077A (en) * | 2018-04-10 | 2018-09-18 | 武汉迈德森医药科技股份有限公司 | A kind of mesoporous silica nano-particle and its preparation method and application of disulfiram monomer |
CN108543077B (en) * | 2018-04-10 | 2021-04-30 | 武汉迈德森医药科技股份有限公司 | Mesoporous silica nanoparticle of disulfiram monomer and preparation method and application thereof |
CN110947004A (en) * | 2018-09-26 | 2020-04-03 | 江苏康缘药业股份有限公司 | Pharmaceutical composition, application thereof, sterile container and kit |
CN110947004B (en) * | 2018-09-26 | 2021-05-18 | 江苏康缘药业股份有限公司 | Pharmaceutical composition, application thereof, sterile container and kit |
Also Published As
Publication number | Publication date |
---|---|
GB201608918D0 (en) | 2016-07-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10849899B2 (en) | Combination therapy comprising Varlitinib and an anticancer agent | |
AU2018233032B2 (en) | TEC family kinase inhibitor adjuvant therapy | |
Wuerth et al. | Drug-repositioning opportunities for cancer therapy: novel molecular targets for known compounds | |
Romiti et al. | Metronomic chemotherapy for cancer treatment: a decade of clinical studies | |
Pasini et al. | The role of chemotherapy in metastatic gastric cancer | |
WO2017200492A1 (en) | Method of treating cancer | |
WO2018136010A1 (en) | Combination therapy | |
WO2018136009A1 (en) | Combination therapy | |
US20190134034A1 (en) | Method of Treating Liver Cancer | |
Guo et al. | Advances and challenges in immunotherapy of small cell lung cancer | |
Bhoopathi et al. | The quest to develop an effective therapy for neuroblastoma | |
Hou et al. | Autophagy and tumour chemotherapy | |
Jackson et al. | A review of the anti-tumor potential of current therapeutics targeting the mitochondrial protease ClpP in H3K27-altered, diffuse midline glioma | |
Choudhary et al. | Different chemosensitization approaches in gastric cancer | |
Zhao et al. | Trends of rapamycin in survival benefits of liver transplantation for hepatocellular carcinoma | |
Erika et al. | Old tyrosine kinase inhibitors and newcomers in gastrointestinal cancer treatment | |
Ge et al. | Review and prospect of immune checkpoint blockade therapy represented by PD-1/PD-L1 in the treatment of clear cell renal cell carcinoma | |
Sailo et al. | Molecular alterations involved in pancreatic cancer chemoresistance and chemosensitization strategies | |
WO2021178449A1 (en) | Compositions and methods for the treatment of pancreatic cancer | |
Sookprasert et al. | Systemic therapy for locally advanced and metastatic cholangiocarcinoma | |
Hamza et al. | Recent Concepts in the Pathogenesis and Management of Colorectal Cancer | |
Eckel et al. | Emerging drugs for biliary cancer | |
Balar et al. | A new era of immune therapeutics for pancreatic cancer: Monoclonal antibodies paving the way | |
Thakre et al. | A LITERARY EXPLORATION OF CANCER TREATMENT TECHNOLOGIES | |
JP2023549698A (en) | Compositions of nanoparticles for the treatment of cancer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 17799790 Country of ref document: EP Kind code of ref document: A1 |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 17799790 Country of ref document: EP Kind code of ref document: A1 |